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ABSTRACT 
Advanced stages of papillary and anaplastic thyroid cancer continue to be plagued by a 
dismal prognosis, which is a result of limited effective therapies for these cancers.  This predicament 
has spawned an influx of research defining the signaling mechanisms that promote the progression 
and aggressiveness of late stage thyroid cancers. Due to the high proportion of thyroid cancers 
harboring mutations in the MAPK pathway, the MAPK pathway has become a focal point for 
therapeutic intervention in thyroid cancer.  Unfortunately, unlike melanoma, a similar 
responsiveness to MAPK pathway inhibition has yet to be observed in thyroid cancer patients.  To 
address this issue, we have focused on targeting the non-receptor tyrosine kinase, Src, and have 
demonstrated that the targeting of Src results in inhibition of growth, invasion, and migration both 
in vitro and in vivo. However, as recent studies have demonstrated that resistance to targeted 
therapies is inevitable, it is vital that we uncover mechanisms and strategies to prevent/delay this 
resistance from occurring. 
First, using a model of acquired resistance to the Src inhibitor, dasatinib, we were able to 
demonstrate that the Mitogen Activated Protein (MAP) Kinase pathway was increased in all four of 
the dasatinib-resistant cell lines, despite differential c-SRC gatekeeper mutation acquisition in the 
RAS-mutant cell lines versus the BRAF-mutant cell lines. Furthermore, MAP2K1/MAP2K2 (MEK1/2) 
inhibition restored sensitivity in all four of the dasatinib-resistant cell lines, and overcame acquired 
resistance to dasatinib in the RAS-mutant Cal62 cell line, in vivo. Therefore, suggesting that 
prolonged Src inhibition promotes an increased reliance of thyroid cancer cell lines on the MAPK 
iv 
pathway. In support of this, we further demonstrate that up-front combined inhibition with 
dasatinib and MEK1/2 or ERK1/2 inhibitors drives synergistic inhibition of growth and induction of 
apoptosis, indicating that combined inhibition may overcome mechanisms of survival in response to 
single agent inhibition. 
Second, through the analysis of cell lines with intrinsic resistance to dasatinib, we uncovered 
activation of the Phosphatidylinositol 3-Kinase (PI3K) pathway as an indicator of primary intrinsic 
resistance to dasatinib.  Importantly, despite the increased activity in the PI3K pathway, the 
combined inhibition of Src and the MAPK pathway is able to overcome intrinsic dasatinib resistance 
in BRAF- and RAS-mutant cell lines, however no efficacy is observed for the combination therapy, in 
the PIK3CA-mutant cell lines. Along these lines, Src appears to regulate the PI3K pathway in the 
BRAF- and RAS-mutant cell lines, which correlates with effective inhibition of both the MAPK and 
PI3K pathways upon combined inhibition of Src and MAPK pathway in the BRAF- and RAS-mutant 
cell lines. Interestingly, downstream phosphorylation of rpS6 appears to be an important biomarker 
of responsiveness to the combination therapy, and therefore cells treated with the combination 
therapy that maintain Ribosomal Protein S6 (rpS6) phosphorylation may represent important 
therapeutic targets, as these cells likely represent drug tolerant persisters, which have the potential 
to give rise to a resistant population.  
Overall, the combined inhibition of Src and the MAPK pathway holds great promise for the 
treatment of advanced thyroid cancer, in patients with BRAF- and RAS-mutations, and activation of 
the PI3K pathway and rpS6 phosphorylation status represent important biomarkers for patients 
treated with this therapy. Taken together, these discoveries aim to ultimately improve the overall 
survival of patients with advanced thyroid cancers. 
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The Thyroid (Normal Function and Biology)  
The thyroid gland is composed of two main cell types, including follicular cells, and 
parafollicular c-cells. Thyroid stimulating hormone (TSH) secreted from the anterior pituitary can 
bind and activate the TSH Receptor (TSH-R) promoting the uptake of iodide by the sodium iodide 
symporter (NIS) 1. Follicular cells utilize iodine to produce the thyroid hormones triiodothyronine 
(T3) and thyroxine (T4), which act to control heart rate and basal metabolism, as well as normal 
development 2,3. The parafollicular cells surround the follicles and secrete calcitonin to regulate the 
plasma levels of calcium 4. 
Thyroid Cancer 
Incidence and Histological Classification 
Thyroid cancer is one of the most common endocrine malignancies, and makes up about 
3.8% of cancer-related malignancies in the United States 5.  The incidence of thyroid cancer has 
tripled over the past 40 years with an estimated 64,300 new cases in 2016 5,6. However a majority of 
the increased incidence has been suggested to be associated with increased detection, as a similar 
increase in mortality has not been identified 5,6. That said, in the USA, there is an increase in the 
incidences of papillary thyroid cancers of all sizes and stages at diagnosis, as well as a lack of a 
decrease in disease related mortality, which supports an argument for an increase in environmental 
factors in driving the increased rates of thyroid cancer detection 7.  Along these lines, increases in 
thyroid cancer incidences, especially in relation to increases in environmental risk factors, signifies 
an important area of clinical concern and therapeutic development.  
2 
Thyroid cancers are classified based upon four distinct subtypes as a result of the histology 
of the tumors: medullary, papillary, follicular, and anaplastic 8.  Approximately 3% of thyroid cancers 
are classified as medullary thyroid cancers (MTC), and these tumors are derived from the 
parafollicular C-cell. 70-80% of medullary thyroid cancers are sporadic and around 20-30% are 
hereditary 8.  The most common mechanism driving MTC tumorigenesis is through aberrant 
activation of RET signaling caused by RET mutations 9.  Medullary thyroid cancer was included for 
completeness, however the primary focus of this thesis relates to advanced thyroid cancers of 
follicular origin, and therefore medullary thyroid cancer will not be further expanded on. 
More than 95% of thyroid cancers are derived from the thyroid follicular cell. Tumors 
derived from the thyroid follicular cell have multiple distinctions including: well-differentiated, 
poorly-differentiated, and undifferentiated/anaplastic.  Well-differentiated thyroid cancers have 
histological designations of either papillary or follicular, and most well differentiated cancers are 
relatively dormant and have a very good prognosis. Of the two, papillary thyroid cancer (PTC) is the 
most prevalent making up 85% of all thyroid cancers with follicular thyroid cancer (FTC) accounting 
for 2-5% of thyroid cancers 6. Both PTC and FTC tumors maintain evidence of follicular epithelial cell 
differentiation, and importantly this state of differentiation promotes the uptake and concentration 
of iodide 10. Papillary thyroid cancers are distinguished from follicular thyroid cancers based on their 
unique histology mimicking papillae or finger like projections into the surrounding 
microenvironment 10.  
In contrast to papillary or follicular cancers, undifferentiated or anaplastic thyroid cancers 
(ATC) account for 1% of thyroid cancers, and are highly aggressive and no longer contain signs of 
follicular cell differentiation 6,10. As a result of a lack of differentiation, ATCs no longer concentrate 
iodine, and have a very poor prognosis with an overall survival of less than 1 year.  Poorly 
differentiated thyroid cancers (PDTCs) account for 6% of thyroid cancers, and have a prognosis in 
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between well-differentiated and undifferentiated cancers 6,11. PDTC can be distinguished from ATC 
based on the identification of PTC or FTC foci present in an undifferentiated tumor, suggesting a 
transitory state towards ATC 10. 
Current Therapeutic Strategies 
The majority of well-differentiated thyroid cancers are treated by either surgery or surgical 
resection in combination with the administration of radioiodide.  For these cancers, this therapeutic 
strategy results in a 10 year overall survival rate of 95%6.  Due to the propensity of well-
differentiated thyroid cancers to concentrate iodine, disseminated thyroid cancer cells, which 
remain after surgical resection, will readily take up iodide-131 resulting in their elimination.  
Unfortunately, differentiated thyroid cancers that harbor BRAFV600E-mutations, poorly 
differentiated thyroid cancers, and undifferentiated thyroid cancers tend to be refractory to 
radioiodide 6,9,12. The current therapeutic approaches for radioiodide refractory tumors includes 
surgery, radiation, chemotherapy, and more recently, the FDA approved VEGFR inhibitors, sorafenib 
and lenvatinib, with lenvatinib appearing to have the greater overall efficacy, significantly extending 
progression free survival from 3.6 months to 18.3 months 13–15. Despite the success of lenvatinib, 
significant toxicities have been associated with this therapy, with 60-80% of patients requiring dose 
interruptions and reductions, and approximately 15% of patients requiring discontinuation of 
therapy 14.  Confounding the efficacy of lenvatinib, 6 deaths in the lenvatinib treatment group were 
thought to be associated with toxicities derived from therapy 13. Lenvatinib is a multikinase inhibitor 
with multiple off-target effects outside of its inhibitory role on VEGFR, however very little is 
understood about how lenvatinib might directly affect the tumor cells.  Therefore an increased 
understanding of the function of lenvatinib, as well as the underlying signaling networks that thyroid 
cancers are reliant on, will aid in our ability to design therapeutic strategies that enhance response 
rates and decrease toxicity.   
4 
Molecular Alterations 
Until recently, the thyroid cancer field has had a limited understanding of the genetic 
alterations that drive thyroid cancer, with a majority of studies focused on defining the oncogenic 
potential of BRAFV600E mutations. The BRAF point mutation at residue 600 on nucleotide 1799 
(V600E; T1799A) results in a valine-to-glutamate substitution that disrupts autoinhibitory 
interactions, promoting an adoption of the catalytically active state, and resulting in constitutive 
activation of BRAF 16. Importantly, studies in thyroid cancer have uncovered a 25% rate of tumor 
recurrence in BRAFV600E-mutant PTCs in comparison to a 9% rate of tumor recurrence in wild type 
BRAF PTCs.  However, despite the increased aggressiveness associated with BRAF-mutations in PTC, 
a major issue still remained in the thyroid cancer field, as a BRAF mutation alone is unlikely to be 
able to distinguish malignant and non-malignant thyroid nodules 17. Thus, major sequencing efforts 
were performed to better define thyroid cancer at the molecular level. One such sequencing effort 
was performed on papillary thyroid cancers by The Cancer Genome Atlas (TCGA) 18. These studies 
have aided in the ability of the field to better determine PTC progression, but unfortunately they do 
not represent the more aggressive cases of undifferentiated or anaplastic thyroid cancer 18. 
Therefore, with a dearth of therapies for anaplastic thyroid cancer, it was important to better define 
this aggressive subtype. To address this issue, Dr. James Fagin and colleagues from Memorial Sloan 
Kettering sequenced 117 tumors from both poorly differentiated and undifferentiated thyroid 
cancer cases, using a next-generation sequencing platform for targeted sequencing of 341 cancer 
genes (MSK-IMPACT) 19,20. Taken together, these sequencing efforts further supported past findings 
demonstrating a high prevalence of mutations in the mitogen activated protein kinase (MAPK) 
pathway, as these studies identified that 60% of PTCs harbor BRAF-mutations, and 33% and 45% of 
PDTCs and ATCs harbor BRAF-mutations, respectively 6.  In addition, a high percentage of thyroid 
cancers also harbored mutations in RAS with point mutations occurring at codon 12 or 13 resulting 
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in increased affinity for GTP or mutations occurring at codon 61 resulting in a disruption of the 
guanosine triphosphatase (GTPase) function of the protein, which results in constitutive activation 
of Ras.  RAS-mutations were found in 13% of PTCs, 28% of PDTCs, and 24% of ATCs, which suggests 
an association of RAS-mutant cell lines and increased aggressiveness (Figure 1.1) 6. Interestingly, 
approximately 55% of RAS-mutant thyroid cancers harbor mutations in NRAS, 25% harbor KRAS-
mutations, and 20% harbor HRAS-mutations 21. 7% of PTCs were also found to harbor RET 
rearrangements, which act to promote increased activation of the MAPK pathway (Figure 1.1a) 18. 
Progression from PTC to PDTC or ATC is associated with an increase in mutational burden (Figure 
1.1) 19. These mutations include an increase in telomerase reverse transcriptase (TERT) promoter 
mutations, mutations in effectors of the phosphatidylinositol 3-kinase (PI3K)–AKT– mammalian 
target of rapamycin (mTOR) pathway, mutations in epigenetic modifiers and mutations in EIF1AX 
(Figure 1.1b&c).  An increase in mutations in both PIK3CA and PTEN are observed in ATC (18% and 
15%) in comparison to PDTC (2% and 4%), respectively (Figure 1.1b&c) 19.  The most frequent point 
mutations in PIK3CA occur in exon 9 (E542K; G1624A) and exon 20 (H1047R; A3140G) 22.  Both 
mutation sites act to promote constitutive activation of PIK3CA, with mutations in exon nine 
promoting an escape from the inhibitory effect of the regulatory p85 domain and mutations in exon 
20 likely promoting an active state conformation 23. PTEN mutations were found to be primarily 
truncating mutations, which would act to disable the tumor suppressor functions of PTEN allowing 
for decreased regulation of PI3K activity 19. In addition, progression from poorly-differentiated to 
undifferentiated/anaplastic cancers is defined by an increase in mutations in the tumor suppressor 
TP53 from 10% to 60% (Figure 1.1c) 6,18,19. The recent efforts to define the mutational landscape 
have greatly enhanced our ability to more accurately determine subgroups amongst these benign 









Figure 1.1: Mutational landscape of thyroid cancer.  A) Papillary Thyroid Cancers exhibit a high 
prevalence of mutations in the MAPK pathway. B) Acquisition of PI3K, AKT, mTOR pathway, 
EIF1AX, and TERT promoter mutations promote a progression towards poorly differentiated 
thyroid cancers. C) Acquisition of PI3K, AKT, mTOR pathway, EIF1AX, TERT promoter, mismatch 
repair, SWI/SNF, and histone methyltransferase mutations promote a progression towards 
poorly differentiated thyroid cancers promotes the progression from papillary to anaplastic 
thyroid cancer.  TP53 mutations can promote the progression to anaplastic from either papillary 
or poorly differentiated thyroid cancers. Adapted from Fagin, J.F. et al. Biologic and Clinical 
Perspectives on Thyroid Cancer  N. Engl. J. Med. (2016) 
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and responses to targeted therapies. In support of this, other laboratories have already 
demonstrated that progression free survival is significantly shorter for patients with BRAF-mutations 
and telomerase reverse transcriptase (TERT) promoter mutations, in comparison to BRAF mutations 
alone 24. 
Protein Kinases 
Along with evidence from other tumors, the improved responses observed with both 
lenvatinib and sorafenib provide rationale for targeting protein kinases in advanced thyroid cancer.  
The human protein kinase gene family consists of 518 genes, 244 of which have been mapped to 
disease loci and cancer amplicons 25. Kinases are divided into two groups composed of tyrosine and 
serine/threonine kinases, which is dependent on the nature of the phosphorylated OH group, 
whether it is a phenol or alcohol, respectively.  There are 388 serine/threonine kinases and 90 
tyrosine kinases in human cell biology, and of the 90 tyrosine kinases: 58 are receptor and 32 are 
non-receptor tyrosine kinases26.  Serine/Threonine and Tyrosine kinases have a relatively conserved 
catalytic domain that sits between the N-terminal and C-terminal lobes. The C-terminal lobe 
contains the activation segment which is located between a conserved DFG motif and a less 
conserved APE motif. In the active conformation the aspartate residue of the DFG motif chelates an 
Mg+ ion to orient Adenosine Triosphosphate (ATP) (DFG-IN), and in the inactive conformation the 
phenylalanine residue points in toward the ATP binding site (DFG-OUT) (Figure 1.2) 27.  For many 
kinases, phosphorylation of the activation segment results in a conformational change that allows 
for the rearrangement of the activation loop and increased enzymatic activity  28.  The binding of 
ATP allows for the kinase to catalyze the transfer of the gamma phosphate onto a downstream 
target, which likely results in activation or inhibition of a biological activity in the downstream target 











Figure 1.2: Active kinase conformation. Representative conformation of a kinase in the DFG IN 
or active conformation. This representation highlights the binding of ATP and transfer of the 
gamma phosphate onto a substrate. In addition, the tyrosine residue located in the activation 
loop is phosphorylated and the gatekeeper threonine residue is arranged in the hydrophobic 
binding pocket.  Adapted from Kornev, A.P. et al. “u fa e o pa iso  of a ti e a d i a ti e 
p otei  ki ases ide tifies a o se ed a ti atio  e ha is .  Proc. Natl. Acad. Sci. (2006) 
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BCR (breakpoint cluster region)-ABL1 fusion protein results in enhanced antileukemic activity and 
increased clinical responsiveness has led to a wave of interest in targeting oncogenic kinases 29. DFG-
IN or Type I kinase inhibitors constitute the majority of kinase inhibitors, which compete directly 
with ATP for the binding of the active site. Most type I tyrosine kinase inhibitors take advantage of a 
hydrophilic threonine residue located in the hydrophobic spine that is rearranged upon 
phosphorylation of the activation segment (Figure 1.2).  The similarity of the ATP binding pocket 
decreases our ability to develop highly specific inhibitors that target this region, and therefore, Type 
II-IV inhibitors are also in development to increase target specificity. DFG-out or Type II kinase 
inhibitors bind to the inactive conformation of the kinase. Type III inhibitors are termed allosteric, as 
they regulate kinase activity by binding outside of the ATP binding pocket in a unique binding 
pocket, which promotes increased selectivity. Lastly the type IV inhibitors, termed covalent 
inhibitors, are irreversible kinase  inhibitors that target a cysteine residue at the lip of the ATP 
binding pocket 30. Phosphatases can act as intrinsic kinase inhibitors through their ability to remove 
and transfer phosphate groups onto  water molecules 31.  
The PI3 Kinase Pathway  
From a cancer perspective, the four class I phosphoinositide 3-ki ases PI Kα, PI Kβ, PI K , 
and PI K ) are thought to be the most relevant.  The four PI3K isoforms exist as heterodimers 
composed of the p85 regulatory subunit (PIK3R1 & PIK3R2) and the p110 catalytic subunit (PIK3CA, 
PIK3CB, PIK3CD, PIK3CG) 32. I te esti gl , the PIK CA ge e hi h e odes the p α su u it is the 
only isoform that is frequently mutated in cancer, whereas overexpression and amplification of all 
four class I PI3K isoforms has been well documented in a number of different tumor types 33. 
Activation of growth factor receptors results in the generation of SH2 binding sites and the 
recruitment of PI3K to the plasma membrane (Figure 1.3). The binding of p85 to SH2 binding sites 









Figure 1.3: Regulation of the PI3K pathway.  Binding of ligands to growth factor receptors 
promotes the recruitment of PI3K to the plasma membrane.  Binding of the P85 subunit of 
PI3K promotes increased activity of the P110 subunit of PI3K and phosphorylation of PIP2 to 
PIP3, which promotes the binding of AKT and activation of the PI3K-AKT signaling cascade. 
Adapted f o  Me doza et al. The ‘as-ERK and PI3K-mTOR pathways: Cross-talk and 
o pe satio .  Trends Biochem Sci (2011).  
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phospho latio  of the  positio  o  Phosphat li ositide , -bisphosphate (PtdIns(4,5)P2) to 
generate Phosphatylinositide 3,4,5-trisphosphate (PtdIns(3,4,5)P3) 33. PIK3CA mutations typically 
occur in either the helical (E542K and E545K) or the kinase domain (H1047R), which act to reduce 
the inhibition of p110 by p85, or increase the interaction between p110 and the lipid membranes, 
respectively 33.  In addition, mutations or deletions can also occur in the tumor suppressor PTEN 34, 
as PTEN functions to counteract and remove the p  ediated  phospho latio  of 
PtdIns(3,4,5)P3 32. Generation of PtdIns(3,4,5)P3 creates a binding site for the pleckstrin homology 
(PH) domain of AKT, which allows AKT to adopt an open active conformation 35.  At this point, AKT is 
then able to be phosphorylated by PDK1 at T308 and/or by mTORC2 at S473 35.  Phosphorylation of 
AKT allows for AKT to phosphorylate and inhibit TSC2 resulting in an activation of mTORC1.  mTORC1 
then activates P70S6K and phosphorylates and negatively regulates 4EBP1.  Activation of P70S6K 
then proceeds to phosphorylate a number of downstream targets including rpS6 36.  
Phosphorylation of 4EBP1 allows for the release of EIF4E and a subsequent increase in translation. 
The RAS-ERK MAPK Pathway 
 The binding of growth factors, cytokines, and mitogens to their respective receptors 
promotes dimerization and autophosphorylation, which results in the creation of binding sites for 
the adaptor proteins Shc and growth factor receptor bound protein 2 (GRB2), as well as other 
downstream effectors (Figure 1.4). Binding of Shc and Grb2 to phosphorylation sites on growth 
factor receptors promotes the recruitment of the Guanine Nucleotide Exchange Factor (GEF), son of 
sevenless (SOS), which in turn promotes the exchange of Guanosine diphosphate (GDP) for 
Guanosine-5'-triphosphate (GTP) on one of the three Ras isoforms, K-Ras, N-Ras, or H-Ras 37.  GTP 
bound RAS is then able to bind to the N-terminus of one of the three Raf isoforms, A-Raf, B-Raf, or c-
Raf, which results in Raf dimerization and autophosphorylation through the release of autoinhibitory 









Figure 1.4: Regulation of the MAPK pathway.  Binding of ligands to growth factor receptors 
promotes the recruitment of Ras to the plasma membrane.  Exchange of GDP for GTP on Ras 
facilitates the interaction of Ras and B-Raf allowing for signaling through the MAPK cascade. Adapted 
f o  Me doza et al. The ‘as-ERK and PI3K-mTOR pathways: Cross-talk a d o pe satio .  Trends 
Biochem Sci (2011).  
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MEK1/2, followed by subsequent phosphorylation of extracellular signal-regulated kinase 1/2 
(ERK1/2) by the dual specificity MEK1/2 kinases. These sequential phosphorylations are spatially 
coordinated by the scaffolding protein KSR, which has multiple binding sites that bring Raf, MEK1/2, 
and ERK1/2 together at the plasma membrane 39.  Upon activation of the signaling cascade, ERK1/2 
can then signal to downstream transcription factors including: c-Myc, E26 transformation-specific 
(ETS) family members, and c-Jun, as well as the downstream effector ribosomal S6 kinase (RSK), 
which can lead to an increase in cell cycle activation, regulation of apoptosis, and transcriptional 
changes 40.  
Efficacy of MAPK Targeted Therapies in Thyroid Cancer 
Much attention has been focused on targeting the protein kinases in the MAPK pathway due 
to the high prevalence of mutations in this pathway. Thus, many researchers predicted that 
therapies such as vemurafenib, which target mutant BRAFV600E in melanoma, would likewise be 
effective in other tumors harboring BRAFV600E mutations including: thyroid and colorectal cancer 41.  
Interestingly, studies have instead shown that therapies targeting the MAPK pathway had limited 
efficacy in other tumor types when compared to melanoma 42–44.  Specifically, in vitro analysis of 
melanoma cell lines, in comparison to the thyroid cancer cell lines, identified that the melanoma cell 
lines exhibit IC50 values to vemurafenib that are less than 100 nM, whereas 5 out of 6 the thyroid 
cancer cell lines tested, exhibited IC50 values to vemurafenib that are greater than 1000 nM (Figure 
1.5). Consistent with an increased intrinsic resistance in thyroid cancer, vemurafenib is unable to 
sustain inhibition of the MAPK pathway in thyroid cancer cell lines, whereas vemurafenib effectively 
inhibits the MAPK pathway in melanoma cell lines.  Importantly, these pre-clinical studies 
recapitulate what is observed in the clinic as well, as a clinical trial with the Raf-1 inhibitor sorafenib 
resulted in only 10% of thyroid cancer patients exhibiting a partial response and 28% exhibiting 
stable disease 45. In addition, a phase II trial with selumetinib, in iodine-131 refractory papillary 
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thyroid cancers, resulted in only 3% of patients exhibiting a partial response, 54% with stable 
disease, and 28% with progressive disease, which failed to meet the 20% overall response rate 
criteria, and thus failed the clinical trial 46.  Interestingly, a recent basket trial for patients with 
BRAFV600E-positive tumors was performed to determine responsiveness to the B-Raf inhibitor, 
vemurafenib. The trial included seven patients with anaplastic thyroid cancer, of which one patient 
exhibited a complete response, and one patient exhibited a partial response 47.  Furthermore, in a 
recent phase II clinical trial of BRAFV600E –mutant papillary thyroid cancer patients with recurrent or 
metastatic radioactive iodine resistant disease, 38% of these patients exhibited a partial response to 
the B-Raf inhibitor, vemurafenib 48. Despite these recent promising results with vemurfenib, thyroid 
cancers still fall short of the 81% response rate observed upon B-Raf inhibition in BRAF-mutant 
melanoma 49.  Taken together, these clinical findings are consistent with the preclinical data 
demonstrating that there is a lack of efficacy for single agent MAPK pathway targeted therapies in 
thyroid cancer in comparison to melanoma. Importantly however, it also suggests that through a 
better understanding of why thyroid tumors exhibit increased resistance to targeted therapies 
against the MAPK pathway, we might be able to define biomarkers that will better define which 
patients will respond to MAPK pathway targeted therapies. Intriguingly, it has been demonstrated 
that inhibition of the MAPK pathway in advanced thyroid cancers that are refractory to radioiodine 
therapy promotes an increase in expression of the sodium iodide symporter (NIS) 50,51. Furthermore, 
after 4 weeks of treatment with the MEK1/2 inhibitor, selumetinib, patients with radioactive iodide 
refractory differentiated thyroid carcinomas exhibited enhanced radioactive iodide uptake (Figure 
1.6) 52.  Furthermore, it was identified that a sustained reduction in ERK1/2 phosphorylation 
correlates with enhanced uptake of radioactive iodide 50. Therefore, by defining mechanisms of 
resistance to MAPK pathway targeted therapies, we will hopefully identify combination strategies 




Figure 1.5: B-Raf inhibitor, vemurafenib, sensitivity.  Comparison of BRAFV600E-mutant 
melanoma, thyroid, and colon cancer cell line sensitivity to the B-Raf inhibitor, vemurafenib 
(PLX4032). Data represents the 50% inhibitory concentration for each cell line. Adapted from 
Montero-Conde, C. et al. Relief of feedback inhibition of HER3 transcription by RAF and MEK 
inhibitors attenuates their antitumor effects in BRAF- uta t th oid a i o as  Cancer Discov. 
(2013).  
Figure 1.6: Maximal standardized uptake value (SUVmax) for iodine in all tumors in a patient 
with an NRAS –mutant poorly differentiated thyroid cancer.  Each bar represents one 
malignant lesion identified on the iodine-124 PET-CT SCAN. The bars (red) represent the 
increases in iodine-124 avidity achieved after selumetinib administration.  Adapted from Ho, A.L. 
et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer  N. Engl. J. Med. 
(2013). 
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efficacy of standard of care radioactive iodine therapy. Whereas MAPK pathway regulation of NIS 
has primarily been demonstrated to function at the transcriptional level, it has also been 
demonstrated that the cellular localization of NIS can also be regulated by the pituitary tumor–
transforming gene-binding factor (PBF) 53.  Src mediated phosphorylation of PBF at Y174 results in an 
increased association between PBF and NIS, which sequesters NIS from the plasma membrane, and 
results in a reduction in iodine uptake 54.  Taken together, both the MAPK pathway and Src may play 
important roles in regulating NIS expression and localization, as well as radioactive iodine uptake in 
thyroid cancers.   
Mechanisms of Resistance to MAPK Pathway Inhibitors 
In order to develop more effective strategies to target the MAPK pathway in thyroid cancer, 
it is important to understand the mechanisms that drive resistance to MAPK pathway inhibition. 
Despite the remarkable responses observed upon B-Raf inhibition in melanoma, these responses are 
not durable, with a median time to progression of 5.3 months 55.  Fortunately, the melanoma field 
has made great progress in enhancing our understanding of these mechanisms, which include 
acquisition of RAS or MEK1/2 mutations, overexpression of PDGFRB, acquisition of a BRAFV600E splice 
variant that enhances dimerization, B-Raf and c-Raf dimerization, overactivation of RTKs, loss of 
NF1, overexpression of MAP3K8 (COT), and mechanisms of PI3K pathway activation 56,57.  Many of 
these mechanisms function to reactivate the MAPK pathway, which prompted a clinical trial that led 
to the FDA approval for co-targeting B-Raf and MEK1/2 in melanoma.  The combined inhibition of B-
Raf and MEK1/2 led to enhanced progression free survival, which improved from 5.8 months to 9.4 
months 58.  As mechanisms of resistance to MAPK pathway inhibitors function to reactivate the 
MAPK pathway, there has been a recent influx of interest in the clinical development of ERK1/2 
inhibitors 59.  Importantly, recent evidence demonstrates that the ERK1/2 inhibitor, SCH772984, 
effectively inhibits cells resistant to the dual combination of B-Raf and MEK1/2 inhibitors 60. 
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Recent studies in thyroid cancer and colorectal cancer found that increased activation of 
HER2/HER3 and EGFR drive resistance to BRAFV600E inhibitors, which was likely a result of a release 
on negative feedback inhibition 42–44.  Importantly, release of negative feedback has been 
demonstrated to promote Ras-activation in BRAF-mutant cancers and reactivation of the MAPK 
pathway through Ras-mediated B-Raf and c-Raf dimerization (Figure 1.9)  42,61. Interestingly, 
comparison of the BRAF-mutant thyroid cancer cell line, SW1736, to the BRAF-mutant melanoma 
cell line, SK-MEL-28, demonstrated a higher level of baseline Ras activation, and a more robust 
increase in Ras activation and Raf dimerization, upon administration of the B-Raf inhibitor, 
vemurafenib, in the SW1736 cell line in comparison the SK-MEL-28 melanoma cell line.  This also 
correlated with a faster rebound in ERK1/2 phosphorylation in the thyroid and colorectal cancer cell 
lines, likely due to the ability of activated Ras to more quickly drive reactivation of the MAPK 
pathway through B-Raf and c-Raf dimerization 42.  
Multiple growth factor receptors have also been demonstrated to become activated in 
response to inhibition of the MAPK pathway and release of feedback inhibition, which thus 
confounds our ability to predict which growth factor receptors should be targeted in relation to 
MAPK pathway inhibition 42,62.  In addition, higher levels of growth factor receptor activation at 
baseline in thyroid cancers further poses complications for therapeutic efficacy of targeting the 
MAPK pathway 42.  Since many growth factor receptors have been demonstrated to signal through 
Src, many labs have hypothesized that Src represents a promising therapeutic target 63.  In support 
of this, Src activation has been demonstrated to increase in response to prolonged inhibition of the 
MAPK pathway in BRAF-mutant melanoma, resulting in enhanced therapeutic efficacy when 
targeting both the MAPK pathway and Src 64. Therefore, Src represents a promising therapeutic 
target in tumors harboring activating mutations in the MAPK pathway that are unresponsive to 
MAPK pathway inhibitors.   
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Src Family Kinases 
Regulation and Structure of Src Family Kinases 
Src has consistently remained a focal point throughout the history of cancer biology.  In 
1978, Drs. Brugge and Erikson discovered Src as the transforming element of the Rous sarcoma 
virus, and later, identified by Drs. Collett and Erikson, as the first protein tyrosine kinase, launching 
the search for additional protein kinases  65. The Src family Kinases (SFKs), are a family of nine non-
receptor tyrosine kinases that include: c-Src, Fyn, Lyn, Yes, Blk, Lck, Hck, and Yrk. Of the 9 SFKs, c-Src, 
Fyn, and Yes are ubiquitously expressed in mammals.  SFKs are structurally very similar apart from a 
unique domain that links the catalytic, SH3 and SH2, domains to the membrane anchoring SH4 
domain (Figure 1.7a).  Despite the lack of similarity in the unique domain across different SFKs, this 
domain is relatively conserved across species, which suggests that it plays a large role in regulation 
of the individual SFKs 66.  Mouse models in which a single SFK family members have been deleted, 
has shed light on the differential roles of the individual SFKs in the regulation of normal physiology. 
Loss of c-Src results in osteopetrosis, which results from an increase in osteoclast number and 
increased bone formation 67. c-Src knockout mice are viable, however survival is greatly reduced 
after weaning 67.  In addition, knockout models have demonstrated roles for Lyn, Fgr, Hck, Blk, and 
Lck, in the development and function of Leukocytes, with loss of Lyn mediating B-cell function, loss 
of Fgr mediating eosinophil recruitment, loss of Hck impairing macrophage function, and loss of Blk 
and Lck blocking T-cell development 67,68. Lastly, loss of Fyn has been demonstrated to play 
important roles in neuronal development 67,68.  In addition, SFKs have been demonstrated to 
regulate a number of pro-tumorigenic pathways, as well as integrating and mediating signaling from 
a number of growth factor receptors 63,69.  Due to the sequence similarity of the SFKs, the primary 
phosphorylation sites are typically referred to by the amino acid sequence of c-Src, with Y419 










Figure 1.7. Src structure: active and inactive conformations.  A.) Src structural domains. B.) 
Phosphorylation of Src at the Y527 site promotes the closed inactive conformation.  C.) 
Dephosphorylation of Y527 and phosphorylation at the Y416 site promotes an open and active 
o fo atio . Adapted f o  Tatos a  et al. Ki ases of the “  fa il : st u tu e a d fu tio s.  
Biochemistry (2000). 
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for humans. In addition, early identification of viral-Src from the Rous Sarcoma Virus led to the early 
literature reporting results based on the chicken amino acid sequence in which Y416 and Y527 
represent the activation and inhibitory phosphorylation sites, respectively 70. At this point going 
forward, SFKs will be referred to as Src, and cellular Src will be referred to as c-Src. Growth Factor 
Receptor phosphorylation of Src at the Y419 activation site results in an open and active 
conformation (Figure 1.7c).  Upon activation, Src can mediate the activation of a number of 
pathways including the STAT3/MYC, RAS/MAPK, PI3K, FAK, and P190 Rho-GAP, which results in 
increased growth, invasion, and migration (Figure 1.8). Removal of Tyr 419 phosphorylation by PTP-
BAS as well as phosphorylation of Src by the negative regulator, C-terminal Src Kinase (CSK), at 
Tyrosine 530, promotes the binding of the SH2 domain and a closed conformation of Src (Figure 
1.7b) 71. CSK inactivation in mice leads to an overactivation of Src in cell lines, and due to a role for 
Src regulation in normal development, homozygous deletion of CSK, in mice, results in embryonic 
lethality 72. Tyr 530 phosphorylation can be removed by the PTP1B, Shp1, and/or Shp2 phosphatase 
promoting activation 70,73.  
Role of Src Family Kinases in Tumorigenesis 
Interestingly, Src is neither mutated nor amplified in many cancers, however it plays a key 
role in mediating oncogenic signals, and has been demonstrated to be an important driver in many 
tumor types 63, including thyroid and colorectal cancer 69,74–76.  Consistent with its tumorigenic role in 
many different tumors, Src has been demonstrated to regulate numerous hallmarks of cancer 
including: promoting invasion and metastasis, sustaining proliferative signaling, evading growth 




Invasion and Metastasis  
Due to “ s i te a tio  ith i teg i s a d Fo al Adhesio  Ki ase FAK , a significant 
e phasis has ee  pla ed o  u de sta di g “ s ole i  ediati g i asio  a d ig atio . Integrins 
are transmembrane adhesion receptors that link the extracellular matrix (ECM) to the actin 
cytoskeleton, and interact with numerous cell signaling molecules 78.  The cytoplas i  tail of β  
integrins have been demonstrated to interact with the SH3 domain of Src, where Src appears to play 
an important role in mediating a weakening of the interactions between ECM, integrins, and the 
actin cytoskeleton, to induce adhesion turnover and cell migration 79,80.  In addition, Src binds to the 
autophosphorylation, Y397, site on FAK and promotes further phosphorylation of FAK at Y576 and 
577 to increase catalytic activity, as well as phosphorylation of Y861 and Y925 to create downstream 
effector binding sites 81.  This se tio  o  “ s ole i  i asio  as added fo  o plete ess, however 
the majority of the work presented in this thesis will focus on the growth and survival mechanisms 
mediated by Src.  
Sustaining Proliferative Signaling, Evasion of Growth Suppressors, and Resisting Cell Death 
Src Regulation of RTKs - Src family kinases have been demonstrated to interact with many 
RTKs including: PDGFR, EGFR, ERBB2, FGFR, IGF1R, HGFR, CSF1R, SCFR, c-MET, as well as others 70,82.  
The Src homology 2 (SH2) domain of Src has been demonstrated to interact with tyrosine 
phosphorylation sites on RTKs, and this association is thought to release the intramolecular 
autoinhibitory interaction of the SH2 domain and the C-terminal tail, which allows Src to adopt an 
active conformation 82.  This association has been demonstrated to be important for the activation 
of pathways downstream of RTKs, as well as Src mediated RTK regulation through phosphorylation 
65. Interestingly, in normal Rat alveolar cells, it was demonstrated that the thyroid hormone, T3, 
promotes activation of Src, ERK1/2, and AKT, and that inhibition of Src, but not ERK1/2 or AKT, can 
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effectively decrease the increased phosphorylation of both ERK1/2 and AKT 83. In addition, Src was 
also demonstrated to regulate MAPK and PI3K pathway activation downstream of activated PDGFR 
in mesangial cells 84. Taken together, these data support a role for Src in directly mediating 
activation of both the MAPK pathway and the PI3K pathway in normal cellular biology, which 
represent two major pathways that are also important regulators of cancer cell growth and survival. 
Src Regulation of the MAPK Pathway - phosphorylation of FAK at Y925 is Src-dependent, and 
has been demonstrated to promote Grb2 binding, which further promotes Ras activation and 
subsequent activation of the MAPK pathway 85. In addition, Src has also been demonstrated to 
phosphorylate Ras at Y32 86.  Phosphorylation of Ras at Y32 promotes the dissociation of Ras and Raf 
and results in an increase in the GTPase activity of Ras 86. Thus it has been hypothesized that 
activation of Src has the potential to downregulate Ras activity. However, intriguingly Src has been 
demonstrated to promote much higher levels of tyrosyl phosphorylation on wild type Ras in 
comparison to the mutant G12D Ras, which suggests that Src phosphorylation of wild type Ras could 
potentially allow for increased tumorigenesis mediated by oncogenic Ras 86. In support of this 
hypothesis, it was recently demonstrated that wild type H-Ras can suppress the early stages of 
tumorigenesis in a KRASG12D model of pancreatic cancer 87. Src-mediated phosphorylation of Ras 
promotes Shp2 recruitment, and subsequent dephosphorylation of Ras by Shp2 promotes 
interaction between Ras and Raf 88.  Lastly, the N-terminal acidic motifs of C-Raf and A-Raf contain 
two tyrosine phosphorylation sites, and Src plays a role in the phosphorylation of these sites when 
these proteins are recruited to the plasma membrane, whereas these amino acids in B-Raf are 
already acidic aspartic acid residues and do not require phosphorylation 38.  
Src Regulation of the PI3K Pathway – The PI3K pathway is a key pathway in mediating cell 
cycle, cell survival, and metabolism through nutrient sensing, and Src has been demonstrated to 
activate the PI3K pathway through numerous mechanisms.  One mechanism is through the direct 
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phosphorylation of AKT at Y315 and Y326, or phosphorylation of p85 at Y688.  Specifically, tyrosine 
phosphorylation of AKT at Y315 and Y326 has been demonstrated to increase the kinase activity of 
AKT, and tyrosine phosphorylation of p85 at Y688 can relieve its inhibitory activity against the p110 
subunit, promoting increased catalytic activity 89,90.  Interestingly, the Y315 and Y326 sites on AKT 
have also been demonstrated to be phosphorylated by PTK6, suggesting that multiple mechanisms 
exist to modulate phosphorylation at these sites 91.  Src has also been demonstrated to regulate the 
PI3K pathway through phosphorylation of the tumor suppressor PTEN, which results in an inhibition 
of PTEN association with the plasma membrane, and a decreased ability of PTEN to dephosphorylate 
the  positio  of Phosphatidylinositol (3,4,5)-trisphosphate 92. Lastly, Src can regulate activation of 
the PI3K pathway through the promotion of increased p130Cas phosphorylation. Phosphorylation of 
p130Cas promotes an increased association between p130Cas and the p85 regulatory subunit of 
PI3K 93. Src can both directly and indirectly lead to increased p130Cas phosphorylation, as Src 
directly phosphorylates p130Cas at Y128, and indirectly through Src phosphorylation of Paxillin at 
Y88, which promotes p130Cas phosphorylation at Y165 94,95.    
Src regulation of the JAK-STAT Pathway – Src has previously been demonstrated to regulate 
cell survival through its interaction with signal transducer and activator of transcription (STAT) 
family members 96.  In both head and neck squamous cell carcinoma and non-small cell lung cancer, 
Src has been demonstrated to signal through STAT3. However, an issue arises from attempting to 
target Stat activation with Src inhibitors, as upon inhibition of Src, there is an initial reduction in 
STAT phosphorylation that quickly recovers, leading to resistance 97,98. These results will therefore 











Figure 1.8:  Src signaling pathways. Src can be activated by a number of growth factor 
receptors and can function in multiple tumorigenic signaling pathways promoting 
growth, invasion, migration, and survival. Adapted fro  ‘oskoski “  p otei -tyrosine 
kinase structure, mechanism, and small molecule inhibitors  Pharmacological 
Research (2015). 
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Src Family Kinases in Thyroid Cancer 
In response to the limited therapeutic efficacy against therapies targeting the MAPK 
pathway, our group and others have recently identified Src as a novel oncogenic driver in thyroid 
cancer 99–103.  In addition, reports have also confirmed expression and activation of the downstream 
effector of Src, FAK, in which FAK expression was observed in patient tumor samples, but was not 
observed in thyroid normal tissue 104.  Furthermore, FAK mRNA expression has been correlated with 
thyroid cancers exhibiting more aggressive phenotypes 105. Consistent with previous reports 
suggesting that Src is rarely mutated in cancer, sequencing efforts in thyroid cancer have also 
observed no Src mutations present in either papillary, poorly differentiated, or anaplastic thyroid 
cancer 18,19. The Schweppe lab was the first to demonstrate that Src is active in a number of papillary 
and anaplastic thyroid cancer cell lines, and that there is an increase in phosphorylation of the Src-
dependent FAK phosphorylation site in papillary thyroid cancer tissue 101. In addition, the Schweppe 
lab also identified c-Src and Lyn as the most prominent Src family kinase members expressed in 
thyroid cancer cell lines 100.  Many labs, including ours, have since demonstrated that targeted 
inhibition of Src in thyroid cancer results in the inhibition of growth, invasion, migration, and survival 
99,100,103. In addition, many recent publications have demonstrated that combined inhibition of Src 
and the MAPK pathway results in enhanced inhibition of growth 102,103,106, which our data suggests is 
due to an increased reliance on the MAPK pathway in response to prolonged Src inhibiton 106.  In 
addition, BRAFV600E syngeneic mouse thyroid tumor xenograft studies have demonstrated an 
increase in immune cell infiltration upon inhibition of the MAPK pathway with the B-Raf inhibitor 
PLX4720, which is further elevated with combined B-Raf and Src inhibition 102.  It is therefore 
interesting to speculate whether there may be an added benefit to combined Src and MAPK 
pathway inhibition, through the elimination of the cancer cells mediated by an influx of immune 
cells.  Finally, recent development of an inhibitor that targets both B-Raf and Src could have 
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important therapeutic benefits in thyroid cancer.  Briefly, these inhibitors were developed based on 
previous reports identifying a role for Src signaling in the promotion of resistance to B-Raf inhibition 
in melanoma 107, and importantly these inhibitors effectively inhibit the growth and survival of cells 
resistant to B-Raf inhibition 64. 
Efficacy of Src Family Kinase Inhibitors in the Clinic 
Due to “ s large role in tumorigenesis, many inhibitors have been developed to target this 
family of kinases.  In addition, due to the similarity of the ATP-binding pockets between Src and ABL, 
many type I inhibitors developed to target BCR-ABL also target Src 108.  There are currently four FDA 
approved Src inhibitors which include: dasatinib, bosutinib, ponatinib, and vandetinib 70.  With the 
exception of vandetanib, these inhibitors are clinically approved for the treatment of hematological 
malignancies, as they have increased efficacy in comparison to the first generation (type II) BCR-Abl 
inhibitor, imatinib 108. In addition to being potent inhibitors of Src and Abl, dasatinib and bosutinib 
are also potent inhibitors of the Ephrin family of proteins, EGFR, and DDR2. Interestingly dasatinib 
and bosutinib also have distinct targets, as dasatinib is a potent inhibitor of c-Kit, PDGFR, DDR1, 
while bosutinib is a more effective inhibitor against c-Mer, Axl, VEGFR, MAP2K1 109,110. In addition, 
ponatinib has increased efficacy against VEGFR, PDGFR, c-Kit, and FGFR, whereas vandetinib, which 
is approved for medullary thyroid cancer, has increased efficacy against RET, EGFR, VEGFR, and 
Ephrins 70. Since the majority of the studies in this thesis will focus on the Src inhibitor, dasatinib, 
this inhibitor will be expanded upon in more detail. 
Dasatinib is FDA approved for the treatment of CML, as it was demonstrated to have 
increased efficacy over the BCR-ABL specific inhibitor, imatinib, and is able to overcome many 
mutations that disrupt the binding of imatinib 108. Unfortunately, dasatinib has not been nearly as 
successful in the treatment of solid tumors, which is potentially due to the increased mutational 
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burden, and role of the microenvironment in solid tumors in comparison to CML.  To date clinically, 
dasatinib has been tested in breast cancer, lung cancer, colorectal cancer, prostate cancer, head and 
neck squamous cell carcinoma, and ovarian cancer, and unfortunately has not performed as well as 
expected based on preclinical data as a single agent 111–116.  One potential explanation for a lack of 
efficacy to Src inhibitor therapies could be due to ineffective inhibition of Src, as a clinical trial in 
breast cancer demonstrated average reductions in Src and FAK phosphorylation were only around 
20% after 4 weeks of therapy 117. 
 Despite the discouraging clinical data, there have also been some promising indications for 
the success of Src inhibitors in solid tumors.  As a phase II study of single agent dasatinib in 
metastatic castrate resistant prostate cancer (in which 87% of the patients had bone metastasis) 
resulted in 43% of patients exhibiting stable disease at 12 weeks, and 19% of patients exhibiting 
disease stability at 24 weeks 115. These results are not entirely surprising, as Src has been known to 
play a role in osteoclast activity, as well as being a downstream activator of survival signals in 
response to CXCL12 and TRAIL which are expressed in the bone metastatic microenvironment 118,119. 
Furthermore, disruption of Src activity has been demonstrated to promote osteopetrosis due to a 
disruption in osteoblast and osteoclast function, therefore suggesting that the bone 
microenvironment may more effectively support the outgrowth of disseminated Src driven cancer 
cells 67. 
In addition, a surprising discovery in non-small cell lung cancer (NSCLC) identified one 
patient that exhibited a complete response to dasatinib therapy 113.  This patient was later identified 
as having a kinase impaired BRAF mutation, which promotes dimerization of BRAF with CRAF and 
activation of the MAPK pathway 120.  
Taken together, these data highlight a need to better understand the role of Src in 
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tumorigenesis, and mechanisms of resistance to Src inhibition so that we can more effectively target 
Src in the clinic. 
Resistance Mechanisms to Targeted Therapies 
In the field of microbiology, it has been well documented that anti-microbials are unable to 
kill off the entire population of microorganisms, but rather a population of drug tolerant cells 
persist. Building off of the knowledge of anti-microbials, a similar hypothesis was developed in 
regards to cancer cell resistance in which a small subset of drug tolerant persisters survive therapy 
121. This persistence has been rationalized through the discovery of multiple mechanisms of 
resistance that can arise in response to targeted therapeutics. The most common mechanisms for 
drug resistance in cancer cells include: mutation of the drug binding site, bypass pathways, 
phenotype switching, and inhibitor evasion through drug efflux, drug metabolism, and gene 
amplification 121,122 (Figure 1.9 a-d). In addition to acquiring these mechanisms of resistance, these 
mechanisms can also be present in the original tumor giving rise to intrinsic resistance (Figure 1.9 e).   
Mutation of the Drug Binding Site (Gatekeeper Mutations) (Figure 1.9a) 
 The ATP binding pocket of many tyrosine kinases contains a hydrophobic spine, and these 
residues form a chain of hydrophobic interactions, which connect the active site and the activation 
loop, when the kinase is in an active conformation. Situated near the hydrophobic spine is a 
hydrophilic threonine residue. Mutation of this residue to a bulkier, more hydrophobic residue, such 
as isoleucine or methionine (Fig. 1.10), results in an increase in stability of the hydrophobic spine, 
which is characteristic of the active conformation and promotes an increase in kinase activity 123. 
The threonine residue, also termed the gatekeeper residue, is also important for the binding of 
many type I tyrosine kinase inhibitors, however it is not necessary for the binding of ATP 123. 
Mutation of the gatekeeper residue disrupts the binding of many tyrosine kinase inhibitors through 
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Figure 1.9: Mechanisms of resistance. A. Mutation of the drug binding site. B. Bypass pathways. 
C. Phenotype switching from a differentiated to undifferentitated state upon inhibitor 
treatment. D. Inhibitor evasion through drug efflux, drug metabolism, and gene amplification. E. 
Intrinsic resistance – cells highlighted in red are sensitive and cells highlighted in yellow 
ep ese t i hi ito  esista t ells that su i e the ap . Adapted f o  Gli k a  et al Converting 
cancer therapies into cures: lessons from infectious diseases.  Cell (2012), and Kemper et al 
Phenotype switching: Tumor cell plasticity as a resistance mechanism and target for therapy.  
Cancer Res (2014). 
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a loss of inhibitor-kinase hydrogen bonding, and from steric hindrance due to an inflexibility in a 
phenyl ring attached to the inhibitor 124. Therefore the development of inhibitors that are not reliant 
on the gatekeeper residue, or have increased flexibility, have the potential to overcome resistance 
mediated by this mutation 123,124. This type of drug resistance mechanism was first discovered in 
BCR-ABL positive CML, in which upon treatment with the BCR-ABL inhibitor, imatinib, a drug 
resistant population grew out that contained a T338I gatekeeper mutation 125. Interestingly, 
gatekeeper mutations have also been observed in c-Kit (Thr670) and platelet derived growth factor 
receptor-α PDGF‘A  Th  i  espo se to imatinib in gastrointestinal stromal tumor (GIST) and 
hypereosinophilic syndrome (HES), respectively 123,126.  As kinase inhibitors can often target multiple 
kinases, these findings demonstrate a selection process, in which gatekeeper mutations are selected 
for based on an increased dependence for that particular protein in mediating tumorigenesis. In 
accordance with this, resistance to treatment with the Src inhibitor, dasatinib, has been 
demonstrated to select for gatekeeper mutations in c-Src, Abl, DDR2, c-Kit, and PDGFR 123,127–129.  
Gatekeeper mutations have also been demonstrated to arise from both EGFR and ALK inhibition in 
lung cancer, in response to gefitinib/erlotinib and crizotinib treatment, respectively 130,131. In both 
lung cancer and CML it has been demonstrated that a small subset of cells harbor the gatekeeper 
mutation prior to treatment, and that upon treatment, the outgrowth of these clones is selected for 
132,133. However, it was also demonstrated by Hata et al in EGFR-mutant NSCLC that gatekeeper 
mutant cells can either pre-exist or evolve from drug tolerant cells 134. Interestingly, these authors 
also discovered that prolonged periods of reprogramming prior to the acquisition of the gatekeeper 
for the complex heterogeneity observed in patients in response to targeted therapy and the 














Figure 1.10: Amino acid substitutions of the gatekeeper threonine residue.  The gatekeeper 
threonine residue can be mutated to isoleucine or methionine to promote resistance to type I 
tyrosine kinase inhibitors.  Preference for acquisition of either isoleucine or methionine is 
primarily dependent on the codon composition of threonine, and the substitution that requires 
the fewest number of mutations. 
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Bypass Pathways (Figure 1.9b) 
 Regardless of whether or not a cancer cell is highly reliant on a particular oncogenic driver, 
gatekeeper mutations are not always selected as the primary mechanism of resistance.  BRAF 
gatekeeper mutations are one example of this, as they are not selected for upon B-Raf inhibition 
even though BRAF gatekeeper mutations can increase resistance to B-Raf inhibition 136. Instead, 
activation of RTKs represent a common alternative mechanism of resistance that can bypass the 
inhibitory effects of the targeted therapeutic. A total of 58 receptor tyrosine kinases have been 
identified that contain similar structural organization with an extracellular ligand binding domain, a 
transmembrane helix, and a cytoplasmic tyrosine kinase domain 137. Many therapeutic studies 
targeting RTKs have also highlighted a role for activation of an alternative RTK in mediating 
resistance, with MET amplification and FGFR signaling promoting resistance to EGFR inhibition in 
lung cancer 138,139.  In addition, treatment with MAPK pathway inhibitors has shed light on a 
mechanism of release on negative feedback, which allows for activation of RTKs and promotion of 
bypass mechanisms 61.  One of the more characterized mechanisms is the release of feedback on 
RTKs when treating with a BRAFV600E inhibitor (Figure 1.11) 61,140,141.  The BRAFV600E inhibitors, 
vemurafenib and dabrafenib, through release on negative feedback, promote an increase in Ras 
activation which is likely facilitated through the downregulation of the dual specificity phosphatases 
(DUSPs) that dephosphorylate ERK, and the Sprouty proteins which, sequester Grb2 and decrease 
Ras activation 61.  It has been demonstrated that the downregulation of these negative regulators 
allows for growth factor receptor mediated activation of Ras leading to an increase in B-Raf and c-




BRAF and CRAF Dimerization 
Interestingly, due to the unique complexities of Raf regulation, inhibitors that target B-Raf 
not only promote a downregulation of the negative regulators of the MAPK pathway, but they also 
promote an increase in B-Raf and c-Raf dimerization, which allows for the reactivation of the MAPK 
pathway through c-Raf.  This e ha is  te ed pa ado i al a ti atio  results from the ability of 
the kinase inhibitor to stabilize a closed conformation of the kinase domain of B-Raf 142.  Kinase 
inactive or kinase dead B-Raf mutants have previously been demonstrated to increase their 
association with c-Raf, promoting a release of auto-inhibitory phosphorylation and activation of c- 
Raf 143,144.  B-Raf and c-Raf dimerization was originally discovered in RAS-mutant melanoma, as 
treatment of these cancers with the B-Raf inhibitor, vemurafenib, promoted a paradoxical 
reactivation of the pathway due to a promotion of B-Raf and c-Raf dimerization 145.  It was originally 
hypothesized that this only occurred in RAS- uta t tu o s, as it as t o se ed i  B‘AF-mutant 
tumors at early treatment timepoints 145. However, it was interestingly discovered later that B-Raf 
and c-Raf dimerization can also occur in BRAF-mutant tumors, as growth factor receptor mediated 
activation of Ras can promote dimerization and subsequent reactivation of the MAPK pathway 42,61. 
In addition, mutations in RAS as well as BRAF splice variants can promote a reactivation of the MAPK 
pathway through B-Raf and c-Raf dimerization, upon inhibition of the MAPK pathway 146.   
Pathway Crosstalk and Convergence 
 Pathway crosstalk can mediate an increase in signaling through activation of bypass 
pathways. The MAPK pathway and the PI3K pathway have both emerged as primary mediators of 
cell growth and survival, especially in the setting of oncogenesis.  Initially these pathways were 
thought to be independent signaling entities, however recent evidence has shed light on a large 











Figure 1.11. Release on negative feedback.  A.) Steady state ERK-mediated negative feedback 
promotes a downregulation of growth factor receptor signaling. B.) Inhibition of B-Raf results in a 
reduction in ERK activity and therefore a release of growth factor receptors from feedback 
inhibition. C.) As cells adapt to B-Raf inhibition a new steady state is acquired in which growth 
factor receptors reactivate the MAPK pathway through activation of Ras, which promotes B-Raf 
and c-Raf dimerization and c-Raf- ediated path a  a ti atio . Adapted f o  Lito et al. Relief of 
profound feedback inhibition of mitogenic signaling by Raf inhibitors attenuates their activity in 
BRAFV600E ela o as.  Cancer Cell (2012).  
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Cross Inhibition - A release of cross inhibition is a common mechanism for activation of an 
alternative pathway. Cross inhibition is the actions of one pathway on another in order to negatively 
regulate signaling.  Important for these studies, it has been frequently demonstrated that MEK1/2 
inhibition results in activation of the PI3K pathway, as ERK has been demonstrated to phosphorylate 
and negatively regulate GAB1, which is an important regulator of PI3K recruitment to growth factor 
receptors 148,149.  In addition, the PI3K pathway negatively regulates the MAPK pathway through AKT, 
which can phosphorylate and inhibit c-Raf. Phosphorylation of c-Raf in the N-terminus by AKT results 
in 14-3-3 sequestration 150,151.  Lastly, studies analyzing the effects of the mTORC1 inhibitor, 
rapamycin, identified a feedback loop stemming from mTORC1 that regulates IRS-1/PI3K activity.  
Release of feedback allows for increased IRS-1/PI3K signaling to both the RAS/MAPK and PI3K 
pathways, which results in an increase in both ERK1/2 and AKT phosphorylation 152.   
Cross Activation - Interestingly, cross activation can also occur, in which the actions of one 
pathway bolster the signaling of another pathway.  Important for these studies, Ras has been 
demonstrated to directly bind and activate the catalytic p110 subunit of PI3K, which enhances the 
activation of PI3K mediated by the binding of the SH2 domains of the p85 subunit to sites of tyrosine 
phosphorylation  153,154.  Interestingly, the MAPK pathway can also regulate mTORC1 in a PI3K 
independent manner, as both ERK and RSK have been demonstrated to phosphorylate and 
inactivate the GTPase-activating protein (GAP) function of the negative regulator of MTORC, TSC2, 
allowing for increased MTORC1 activity 155,156.  In addition, multiple serine residues on mTORC1 have 
been demonstrated to be directly phosphorylated by ERK and RSK. Importantly, the expression of 
mTORC1 mutant alleles, that are phospho-deficient at these sites, indicates that phosphorylation at 
these residues is important for the activation of downstream substrates of mTORC1.  
Nodes of Convergence (Fig. 1.13) – In addition, there are multiple nodes in which both the 






Figure 1.12: MAPK and PI3K crosstalk. Red lines with crosses represent an inhibitory 
phosphorylation that acts to downregulate the alternate pathway. Green lines with crosses 
represent inhibitory phosphorylation that acts to upregulate the alternate pathway. Green lines 
with arrows represent activating phosphorylation that acts to upregulate the alternate pathway. 
Adapted f o  Me doza et al. The ‘as-ERK and PI3K-mTOR pathways: Cross-talk and 









Figure 1.13: MAPK and PI3K pathway nodes of convergence.  Proteins labeled in purple, as 
well as S6, represent nodes of convergence between both the PI3K and MAPK pathway. Red 
lines represent phosphorylation sites that promote inhibition of the target protein, and green 
arrows represent phosphorylation sites that promote activation of the target protein. 
Adapted from Mendoza et al. The ‘as-ERK and PI3K-mTOR pathways: Cross-talk and 
o pe satio .  Trends Biochem Sci (2011). 
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inhibition of either of the two pathways, and can therefore lead to resistance.  Significant 
downstream targets include: the forkhead box O (FOXO) family members, c-myc, BCL2-associated 
agonist of cell death (BAD), and GSK3, which are important cell cycle and apoptotic effectors 147. In 
addition, and important for the data presented in this thesis, the MAPK and PI3K pathways also 
converge on rpS6, which is phosphorylated downstream of the MAPK pathway by p90 ribosomal S6 
kinase (RSK) at Y235/236, and phosphorylated downstream of the PI3K pathway by p70S6K at both 
the Y235/236 and Y240/244 phosphorylation sites 147. rpS6 is an important component of the 
translational machinery (ribosomes) within cells, as it resides near the interface of the large and 
small ribosomal subunits 157.  rpS6 has been demonstrated to interact with tRNA, initiation factors, 
and mRNA, and was the first component of the eukaryotic 40S ribosome to be identified as having 
post-translational modifications, which include the sequential phosphorylation of Ser236, Ser235, 
Ser240, Ser244, and Ser247 157,158. Thus, many labs hypothesized that phosphorylation of rpS6 would 
directly impact protein translation, however, phosphorylation was later determined to be 
unnecessary for translation, as rpS6P-/- mice, in which all five serine residues are mutated to alanine, 
exhibited a similar proportion of ribosomes associated in active translation (polysome formation) in 
the liver, as well as mouse embryo fibroblasts (MEFs) derived from these mice failing to exhibit a 
reduction in protein synthesis 159.  Instead, the development of rpS6P-/- mice, rather determined a 
role for rpS6 phosphorylation in the regulation of cell size, cell proliferation and glucose homeostasis 
159.  These results suggest that the phosphorylation of rpS6 mediates either extraribosomal or 
extratranslational effects in normal physiology. Consistent with this hypothesis, co-
immunoprecipitation studies have demonstrated that rpS6 can interact with numerous non-
ribosomal proteins including: heat shock protein 90 (HSP90), death-associated protein kinase 
(DAPK), huntingtin, and mechanistic target of rapamycin (mTOR) complex 2 (mTORC2). In addition, 
recent cancer studies have demonstrated a correlation with inhibition of rpS6 phosphorylation and 
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sensitivity to targeted therapies 160–162, as well as increased rpS6 phosphorylation correlating with 
poor clinical survival 163.  One of these studies was performed in thyroid cancer, analyzing the effects 
of targeted inhibition of MEK1/2, AKT, and/or mTOR in BRAF- or RAS-mutant thyroid cancer cell lines 
161.  Importantly, drug combinations that resulted in the largest growth inhibition correlated with 
their ability to reduce rpS6 phosphorylation 161.  Furthermore, a study analyzing the effects of HER 
family kinase inhibitors in combination with PI3K inhibitors in bladder and head and neck squamous 
cell carcinoma (HNSCC) cell lines also found that an inhibition of rpS6 phophorylation correlated 
with increased sensitivity to the combination therapy 160. Interestingly, this study also found that a 
reduction in P70S6K-mediated rpS6 phosphorylation is a critical node in mediating the cytotoxic 
effects of the combination therapy, as expression of a constitutively active P70S6K construct was 
able to mediate resistance to the combination therapy 160.  Taken together these studies suggest an 
important role for rpS6 in mediating tumorigenesis and therefore it is important to further define 
the role of rpS6 in mediating thyroid tumorigenesis, as it could represent a viable target of interest 
for future therapeutic development. 
Phenotype Switching (Figure 1.9c) 
A switch to a more invasive phenotype and induction of an epithelial mesenchymal 
transition (EMT) has emerged as a relatively new alternative mechanism of resistance to targeted 
therapy 122. Two hypotheses exist for the emergence of this drug resistant state, with the first 
supporting the idea of a subpopulation of slowly proliferating, mesenchymal, cancer stem cell-like 
cells that grow out upon treatment, and the second supports the idea that the cells can upregulate 
EMT programs to switch towards a more mesenchymal state to drive resistance to therapy. 
Selection for an already present subpopulation of cells represents an intrinsic mechanism of 
resistance, whereas a transition towards a more mesenchymal state represents an acquired 
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mechanism likely mediated by transcriptome reprogramming. As an example, it has been well 
established that adaptive reprogramming 
mechanisms can allow for increased transcription of factors mediating resistance to targeted 
therapies, including upregulation of MET and FGFR in response to EGFR targeted therapies 138,164, 
and upregulation of HER family kinases in response to MAPK pathway inhibitors 42,61,62.  These 
studies are further supported by recent evidence identifying activation of histone modifying 
enzymes as primary mediators of these transitions, and that preventing histone modifications 
through targeted inhibition has the ability to prevent these resistance mechanisms from occurring 
165,166.  Interestingly, an observation was made in EGFR mutant NSCLC that a patie t s tu o  iops  
contained a subpopulation of mesenchymal tumor cells that gave rise to the population of cells that 
made up the resistant tumors.  Importantly, this population exhibited enhanced sensitivity to the Src 
inhibitor, dasatinib 167. This data further highlights a role for Src in mediating growth factor receptor 
signaling, and supports a role for Src/FAK in mediating survival in the mesenchymal subpopulations. 
Lastly, these mechanisms are typically reversible mechanisms of drug resistance, as removal of the 
inhibitors allows the cells to rewire to their original state. Along these lines, it was demonstrated 
that discontinuous dosing of the B-Raf inhibitor, vemurafenib, delayed resistance from occurring in 
PDX models of BRAFV600E mutant melanoma 168.   
Drug Evasion (Figure 1.9d) 
In addition to the mechanisms highlighted above, there are additional mechanisms in which 
cancer cells can decrease the efficacy of inhibitors without mutating the drug binding site on the 
intended target.  Two mechanisms that decrease the efficacy of inhibitors are through increased 
drug efflux and amplification of the target oncogene.  Both of these mechanisms require increased 
concentrations of inhibitors in order to effectively inhibit the intended targets, and often times the 
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levels needed to achieve complete inhibition are not feasible due to toxicity associated with the 
inhibitors. Several transporter proteins have been associated with drug resistance through their 
abilities to efflux inhibitors. In total, there are 49 members in the ATP-binding cassette (ABC) 
transporter family, however only three have been thoroughly studied in relation to drug resistance 
169. These include the multi-drug resistance protein 1 (MDR1 or ABCB1), MDR-associated protein 1 
(MRP1 or ABCC1), and breast cancer resistance protein (BCRP or ABCG2) 169. Interestingly, higher 
levels of drug efflux proteins have been associated with cancer stem cells, which may additionally 
correlate with phenotype switching mechanisms of resistance 170.  In addition, amplification of the 
target oncogene can have a similar effect to drug efflux, where it is difficult to obtain sufficient 
levels of inhibitors to efficiently inhibit the target protein. Importantly, amplification of the driving 
oncogene has been demonstrated to drive resistance to MEK inhibition in BRAF or KRAS mutant 
colorectal cancer cell lines 171,172.  Lastly, metabolism of the inhibitor can result in the drug no longer 
being able to bind to the intended target.  Cytochrome P450s (CYPs) are the primary enzymes 
responsible for metabolism of inhibitors, and CYP3A4 is the primary CYP responsible for the 
metabolism of multiple tyrosine kinase inhibitors including: the Src inhibitor, dasatinib, and the 
EGFR inhibitor, erlotinib 173,174.      
Mechanisms of Resistance to Src Family Kinase Inhibitors 
 Despite promising preclinical data for the use of Src inhibitors, the clinical responses have 
not correlated.  Thus many groups have attempted to uncover methods to render Src inhibitors 
more effective. One of these methods is through defining mRNA signatures that may better predict 
and stratify patients that will and will not respond to Src inhibition 175–177. Along these lines, three 
signatures were determined and published in breast cancer, however when tested, clinically, no 
significant increases in sensitivity were observed when patients were stratified based on any of the 
three signatures 178, suggesting it may be more important to determine signatures at the protein 
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level.  Multiple studies have demonstrated that elevated levels of growth factor signaling can 
mediate resistance to Src inhibition. In head and neck squamous cell carcinoma cell lines it was 
demonstrated that Src regulates c-MET signaling in sensitive cell lines, however the regulation of c-
MET by Src was decoupled in the resistant cell lines.  Consistent with this, inhibition of Src in the 
sensitive cell lines decreased c-MET activity, but not in the resistant cell lines 179. In addition, a study 
in prostate cancer demonstrated that IGF1R can mediate resistance to Src inhibition through Src 
independent activation of the PI3K pathway.  Specifically, this study found that AKT1 activation was 
mediated by Src and AKT2 activation was mediated by IGF1R, and therefore combined inhibition of 
both Src and IGF1R was necessary to completely inhibit both AKT1 and AKT2, and promote effective 
inhibition of growth and an increase in apoptosis 180.  Lastly, a study in lung cancer identified 
another role for IGF signaling, albeit utilizing a slightly different mechanism. This study discovered 
that overexpression of the IGFBP2 resulted in an increased resistance to dasatinib, which is due to 
its increased ability to promote autocrine and paracrine effects through IGF1R and integrins.  The 
authors also demonstrated that the increased binding of IGFBP2 to integrins promoted an increase 
in FAK activation, which could be partially overcome using a FAK inhibitor 181. 
Growth factor receptor activation can also promote increased B-Raf and c-Raf dimerization 
through an increase in Ras activation. Along these lines, it has previously been demonstrated that 
the Src inhibitor, dasatinib, has off-target effects against B-Raf, and can drive paradoxical activation 
of the MAPK pathway through the promotion of B-Raf and c-Raf dimerization 182.  In these studies it 
was determined that the increase in dimerization is dependent on Ras activation, and that activation 
of the MAPK pathway can be harnessed to impart synthetic lethality when an inhibitor that drives 
dimerization is paired with a MEK1/2 inhibitor 182. 
 As alluded to in the previous section, Src has been shown to regulate the activation of STAT3 
in HNSCC and NSCLC, however upon inhibition of Src, there is a quick recovery in STAT3 activity 
43 
within 7 hours.  This recovery was demonstrated to be dependent on increased JAK activity and 
increased JAK-STAT3 binding.  Furthermore combined inhibition of Src and JAK-STAT resulted in an 
increase in cell cycle arrest and apoptosis 97,98. This was also demonstrated by Lee and colleagues as 
a response to cell stress, in which the stressed/dying cells secrete factors that mediate autocrine 
survival signaling 183.  In addition, they hypothesized that some cells may be more primed to quickly 
activate STAT3 in order to evade cell death, and that lung cancers with higher levels of STAT3 
regulated genes are associated with poor prognosis 183.  Taken together this data supports a role for 
STAT3 in mediating the early survival of drug tolerant persisters, upon inhibition of Src or other 
oncogenic drivers. 
 Lastly, mutation of the c-SRC gatekeeper residue has also been previously demonstrated to 
mediate resistance to Src inhibition, as the hydrophilic gatekeeper threonine residue facilitates the 
binding of type I Src inhibitors.  It has been demonstrated that mutation of the gatekeeper residue 
to a hydrophobic residue, such as isoleucine or methionine, results in activation through increased 
interactions of the hydrophobic spine, which resembles the active state of the kinase 123.  
Interestingly, methionine can promote an increase in activity in comparison to isoleucine.  
Substitution of the gatekeeper residue for lysine or proline introduces a positive charge, and a kink 
in the hydrophobic backbone reducing the activity and inactivating the kinase, respectively 123. 
Thesis Direction and Summary 
 The use of targeted therapies has been fueled by substantial increases in tumor responses 
and progression free survival, especially in regards to the BCR-ABL inhibitor, imatinib, in chronic 
myelogenous leukemia, the BRAF inhibitor, vemurafenib, in melanoma, and the EGFR inhibitor, 
gefitinib, in lung cancer.  However, even some of the most profound responses observed with 
targeted therapies remain, unfortunately, transient 184. This dilemma has propelled many research 
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efforts to define mechanisms of resistance, which aim to provide the framework for more effectively 
developing secondary inhibitors and combination therapy approaches. For Src inhibitors, the 
responses have not been as a robust as would have been predicted based on preclinical data, and 
therefore it is vital that we understand how to more effectively target Src, clinically.  In response, in 
Chapter III, I will provide evidence that defines a role for the MAPK pathway in mediating resistance 
to Src inhibition in thyroid cancer.  This work will also demonstrate, that both cells that had acquired 
a secondary mutation to generate a drug resistant c-Src protein, as well as cells that did not 
exhibited a reprogramming towards an increased dependence on the MAPK pathway.  This is likely 
based on data demonstrating that the MAPK pathway is activated as an early mechanism of 
resistance in response to Src inhibition.  Along these lines, combined upfront inhibition of Src and 
the MAPK pathway results in a decrease in growth and an increase in cell death in vitro, and a 
decrease in growth and an increased overall survival in vivo. In chapter IV, I will demonstrate that a 
potential mechanism driving the synergy observed with the combined inhibition of Src and the 
MAPK pathway appears to be a result of “ s a ilit  to egulate a ti atio  of the PI K path a  i  
BRAF- and RAS-mutant cell lines. In addition, I will demonstrate that rpS6 phosphorylation status 
represents a potential biomarker of response highlighting the ability of the inhibitors to effectively 
inhibit both the MAPK and Src/PI3K pathways.  Additional data in support of these findings suggests 
that rpS6 phosphorylation status may represent an important indicator of response in other tumor 
types apart from thyroid.  In addition, the identification of biomarkers indicating a lack of 
responsiveness to targeted therapies will provide the groundwork for the future elucidation and 
identification of drug tolerant persister cells and the mechanisms that drive their resistance. Taken 
together, the work included in this thesis highlights important signaling mechanisms that mediate 
resistance to Src inhibition and important clinical biomarkers that should be analyzed when 
monitoring patients treated with combined Src and MAPK pathway inhibitors.  These findings aim to 
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ultimately improve clinical responses and the overall survival for patients with poorly differentiated 




























MATERIALS AND METHODS 
Reagents 
  For the drug screening assays, selumetinib (AZD6244), SCH772984, AT7867, and Everolimus 
were purchased from SelleckChem, trametinib (GSK-1120212) was purchased from LC laboratories 
or SelleckChem, and dasatinib (BMS-354825) was purchased from LC laboratories for the studies 
presented in Chapter IV, and generously provided by Bristol-Meyers Squibb for the studies 
presented in Chapter III. The drugs were dissolved in dimethyl sulfoxide. For in vivo studies, 
dasatinib was dissolved in 80mmol/L sodium citrate buffer, pH3.0 and trametinib (SelleckChem) was 
dissolved in 0.5% hydroxypropylenemethylcellulose (Sigma) and 0.2% Tween-80 in distilled water 
(pH 8.0). 
Cell Culture 
  Human thyroid cancer cell lines C643, SW1736, BCPAP, T238, THJ16T, 8505C, and Cal62 
were grown in RPMI (Invitrogen, Carlsbad, CA) supplemented with 5% FBS (HyClone Laboratories, 
Logan, UT), and the A375 cell line was grown in DMEM and supplemented with 10% FBS.  All lines 
were maintained at 37°C in 5% CO2.  All cell lines were validated using short tandem repeat profiling 
using the Applied Biosystems Identifier kit (#4322288) in the Barbara Davis Center BioResources 
Core Facility, Molecular Biology Unit, at the University of Colorado, as previously described 185. The 
SW1736 and C643 cells were generously provided by Dr. K. Ain (University of Kentucky, Lexington, 
KY), with permission from Dr. N.E. Heldin (University Hospital, Uppsala, Sweden). The BCPAP, 8505C, 
and Cal62 cells were generously provided  D . M. “a to o Medi al “ hool, U i e sit  Fede i o II  
of Naples, Naples, Italy).  The THJ16T cells were generously provided by J.A. Copland (Mayo Clinic 
Comprehensive Cancer Center, Jacksonville, FL). All cell lines were routinely monitored for 
Mycoplasma contamination using the Lonza Mycoalert system (Lonza Walkersville, Inc., 
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Walke s ille, MD , a o di g to the a ufa tu e s di e tio s. For the generation of dasatinib 
resistant cell lines, cell lines were cultured in gradually increasing concentrations of dasatinib 
starting at 50nM, or in DMSO vehicle control alongside, for a period of nine months (20-45 
passages).  The dasatinib concentration was increased when cell confluency reached 70-80%.  
Dasatinib resistance was measured monthly by sulforhodamine B (SRB) growth assays, as previously 
described 100.  Cells e e the  ai tai ed as a hete oge eous populatio  a d i  μM dasati i  o e 
they reached a resistant state.  DasRes cells were also authenticated by STR profiling, as described 
above. 
Sanger Sequencing 
  Sequencing was performed on gDNA.  gDNA was collected using the Quick-gDNA MiniPrep 
kit (Zymo Research) and amplified using exon 9 specific primers for the c-SRC gatekeeper region.  
Exon 9 was sequenced using the forward primer c-“  -CAGGAGGCCCAGGTCATG-  a d e e se 
p i e  -ATCTGAGCAGCCATGTCCAC-  at the U i e sit  of Colo ado, Department of Pathology 
DNA Sequencing core. 
RNA Sequencing 
 mRNA sequencing was performed at the University of Colorado Cancer Center (UCCC) 
Genomics and Microarray Core on the HiSeq2000 (single read 100 cycles).  On average, 70 million 
reads (53.5 - 93 million) per sample were obtained, with an average mapping of 98% (97.2-98.8%) to 
the hg19 reference genome using the tophat/cufflinks workflow as previously described 186. To 
determine the enriched pathways between the control and DasRes cell lines, fragments per kilobase 
per million mapped reads (FPKM) from each sample were estimated and analyzed using Gene Set 
Enrichment Analysis (GSEA). We used the pathways from the Kyoto Encyclopedia Genes and 
Genomes (KEGG) as the gene set and performed 1000 gene set permutations. As this is a discovery 
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step, we considered pathways with nominal p-value < 0.15 as candidate hits for follow-up 
experiments.  
Cellular Growth Assays  
Sulforhodamine B Assay  
Cells (1500/well for BCPAP, SW1736, C643; 1000/ well for Cal62) were plated in triplicate in 
96 well plates.  Cells were treated with increasing concentrations of the indicated drugs and cell 
growth was  measured by SRB assay after 3 days of drug treatment 100,187.  Briefly, after 72 hours of 
treatment, cells were fixed with 10% trichloroacetic acid (TCA) at 4°C, stained with 0.057% SRB 
(Sigma), and unbound SRB was removed using 1% acetic acid.  The remaining SRB bound to protein 
was dissociated using 10 mmol/L unbuffered Tris base, and the optical density of the solubilized SRB 
was measured at an absorbance wavelength of 570 nm using the SynergyH1 hybrid plate reader 
(BioTek).  Cell growth was calculated by the intensity of the SRB staining in relation to a solvent 
control treated well, which was set to 100%. Synergy was calculated using the Calcusyn software, 
which is based upon Chou and Talalay statistics 188. Synergistic values represented as combination 
index values (CI) are indicated using varying shades of green. CI values less than 0.7 are considered 
to be synergistic.   
CellTiter-Glo Assay 
 Cells were plated in opaque-walled 396-well plates i   μl % ‘PMI, and treated with 
dasatinib for 3 days.  μl CellTite -Glo reagent is added to the cell culture media present in each 
well, and mixed on an orbital shaker for 2 min.  The plate is then incubated at room temp for 10 




Clonogenicity was measured by seeding cells at single cell densities (100-1000 cells) in a 6-
well dish and treated with indicated inhibitors 24 hours later.  Cells were maintained in the indicated 
inhibitors for a total of 6 days with media and inhibitors replaced on day 3.  On day 6, the cells were 
washed and released from treatment for an additional 7 days. For experiments involving the AT7867 
inhibitor, cells were only treated for 3 days and were released for 7 days. Wells were then rinsed 
with phosphate buffered saline, fixed with ice cold methanol, stained with 0.5% (wt/vol) crystal 
violet in 6.0% (vol/vol) gluteraldehyde solution (Fisher Scientific), and destained with distilled water.  
The plates were then imaged on the 700 channel and analyzed using the Odyssey CLx imager (Li-
Cor). Signal Intensity was measured by generating an ellipse to best fit a well, and the ellipse was 
then copied throughout the experimental replicates.  A blank plate was imaged and used to 
normalize the background levels for each well. 
Cellular Apoptotic Assay 
  Cells (Chapter III - 7500/well for BCPAP, C643, and Cal62; 8000/well for SW1736) (Chapter 
IV – 6000/well for BCPAP, 8505C, T238, Cal62, C643, THJ16T) were plated in triplicate, in 96 well 
plates, and allowed to adhere overnight. Media was replaced with RPMI containing 0.1% FBS, and 6 
or 22 hours later the cells treated with indicated inhibitors for either 24 or 8 hours.  Cleaved caspase 
3/7 luminescence was measured using the caspase-glo 3/7 assay (Promega) using the Synergy H1 
hybrid plate reader (Biotek). 
Immunoblotting and Immunoprecipitation 
  In Chapter III - Cells were collected in NP-40 lysis buffer (containing 1% NP-40, 20 mmol/L 
Tris-HCl (pH 8.0), 137 mmol/L NaCl, and 10% glycerol) with 1x protease/phosphatase inhibitor  
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cocktail (Thermo)).  In Chapter IV – Cells were collected in CHAPs lysis buffer (containing 10 mmol/L 
CHAPs, 50 mmol/L Tris (pH 8.0), 150mmol/L NaCl, and 2 mmol/L EDTA with  1x 
protease/phosphatase inhibitor cocktail ((Thermo)).  Protein concentration was determined using 
the DC protein assay (Bio-rad). Protein (2  μg  as sepa ated usi g a  % PAGE-SDS gel, and 
transferred to Immobilon-P membranes (Millipore). Membranes were incubated overnight at 4°C 
with the indicated antibodies (Table 2.1). For ECL detection, blots were incubated with secondary 
goat anti-rabbit or goat anti-mouse horseradish peroxidase–conjugated antibodies (GE Healthcare) 
and detected by enhanced chemiluminescence (ECL) (Pierce). For Odyssey CLx imaging blots were 
incubated with secondary goat anti-rabbit (IRDye 800CW) or goat anti-mouse (IRDye 680RD) (Li-
Cor). 
For immunoprecipitation (IP) assays, lysates were rotated with pre-clearing matrix F beads 
fo   i utes at °C.  P otei   μg  i   μl of l sis uffe  as the  i u ated fo   hou  at °C 
ith the i di ated a ti od   μg ‘af-1 (C-20) or rabbit IgG (cell signaling)) prior to being incubated 
with 40 µl of the IP/WB Optima F beads (Santa Cruz) overnight at 4°C.  
Viral Transfections and Generation of Stable Cell Lines 
shPTEN 
8505C and C643 cell lines were transduced with lentiviral particles (pLKO.1-puro) containing 
a short-hairpin RNA (shRNA) targeting human PTEN (Sigma mission TRCN0000002747 and 
TRCN0000002749) and a scramble control (Sigma mission pLKO.1-puro, SHC002). Lentiviral particles 
were generated by the UC Denver Functional Genomics Facility. Briefly, cells were plated in 6 cm2 
dishes and allowed to adhere for 24 hours.  The following day the media was removed and 1.6 ml of 












 μg/ l pol e e as then added to each plate.  24 hours later the media was replaced with fresh 
media and the following day puromycin was added to the media and cells were selected for 7 days.  
Pu o o e t atio s e e  μg/ l fo  the C ell li e a d  μg/ l fo  the C  ell li e.  
c-Src shRNA 
c-Src shRNA Lentiviral transduction particles were purchased from Sigma Aldrich (St. Louis, 
MO).  shRNA target se ue es a e:  -GGCTCGGCTCATTGAAGACAA-  a d  -
GGTCATGAAGAAGCTGAGGCA- .  BCPAP ells e e t a sdu ed fo   hou s a d sele ted fo  usi g 
0.5ug/ml puromycin for 7 days prior to analysis. Results were compared to scrambled control 
(SHC002V), or nontransfected (WT) cells. 
c-Src Wild Type (WT) and Gatekeeper (GK) 
8505C and C643 cell lines were transduced with pBABE-EV-hygro, pBABE-WT-c-SRC 
(Addgene plasmid 26983), or pBABE-GK-c-Src T338I (Addgene plasmid 26980) retrovirus and 
selected with hygromycin 0.5 mg/ml or 0.2 mg/ml, respectively, as previously described 100. 
P70S6K-E389 
 The pSLIK-S6K-(E389-deltaCT)-neo (Addgene plasmid # 58516) construct was packaged for 
lentiviral delivery via HEK293FT cells using Effectene transfection reagent (Qiagen).  Briefly, 5 µg of 
the expression vector and 1.5 µg of the packaging vectors V1 and V2 were added to 450 µl of EC 
buffer, per reaction. Next, 40 µl of the enhancer reagent was added to each reaction, vortexed for 
15 seconds and incubated at room temp for 4 minutes, this was then followed by the addition of 75 
µl of Effectin per reaction, vortexing for 10 seconds and incubating at room temp for 8 minutes.  
Lastly, 1 ml of media is added to each reaction, and then the reaction is added dropwise to the cells.  
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8505C and C643 cell lines were virally transduced with pSLIK-S6K-(E389-deltaCT)-neo (Addgene 
plasmid # 58516) lentvirus and selected with G418 0.5 mg/ml.  
c-Fos-SRE Luciferase Reporter Assay  
The BCPAP cell line was plated at a density of 1000 cells per well in a 96-well plate. The c-
Fos-SRE-luc reporter gene was transfected into cells at a concentration of 50 ng/well in a total 
volume of 100 µl using extremegene 9 transfection reagent (Roche) 5 µl/well. The vector contains 
serum response elements from the c-fos promoter that are activated downstream of ERK1/2, which 
upon activation drive transcription of the firefly luciferase gene. We also transfected a pRL-null 
(plasmid containing renilla luciferase) vector as a transfection control. The cells were then treated 
with 100nM dasatinib for indicated periods of time, and assayed for luciferase activity using the dual 
luciferase reporter assay system (Promega). Luminesence was then measured using the Synergy H1 
hybrid plate reader (Biotek). 
Immunofluorescence 
  Cells were seeded overnight at a density of 20,000 cells / well, the cells were then treated 
with indicated inhibitors for 24 hours.  Upon collection, cells were washed with Phosphate Buffer 
Saline (PBS), Fixed with 2% PFA for 10 mins at room temperature, washed with PBS-T (0.1% Tween-
20), permeabilized in methanol for 10 minutes at room temperature, washed with PBS-T, Blocked 
with Odyssey blocking buffer (PBS) (Leicor) for 1 hour and then incubated with the primary 
antibodies diluted in Odyssey blocking buffer (PBS) overnight at 4°C.  After 24 hours, the cells were 
washed with PBS-T and incubated with secondary antibodies for 1 hour at room temperature, 
washed with PBS-T, washed with PBS, and the dividers were removed and DAPI mounting medium 
was applied. Fluorescence images were then captured using the Nikon T1 Eclipse microscope and 
NIS-Elements software (Nikon), at a magnification of 40x.  For image J analysis - pS6 fluorescent 
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outlines were generated using image J on ten independent images, for each individual cell line, 
across three independent biological replicates. Individual intensities were normalized to the area 
measured, and then a background intensity was subtracted from this value. A threshold of half of 
the average intensity of the DMSO treated group was used as a cutoff for Negative/Low intensity (p-
S6 Low) vs normal/high intensity (p-S6 High), for each independent biological replicate.  The percent 
p-S6 low versus p-S6 high was calculated for each independent replicate and then the percentages 
were averaged across the three biological replicates.  Cl. PARP positive nuclei were counted and 
calculated as a percentage of either the total number p-S6 low or p-S6 high cells for each treatment 
group. The percentage of Cl. PARP positive cells were then averaged across the three independent 
experiments 
Mouse Xenograft Study 
  The Cal62 parental, control, and DasRes cell lines were injected into the left and right flanks 
of athymic nude mice. Briefly, female Athymic Nude-Foxn1nu mice (Harlan Laboratories; 20-30g; 6-8 
weeks old) were anesthetized with isoflourane.  Thyroid cancer cells (Cal62 parental and DasRes) 5 x 
106 in 100ul RPMI and 50% high concentration Matrigel (BD Biosciences) were injected into the left 
and right flanks of athymic nude mice. Tumor establishment and progression were monitored 
weekly through the use of caliper measurements. Mice were randomized 7-10 days post-injections 
and treated with either vehicle, (12.5mg/kg or 25mg/kg) dasatinib, or (0.5mg/kg or 1mg/kg) 
trametinib. Both dasatinib and trametinib were administered daily by oral gavage (5 days/week). All 
animal studies were performed in accordance with the animal procedures approved by the 





 Metabolite analysis was performed as previously reported, in collaboration with Angelo 
D Alessa d o a d T a is Ne ko , i  D . Ki k Ha se s la o ato  189,190. Briefly, Cal62 cells were 
plated in duplicate at a density of 0.75 x 106 in 10cm2 plates, and allowed to adhere for 24 hours. 
One plate was used for metabolomics analysis and the other for counting and western blot analysis. 
Cells were then treated with either DMSO, 100nM trametinib, 100nM dasatinib, or the combination 
for 24, 8, or 2 hours.  For the cells collected for counting and western blot analysis, Cells were 
trypsinized (0.5 ml) and collected in 4.5 ml media, counted, and spun down at 1000 rpm for 5 min.  
The cell pellet was then lysed in 200ul of NP40 lysis buffer + 1x protease and phosphatase inhibitor.  
The cells collected for metabolomics were harvested at 4C.  Briefly, the media was aspirated and 
cells were washed with cold PBS.  Lysis buffer was then added to normalize the lysates to 2x106 
cells/ml, and then cells were scraped and collected.  The lysates were then vortexed at 4C for 30 
minutes.  Lysates were then spun down at 10,000 rpm for 10 min, and then the cell pellet and 
supernatant were separately frozen at -80C.  For metabolite analysis, 2x106 ells a d  μl of ell 
media were extracted in a total volume of 1.0 mL lysis extraction buffer 
(methanol:acetonirtrile:water; 5:3:2).  After discarding protein pellets the water soluble and 
methanol soluble fractions were run through a hydrophilic interaction liquid chromatography and 
C18 reversed phase column through an ultra-high performance chromatographic system (Ultimate 
3000, Thermo Fisher) at 140,000 resolution (at 200 m/z).  For metabolite assignment and peak 
integration quantitation, the Maven software (Princeton) was used, and assignment was based on 
the Kyoto Encyclopedia of Genes and Genomes pathway database and an in-house validated 
standard library (>650 compounds; Sigma; IROATech).   Principle component analysis (PLS-eDA) was 
performed using the GENE-E software (Broad), and heatmaps were generated using Morpheus 
(Broad).  Box and whiskers plots were generated using Graphpad Prism 5 
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Reverse Phase Protein Array 
 Cells were seeded at a density of 0.3 – 0.5 x 106 cells/well of a 6-well plate in 3 ml of 5% 
RPMI and allowed to adhere overnight.  24 hours after plating, the cells were washed with cold PBS 
and then cells were collected in 100 µl of lysis buffer (1% Triton X-100, 50mM HEPES, pH 7.4, 
150mM NaCl, 1.5mM MgCl2, 1mM EGTA, 100mM NaF, 10mM Na pyrophosphate, 1mM Na3VO4, 
10% glycerol, and 1x protease/phosphatase inhibitors (Roche)). Cells were then scraped off of the 
plates and centrifuged at 13,000 rpm for 10 minutes at 4C.  The supernatant was then collected, 
measured for protein content, and adjusted to contain a protein content of 1-1.5 ug/ul.  The cell 
lysate was then mixed with 4x SDS sample buffer (40% Glycerol, 8% SDS, 0.25M Tris-HCL, pH 6.8, 
with 2-mercaptoethanol added at 1/10 of the volume before use), and then boiled for 5 minutes.  
Protein analysis was then performed at the MD Anderson Functional Proteomics RPPA Core Facility.  
Clustering of the RPPA data was performed by extracting all of the phosphorylated antibodies out of 
the dataset, clustering them using Cluster 3.0, and visualizing and generating heatmaps using Java 
TreeView.  Briefly, the cell lines were maintained in dasatinib IC50 order (Fig. 4.1).  The normalized 
linear RPPA values were averaged, and all of the non-phosphorylated proteins were removed, 
except for the tumor suppressors P16, RB, PTEN, and P53.  The antibody expression values were 
then log transformed, centered, and normalized.  The antibodies were then clustered using a 
spearman correlation and average linkage. Elastic-net Linear regression analysis was performed by 
Nikita Pozde e  i  D . B a  Hauge s la , using an alpha value of 0.8 and with minimal error, using 
the R programming language 
Cancer Stem Cells PCR Array 
 The Ca e  “te  Cell PC‘ a a  as pe fo ed a o di g to the a ufa tu e s p oto ol 
(SA Biosciences). Briefly, C643 cells treated with DMSO, 100nM trametinib, 100nM dasatinib were 
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plated in 10cm2 plates at a density of 300,000 cells per plate.  C643 cells treated with both 
trametinib and dasatinib, were plated at a density of 4 x 106 cells per 15cm2 plate in a total of 10 
plates.  Cells were then treated for three days with the indicated inhibitors.  Cells were lifted off of 
the plates using trypsin, collected and centrifuged at 1000 rpm for 5 min, and then lysed in 600 µl 
RLT buffer.  RNA was then isolated using the RNeasy mini kit (Qiagen). Total RNA was then 
converted into cDNA using the High Capacity cDNA Reverse Transcription Kit (Thermo Fisher 
Scientific), and then the cDNA was added to the RT2 qPCR Master Mix (SA Biosciences) and aliquoted 
across the PCR array.  RT-PCR reactions were performed using the 7900HT Fast Real-Time PCR 
System (Applied Biosystems). Delta Ct values were calculated for each gene of interest by 
subtracting the Ct value for the gene of interest by the average Ct value of the house keeping genes 
(ACTB, B2M, GAPDH, HPRT1, RPLP). The delta Ct values were then converted to relative values (2^-
ΔCt) and fold changes were calculated for each treatment group in comparison to the DMSO 
control. 
Statistical Analysis 
  Experiments were performed with at least three separate replicates.  Statistical analysis 
was performed using the GraphPad Prism software and the unpaired Student t test was used to 
compare two means.  Error bars represent the standard error of the mean (SEM), unless otherwise 







THE MITOGEN ACTIVATED PROTEIN KINASE PATHWAY FACILITATES RESISTANCE TO THE SRC 
INHIBITOR, DASATINIB, IN THYROID CANCER1 
Introduction 
The MAPK pathway accounts for the majority of mutations in thyroid cancer with a high 
prevalence of BRAF and RAS mutations 9,191. While there has been great interest in targeting this 
pathway in thyroid cancer, clinically, thyroid cancers appear to exhibit primary resistance to MAPK 
pathway inhibition, falling short of the responses seen in melanoma patients with similar activating 
mutations, but rather mimicking the lack of efficacy observed in colorectal cancer patients 42,46,192. 
Thus, with advanced stages of thyroid cancer continuing to maintain a dismal prognosis, it is clear 
that new therapeutic approaches are desperately needed 193,194. 
To address the current dearth of therapies, our lab has focused on the role of Src due to its 
multiple pro-tumorigenic functions 63,195.  We and others have previously demonstrated that 
inhibition of the Src signaling pathway with the Src inhibitors, dasatinib (BMS-354825) or saracatinib 
(AZD0530) effectively inhibits thyroid cancer growth and metastasis, both in vitro and in vivo 99–102. 
Despite dasatinib being a multi-kinase inhibitor, we have further shown that c-Src is a key mediator 
of these responses 100. Unfortunately however, clinical trials with Src inhibitors have not been as 
effective at this stage, likely due to resistance mechanisms in response to single agent therapy 112–
                                                          
 
 
1 Portions of this chapter were previously published in Molecular Cancer Therapeutics 2016 and are included 
with the permission of the copyright holder. 
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114,117,196. Thus, it is important to define  mechanisms of Src inhibitor resistance in order to  develop 
new strategies to more effectively target this oncogenic pathway in the clinic  63. 
Multiple mechanisms of resistance have been observed in response to single agent targeted 
therapies.  Two major mechanisms include the activation of bypass pathways, and the disruption of 
drug binding due to targeted mutations (e.g. Gatekeeper mutations) 121.  Mutation of the BCR-ABL 
gatekeeper residue has been reported in CML, whereas EGFR and ALK gatekeeper mutations have 
been reported in lung cancer  130,131,197.  Bypass pathway mechanisms have also been frequently 
reported, with Met amplification and FGFR signaling promoting resistance to EGFR inhibition in lung 
cancer, and relief of feedback inhibition of the MAPK pathway in response to vemurafenib 
(PLX4032) treatment in BRAFV600E-mutant melanoma and thyroid cancer 42,61,138,139. Additionally, 
mechanisms of reprogramming can allow for the survival of drug tolerant persisters, which then 
allow for more stable (typically genomic) mechanisms of resistance to be acquired 165. 
 To elucidate mechanisms of resistance and define strategies to more effectively target Src, 
we generated 2 BRAF-mutant (BCPAP and SW1736), and 2 RAS-mutant (C643 and Cal62) thyroid 
cancer cell lines with acquired resistance to the Src inhibitor, dasatinib. Interestingly, we observed 
acquisition of the c-SRC gatekeeper mutation only in the RAS-mutant dasatinib-resistant (DasRes) 
cell lines, whereas reactivation of the MAPK pathway was a conserved mechanism of resistance in 
response to dasatinib treatment in both the BRAF- and RAS-mutant DasRes cell lines. Consistent 
with an increased reliance on the MAPK pathway upon acquisition of resistance, inhibition of the 
MAPK pathway effectively inhibited growth both in vitro and in vivo. Additionally, combined Src and 
MEK1/2 inhibition resulted in synergistic inhibition of growth and increased apoptosis. Overall, 
these results indicate that inhibition of the MAPK pathway represents a promising strategy to 
overcome resistance to the Src inhibitor, dasatinib, and that combined inhibition of Src and the 
MAPK pathway may overcome early mechanisms of survival derived from either monotherapy. 
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Results 
Generation of a Model of Dasatinib Resistance in Thyroid Cancer 
To define mechanisms of resistance to the Src inhibitor, dasatinib,  thyroid cancer cells 
expressing the BRAFV600E (BCPAP and SW1736) or KRASG12R/HRASG13R-mutation (Cal62 and C643) 
were cultured with gradually increasing concentrations of dasatinib (50nM - μM , o  DM“O 
(control), over a period of nine months, until cells demonstrated resistance to dasatinib by SRB 
g o th assa s IC s >  μM .  Upo  a ui ed esistance, pooled populations of cells were 
ai tai ed i  μM dasati i , a d o t ol ell li es e e ultu ed i  o espo di g a ou ts of 
DMSO alongside. We and others have previously shown the IC50 values for the parental cell lines 
range between 35nM and 90nM 99,100, which is consistent with what we observed for the control cell 
lines (Figures 3.1A & Table 3.1).  Upon acquisition of resistance, the DasRes cells exhibit a greater 
than 30-fold increase in relative resistance to dasatinib in comparison to their counterpart controls, 
with IC50 values rangi g f o   μM to >  μM Ta le . ).  Additionally, all four DasRes cell lines 
exhibited cross-resistance to another Src inhibitor, saracatinib, further confirming resistance to Src 
inhibition, and that the observed resistance is not a dasatinib-specific response (data not shown).  
To confirm cell line genetic identity, short tandem repeat (STR) profiling was performed upon 
acquisition of dasatinib resistance (Table 3.2) 185.    
Acquisition of the c-SRC Gatekeeper Mutation Correlates with a Stable Mechanism of Dasatinib 
Resistance  
We first hypothesized that a drug-resistant gatekeeper mutation in c-SRC may be driving 
resistance to dasatinib 123. Sequencing of exon 9 of c-SRC revealed the presence of the c-SRC 
gatekeeper mutation (c.C1022T; p. T341M) in both of the DasRes RAS-mutant cell lines (C643 and 





Table 3.1 Analysis of relative dasatinib resistance 
 
 
Figure 3.1: Generation of a model of Src inhibitor resistance in two BRAF- and two RAS-mutant 
thyroid cancer cell lines. A.) SRB growth analysis of the BCPAP, SW1736, C643, and Cal62 control 
and DasRes cell lines in response to indicated concentrations of dasatinib (µM) after 72 hours of 
treatment. B.) Sanger sequencing for exon 9of c-SRC in both control and dasatinib-resistant cell 




c-SRC gatekeeper mutation in the RAS-mutant cell lines suggests these cells may exhibit a more 
permanent mechanism of resistance.  We therefore released the BRAF- and RAS-mutant DasRes cell 
lines from dasatinib for 2 months (DasRes-2mo; ~10 passages), and observed that the RAS-mutant 
DasRes-2mo cell lines maintained their resistance to dasatinib exhibiting 39- to 86-fold relative 
resistance to dasatinib, whereas the BRAF-mutant DasRes-2mo cell lines returned to a more 
sensitive state, exhibiting only 3-fold to 15-fold relative resistance compared to the control cell lines 
(Fig. 3.2A and Table 3.1).  Of note, the BRAF-mutant DasRes-2mo cell lines did not regain full 
sensitivity to dasatinib, suggesting that mechanisms of transient and stable reprogramming may 
mediate resistance in the BRAF-mutant DasRes cell lines. Consistent with this, basal pY416Src levels 
in the BRAF-mutant DasRes-2mo cell lines more closely resembled the basal pY416Src levels 
observed in the control cell line, suggesting that when released from dasatinib, the DasRes BRAF-
mutant cells are able to reprogram back to being more dependent on Src (Fig. 3.2B; DasRes-2mo).  
As expected, in the BRAF- and RAS-mutant control and BRAF-mutant DasRes cell lines, pY416Src was 
inhibited by dasatinib (Fig. 3.2B & C).  However in the RAS-mutant DasRes and DasRes-2mo cell lines, 
which acquired the c-SRC gatekeeper mutation, pY416Src levels were not inhibited, as expected, and 
interestingly, exhibited a paradoxical increase when treated with 100 nM dasatinib (Fig. 3.2C).  
Together, these data suggest that in the BRAF-mutant DasRes cell lines, transient mechanisms of 
cellular reprogramming are likely mediating resistance to dasatinib, whereas the primary driver of 
resistance in the RAS-mutant cell lines is likely the c-SRC gatekeeper mutation. 
The MAPK Pathway is Activated in Dasatinib Resistant Thyroid Cancer Cell Lines 
To address alternative mechanisms of resistance and reprogramming, we next performed genome-
wide RNA-sequencing on the control and DasRes cell lines. RNA-sequencing results further validated 




Figure 3.2: Analysis of Src inhibition in control versus dasatinib-resistant cell lines. A.) SRB 
growth analysis of the BCPAP, SW1736, C643, and Cal62 dasatinib-resistant cells released 
from dasatinib for 2 months (DasRes-Release) in response to indicated concentrations of 
dasatinib (µM) over 72 hours of treatment. DasRes-Release growth curve is overlaid onto the 
growth curves for both the control and dasatinib-resistant cell lines from Fig. 3.1 A.) & B.) 
whole cell lysates were analyzed by Western blot analysis on the BRAF-mutant (B) BCPAP and 
SW1736 and the RAS-mutant (C) Cal62 andC643 control (Con), dasatinib-resistant (DR), and 
dasatinib-resistant released from dasatinib for 2 months (DR-2mo), which were treated with 
either DMSO or 100 nM dasatinib for 24 hours. Proteins were detected by probing with 
antibodies against phospho-Src Family Kinase (SFK) Y416, SFK, and a-tubulin. 
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RNA-sequencing was unable to detect any additional mutations that may provide evidence for 
genetic mechanisms of resistance in the BRAF-mutant DasRes cell lines (data not shown). Thus, we 
next performed gene set enrichment analysis (GSEA), and observed enrichment of the KEGG 
pathway Melanoma (hsa05218) across all four DasRes cell lines (Fig. 3.3). Consistent with the GSEA 
results, we observed a 1.5-3 fold increase in MAPK3/MAPK1 (ERK1/2) phosphorylation in all four 
DasRes cell lines in comparison to their respective counterpart controls (Fig. 3.4A and 3.5A). In 
addition, this increase in ERK1/2 phosphorylation appears to be a dasatinib specific event, as stable 
knockdown of c-Src does not promote increased ERK1/2 phosphorylation (Fig. 3.5B). Consistent with 
previous reports demonstrating that dasatinib can promote MAPK pathway activation by promoting 
dimerization of B-Raf and c-Raf 182, increased B-Raf and c-Raf dimerization was observed in all four 
DasRes cell lines (Fig. 3.4B & 3.5C). Taken together, in addition to acquisition of the c-SRC 
gatekeeper mutation in the RAS-mutant DasRes cell lines; mechanisms of MAPK pathway activation 
are conserved amongst all four DasRes cell lines.  
MAPK Pathway Activation Occurs as an Early Response to Dasatinib Therapy 
We next examined the response of the MAPK pathway to dasatinib treatment at early time 
points.  Specifically, parental cell lines were treated with 100 nM dasatinib for increasing periods of 
time (0, 2, 4, 8, 24, and 48 hours). Interestingly, dasatinib treatment resulted in an initial reduction 
in ERK1/2 phosphorylation, however a recovery was observed between 4-48 hours (Fig. 3.4C & 
3.5D).   The recovery in ERK1/2 phosphorylation was not a result of dasatinib metabolism, because 
inhibition of the Src dependent phosphorylation site, tyrosine Y925 of Focal Adhesion Kinase 
(FAK/PTK2) was maintained for 48 hours (Fig. 3.4C). To further confirm a functional recovery in 
ERK1/2 phosphorylation, we transfected the BCPAP cell line with a c-fos serum response element 
luciferase reporter construct (c-Fos SRE-luc), which has previously been demonstrated to be 




Figure 3.3: Enrichment of the Melanoma pathway in the dasatinib-resistant cell lines. The Kegg 
pathway Melanoma was enriched (p-value: 0.1465), enriched in the DasRes cell lines. Portrayed are 
the genes in the melanoma pathway. Highlighted in dark red are genes that are enriched in the 
dasatinib-resistant cell lines. Genes enriched include: PIK3R5, E2F3, IGF1R, PIK3CG, PDGFB, FGF7, 
FGF21, FGF22, BRAF, E2F1, FGF2, FGF14, FGF9, MAPK1, EGFR, PDGFC, FGF1, CCND1, MAP2K1 
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Figure 3.4: Increased MAPK pathway activation upon acquisition of dasatinib resistance. A.) 
whole cell lysates were analyzed by Western blot analysis by probing for phospho-ERK1/2 
ppE‘K / , E‘K , a d β-actin in the BCPAP, SW1736, C643, and Cal62 control (C) and dasatinib-
resistant (DR) cell lines. B.) IP of c-Raf and Western blot analysis for co-IP of B-Raf and c-Raf as 
well as whole cell lysate (WCL) immunoblots for B-Raf, c-Raf, a d β-actin in the BCPAP, SW1736, 
C643, and Cal62 control (C) and dasatinib-resistant (DR) cell lines. C.) Western blot for phospho-
E‘K ppE‘K / , E‘K , pFAK Y , FAK, a d α-tubulin following treatment of cells with 100 nM 
dasatinib for 0, 2, 4, 8, 24, 48, or 46 hours plus a 2-hour challenge with 100 nM dasatinib (48+2). 
D, IP for c-Raf and Western blot for B-Raf and c-Raf and Western blot for B-Raf and c-Raf in 
whole cell lysates following treatment of cells with 100 nM dasatinib for 0, 2, 48, or 46 hours 
plus a 2-hour challenge with 100 nM dasatinib (48+2). 
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Figure 3.5: Analysis of MAPK pathway activation upon acquisition of dasatinib-resistance. A.) 
Densitometry quantification of ERK 1/2 phosphorylation. Fold changes were calculated based on 
the control cell lines being normalized to 1. Signals e e o alized to α-tubulin. Quantification 
represents the mean of at least 3 separate experiments for each cell line +/- SEM B.) Western 
blot analysis after c-Src knockdown using two independent shRNAs (1 & 2) in the BCPAP cell line. 
Analysis was performed in comparison to a non-transfected (WT) and scrambled control (-). 
Lysates were probed for c-“ , ppE‘K / , E‘K / , a d α-tubulin. C.) Densitometry quantification 
of B-Raf co-immunoprecipitations after c-Raf pulldown in the control and dasatinib resistant cell 
lines. Fold Changes are relative to DMSO controls, and densitometry was normalized to c-Raf 
pulldown. D.) Quantification of ERK 1/2 phosphorylation based on western blot analysis for 
ppERK 1/2 in whole cell lysates following treatment of cells with 100nM dasatinib for 
0,2,4,8,24,48, or 46 hours plus a 2 hour challenge (48+2). Fold changes were calculated based on 
the DMSO (0hr) treatment being normalized to . “ig als e e o alized to α-tu uli  o  β-
actin. Quantification represents the mean of at least 3 separate experiments for each cell line 
+/- SEM. E.) Cells transfected with the c-Fos-SRE-Luc and pRL-null vectors were assayed for 
luciferase activity using the Dual Luciferase Reporter Assay System (Promega) after being 
treated with 100 nM dasatinib for 0,2,4,8,24,48, or 46 hours plus a 2 hour challenge (48+2). 
Signals were normalized to the DMSO (0hr) treatment. Quantification represents the mean of 3 
separate experiments +/- SEM. 
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decreased after 2-4 hrs of treatment and exhibited a recovery in activity between 8-48 hrs of 
treatment (Fig. 3.5E). Additionally, we challenged the 48 hour timepoint with an additional 100 nM 
dasatinib, 2 hours prior to harvest, and the recovery in ERK1/2 phosphorylation was maintained in 
both the BRAF- (BCPAP) and RAS- (Cal62) mutant cell lines (Fig. 3.4C & 3.5C-E). We therefore 
evaluated B-Raf and c-Raf dimerization in relation to the early recovery in ERK1/2 phosphorylation. 
Accordingly, we observed an increase in dimerization in the RAS- (Cal62) mutant cell line after 
treatment with dasatinib for 48 hours, which was maintained when challenged with dasatinib for 
the last 2 hours (Fig. 3.4D).  Interestingly, Raf dimerization was more variable in the BRAF-mutant 
BCPAP cell line at the 48-hour time point in response to 100 nM dasatinib (Fig. 3.4D).  In contrast, 
he  e tested a highe  dose of dasati i   μM  at a sho te  -hour time point, we observed a 
consistent increase in Raf dimerization in both the BRAF-mutant, BCPAP, and RAS-mutant, Cal62, cell 
line (Fig 3.6 A-C).  To better define the role of B-Raf and c-Raf dimerization in BRAF-mutant thyroid 
cancer cells, we compared responses between the BRAF-mutant melanoma cell line, A375, and the 
thyroid cancer cell line, BCPAP. Consistent with a previous report, we see very little dimerization in 
the A375 cell line, however we observe a larger increase in the BCPAP cell line (Fig 3.6 A & B) 182.  
Additionally, these data are also consistent with previous reports demonstrating that Raf 
dimerization is more robust in RAS-mutant versus BRAF-mutant cells, as we see a larger increase in 
dimerization in the RAS-mutant, Cal62, cell line compared to the BRAF- mutant, BCPAP, cell line 
61,182. Finally, B-Raf and c-Raf dimerization is an off-target effect that does not appear to be 
conserved amongst all Src inhibitors, as the Src inhibitor, saracatinib, does not strongly induce B-Raf 
and c-Raf dimerization in either the BRAF-mutant, BCPAP, or RAS-mutant, Cal62, cell lines (Fig. 3.6C), 
which is consistent with lack of phospho-ERK1/2 induction in response to c-Src knockdown (Fig. 
3.5B). Overall, a recovery in ERK1/2 phosphorylation suggests that the MAPK pathway may promote 











 Figure 3.6: Increased co-immunoprecipitation of B-Raf and c-Raf upon 5 μM treatment with 
dasatinib in thyroid cancer cell lines. A.) Immunoprecipitation of c-Raf and western blot for B-
Raf and c-Raf in whole cell lysates (WCL) following a three hour treatment with 5 μM dasatinib 
or an equivalent amount of DMSO, in the A375, BCPAP, and Cal62 cell lines. B.) Densitometry 
quantification of B-Raf co-immunoprecipitations after c-Raf pulldown in the A375, BCPAP, and 
Cal62 cell lines following a three hour treatment with 5 μM dasatinib or an equivalent amount 
of DMSO. Quantification is based on at least 3 independent replicates for each cell line +/- SEM. 
C.) Immunoprecipitation for c-Raf and western blot for B-Raf and c-Raf and western blot for B-
Raf and c-Raf in whole cell lysates (WCL) following a three hour treatment of with 0, .1, or 5 μM 




MEK1/2 Inhibition Restores Sensitivity in Dasatinib-Resistant Cell Lines 
We next tested whether reactivation of the MAPK pathway in dasatinib-resistant cells 
results in an increased dependence on the MAPK pathway for growth. We therefore performed 
growth assays in the control and DasRes cell lines in the presence of increasing concentrations of the 
MEK1/2 inhibitors, trametinib (GSK-1120202) or selumetinib (AZD6244) (Fig. 3.7A & Fig. 3.8). 
MEK1/2 inhibition with trametinib effectively inhibited growth in all four control and DasRes cell 
li es, ith IC s et ee  .  a d  μM, ith the ‘A“-mutant, C643, cell line exhibiting enhanced 
sensitivity in the DasRes line over the control (Fig. 3.7A and Table 3.3). Interestingly, the BRAF-
mutant (BCPAP and SW1736) and RAS-mutant (C643) control and DasRes cell lines showed 
differential sensitivity to the MEK1/2 inhibitor, selumetinib, with control IC50 values ranging from 6 
μM to >  μM Fig. .  & Ta le .3; control), and enhanced sensitivity in the DasRes cell lines with 
IC  alues a gi g f o  .  μM to  μM (Fig. 3.8 and Table 3.3; DasRes). Despite these differential 
responses, ERK1/2 phosphorylation was completely abrogated in the BRAF- and RAS-mutant control 
and DasRes cell lines (Fig. 3.7B & 3.7C).  As expected, inhibition of the downstream target of Src, 
pY925FAK, was observed in the BRAF-mutant DasRes cell lines, due to maintenance of these cells in 
 μM dasati i  Fig. . B). Consistent with acquisition of the c-SRC gatekeeper mutation in the RAS-
mutant DasRes cells, pY925FAK levels were not inhibited in these cells (Fig. 3.7C).  Overall, these 
results indicate that the DasRes cell lines have an increased dependence on the MAPK pathway 
upon acquisition of dasatinib resistance. 
MEK1/2 Inhibition Overcomes Dasatinib-Resistance In Vivo 
To further define the dependence of the dasatinib-resistant cells on the MAPK pathway, we 
evaluated the ability of MEK1/2 inhibition to overcome resistance to dasatinib in vivo. For these 





Figure 3.7: Increased trametinib sensitivity when DasRes cell lines are maintained in 2 μM 
dasatinib. A.) SRB growth analysis of the BCPAP, SW1736, C643, and Cal62 control and 
DasRes cell lines in response to indicated concentrations of trametinib (μM) for 72 
hours. B.) and C.) Western blot analysis on BRAF-mutant (B) BCPAP and SW1736, and RAS-
mutant (C) C643 and Cal62 control (Con), dasatinib-resistant (DR) treated with either DMSO 
or 100 nM trametinib for 24 hours. Cell lines were probed for ppERK1/2, ERK, pFAK Y925, 




Table 3.3: Increased trametinib and selumetinib sensitivity when 
DasRes cell lines are maintained in 2 μM dasatinib.   
 Figure 3.8: Increased selumetinib sensitivity when dasatinib-resistant cell lines are 
maintained in 2 μM dasatinib. BCPAP, SW1736, C643, Cal62 control (C), dasatinib-
resistant (DR), and dasatinib-resistant cells maintained in 2 μM dasatinib in response to 




and monitored tumor volume weekly (Fig. 3.9A).  Therapies were initiated 7 days after the cells 
were injected, and when tumor volumes were approximately 100 mm3 (parental = 126 mm3; DasRes 
= 104 mm3). Consistent with our in vitro data, the DasRes tumors remained resistant to 25 mg/kg 
dasatinib in vivo after 4 weeks of treatment (Fig. 3.9A, left). Additionally, dasatinib treatment 
resulted in a 30% inhibition of tumor growth in comparison to vehicle treatment in the Cal62 
parental tumors, similar to previous reports (Fig. 3.9A, right) 99. Consistent with the importance of 
the MAPK pathway in dasatinib resistance, MEK1/2 inhibition with trametinib (1 mg/kg) resulted in 
significant inhibition of tumor growth in the Cal62 parental tumors (5.26-fold inhibition; p-value = 
0.0031) and DasRes tumors (20.4-fold inhibition; p-value = 0.0007) in comparison to vehicle controls 
(Fig. 3.9A & B). Notably, MEK1/2 inhibition with trametinib also resulted in 3-fold smaller tumor 
weights in the DasRes cells compared to trametinib-treated parental tumors (Fig 3.10; p < 0.0001). 
Furthermore, the parental tumors started to become resistant to trametinib after only 4 weeks of 
treatment, as demonstrated by increased tumor volume (Fig. 3.9A, right). To further define the 
differential MEK1/2 inhibitor sensitivities between the parental and DasRes tumors, we continued to 
monitor additional tumors treated trametinib (0.5 mg/kg) for 9 weeks (Fig. 3.9B). Interestingly, the 
DasRes tumors had a 5.5-fold greater inhibition of tumor volume in response to trametinib (p = 
0.0009) with two of the DasRes tumors appearing to be completely eradicated, in comparison to the 
parental tumors (Fig. 3.9C).  Taken together our in vivo and in vitro data indicates that the MAPK 
pathway plays an important role in early and late resistance to Src inhibition, and that inhibition of 
MEK1/2 with trametinib is an effective secondary therapy to overcome resistance to Src inhibition 
with dasatinib.     
Increased Sensitivity and Cell Death in Response to Combined Src and MAPK Pathway Inhibition 
To further test the hypothesis that reactivation of the MAPK pathway drives resistance to 









Figure 3.9: Trametinib overcomes dasatinib resistance in a flank model of thyroid 
tumorigenesis. A.) Cal62 DasRes (left) and parental (right) cell lines were injected into the left 
and right flanks of Athymic Nude-Foxn1nu mice and treated with either vehicle, 25 mg/kg 
dasatinib, or 1 mg/kg trametinib, and tumors were measured by caliper weekly. Day 0 represents 
treatment initiation (7 days after cell injection). B.) comparison of the Cal62 parental and DasRes 
growth curves in the presence of 0.5 mg/kg trametinib. C.) comparison of the Cal62 parental and 
DasRes final tumor volumes after 63 days of treatment with 0.5 mg/kg trametinib. Data as mean 













 Figure 3.10: Trametinib Significantly Reduces Tumor Volume in Dasatinib Resistant Tumors in a 
Flank model of thyroid tumorigenesis. Tumor weights were measured upon euthanasia for both 
the Cal62 DasRes and Parental cell lines treated for 29 days with 1mg/kg QD trametinib. Data as 
means +/- SEM (n=8; student t-test; ***, P < 0.0005) 
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Thus, we treated all four parental cell lines with increasing concentrations of dasatinib (0.019 – 1.25 
μM  i  o i atio  ith the MEK /  i hibitors, trametinib (0.001 - .  μM  o  selu eti i  .  - 
.  μM , as ell as the BCPAP a d Cal  ell li es ith the E‘K /  i hi ito , “CH  .  - 0.5 
μM . I  suppo t of the MAPK pathway mediating resistance to dasatinib, all three MAPK pathway 
inhibitors resulted in synergistic inhibition of growth when combined with dasatinib across all four 
cell lines (Figure 3.11A, 3.12A & B) 188, with combination index (CI) values < 0.7, indicated by varying 
shades of green along the curve. Additionally, combined Src and MEK1/2 inhibition also resulted in 
decreased clonogenic growth in both the BRAF- (BCPAP) and RAS- (Cal62) mutant cell lines in 
comparison to single agent treatments (Fig. 3.13A & B). To better understand if the combination 
therapy results in greater elimination of cancer cells, we analyzed cleavage of the downstream 
effectors of the apoptosis pathway, caspase 3/7. Consistent with a potential role for apoptosis 
driven drug synergy, we observed enhanced induction of caspase 3/7 activity in response to 
combination therapy compared to single-age t ≥ -fold; Fig. 3.11B). Lastly, we tested the combined 
treatment with the Src inhibitor, dasatinib, and the MEK1/2 inhibitor, trametinib in the RAS-mutant 
parental Cal62 tumors in vivo (Fig. 3.11C).  Therapies were initiated 10 days after the cells were 
injected and when tumor volumes were approximately 100 mm3.  After 42 days of treatment both 
the vehicle control and dasatinib treated groups reached the criteria for euthanasia. At this 
timepoint, a subset of the trametinib and combination treated tumors were harvested alongside for 
comparison of tumor volumes.  Both the single agent trametinib and combination treatment groups 
exhibited significantly smaller tumor volumes (>3-fold; Fig. 3.13C).  In addition, a subset of the 
trametinib and combination treated mice remained on therapy, however consistent with data from 
Fig. 3.9B, the single agent trametinib treatment group started to develop resistance to therapy after 
approximately 50 days of treatment resulting in a significant 1.89-fold increase in tumor volume 
compared to the combination group at day 67 (Fig. 3.11C; p = 0.0182).  The prolonged inhibition of 
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tumor growth in the combination therapy group also resulted in enhanced survival (110 vs. 81 days) 
in comparison to the single agent trametinib group (Fig. 3.11D; p = 0.0837). Thus, this data indicates 
that combined treatment with the Src inhibitor, dasatinib, and the MEK1/2 inhibitor, trametinib can 
overcome resistance to either single agent therapy, in vivo. Taken together, these data demonstrate 
that co-targeting the Src and MAPK signaling pathways more effectively eliminates cancer cells than 
inhibition of either pathway alone, and represents a promising therapeutic strategy for advanced 
thyroid cancer patients for which few effective therapies are available.  
Discussion 
The development of Gleevac (imatinib) shed light on our ability to effectively inhibit cancer 
progression through the targeting of oncogenic drivers 29. Likewise, targeted therapies including 
vemurafenib and gefitinib, have exhibited strong therapeutic efficacy against specific onogenic 
drivers in other cancers including BRAF-mutant melanoma and EGFR-mutant non-small cell lung 
cancer, respectively. Unfortunately, this is not the case for all cancer types defined by a common 
oncogenic driver, as both BRAF-mutant thyroid and colorectal cancers do not exhibit similar 
sensitivities to MAPK pathway inhibition, in comparison to BRAF-mutant melanoma 42,192. Due to the 
limited  efficacy of targeted pathway inhibition in thyroid cancer, we have focused on the role of Src 
as an alternative, clinically relevant target, and have demonstrated that Src inhibition with dasatinib 
or saracatinib has strong therapeutic efficacy against multiple thyroid cancer cell lines in vitro and in 
vivo, and that c-Src is a key mediator of these responses 100,101.  However, despite promising 
preclinical results, the efficacy of Src inhibitors has also been limited in the clinic 112–114,117,196. Thus, it 
is important to understand resistance mechanisms in order to effectively target this pathway in the 
clinic. 
To further understand mechanisms of resistance to Src inhibition, we engineered four 
















Figure 3.11: Increased sensitivity of thyroid cancer cells to dasatinib when combined with 
MEK1/2 inhibition. A.) cell lines C643, Cal62, BCPAP, and SW1736 were treated with increasing 
doses of dasatinib ranging from 0.019 μM to 1.25 μM for 72 hours, in combination with 
increasing doses of trametinib (0.001 μM to 0.1 μM). Cell growth was measured using the SRB 
assay. Synergy was measured by determining the CI using the Calcusyn software. Combinations 
that elicited a synergistic response are depicted by their corresponding shade of green (0.3–0.7, 
synergism; 0.1–0.3, strong synergism; <0.1, very strong synergism). B.) cleaved caspase 3/7 was 
measured after a 24-hour incubation with indicated inhibitors in the BCPAP, SW1736, C643, and 
Cal62 cell lines. Data as mean ± SEM (n = 4–5; Student t test; *, P < 0.05; **, P < 0.005; ***, P < 
0.0005). Combination treatments were compared to respective single-agent MEK1/2 inhibitors. 
C.) the Cal62 parental cell line was injected into the left and right flanks of Athymic Nude-
Foxn1nu mice and treated with either vehicle, 12.5 mg/kg BD dasatinib, 0.5 mg/kg QD 
trametinib, or the combination, and tumors were measured by caliper weekly. Day 0 represents 
treatment initiation (10 days after cell injection). Data as mean ± SEM (n = 8–10; Student t test; 
*, P < 0.05). D, overall survival analysis comparing the single-agent trametinib-treated tumors 
with the combination-treated tumors [log-rank (Mantel–Cox) test; P = 0.0837]. 
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Figure 3.12: Synergistic inhibition of thyroid cancer cell growth to dasatinib when combined 
with MEK 1/2 Inhibition. A.) Cell lines C643, Cal62, BCPAP, and SW1736, were treated with 
increasing doses of dasatinib ranging from (0.019 μM to 1.25 μM) for 72 hours, in 
combination with increasing doses of selumetinib (0.025 μM  to 1 μM). Cell growth was 
measured using the Sulforhodamine B assay.  Synergy was measured by determining the 
combination index using the Calcusyn software.  Combinations that elicited a synergistic 
response are depicted by their corresponding shade of green. (0.3-0.7,Synergism; 0.1-0.3, 
Strong Synergism; <0.1, Very Strong Synergism).  B.) Cell lines BCPAP and  Cal62 were treated 
with increasing doses of dasatinib ranging from (0.019 μM to 1.25 μM) for 72 hours, in 
combination with increasing doses of the ERK1/2 inhibitor SCH772984 (0.005 μM  to 0.5 μM). 
Cell growth was measured using the Sulforhodamine B assay.  Synergy was measured by 
determining the combination index using the Calcusyn software.  Combinations that elicited a 
synergistic response are depicted by their corresponding shade of green. (0.3-0.7, Synergism; 




Figure 3.13: Prolonged inhibition of both Src and the MAPK pathway results in a reduction 
in colony and tumor formation. A.) Clonogenic growth was detected by crystal violet staining 
in the BCPAP and Cal62 cell lines following 6 days of treatment with indicated inhibitors and 
6 days of treatment release. B.) Colony area signal intensity was measured using Odyssey CLx 
imager (Li-Cor), and presented as percent fold change relative to the DMSO treated wells. 
Data as means +/- SEM (n=3; student t-test; *, P < 0.05, **, P < 0.005).  C.) Comparison of the 
Cal62 Parental tumor volumes after 42 days of treatment with vehicle, 12.5 mg/kg dasatinib 
BD, 0.5 mg/kg trametinib QD, or the combination.  Data as means +/- SEM (n=8; student t-
test; **, P < 0.005) 
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acquisition of the c-SRC gatekeeper mutation in the RAS-mutant cell lines, but not in the BRAF-
mutant cell lines (Fig 1C). Reports of gatekeeper mutation acquisition have been previously 
observed in response to targeted therapies directed against mutated oncogenic drivers (BCR-ABL-
imatinib (CML); EGFR-gefitinib (Lung); DDR2-dasatinib (lung) 127,199,200, however in contrast, our study 
discovered c-SRC gatekeeper mutation acquisition specifically in RAS-mutant thyroid cancer cell 
lines. To the best of our knowledge, this is the first demonstration of differential mechanisms of 
gatekeeper acquisition in the context of different oncogenic mutations (BRAF versus RAS).  As 
acquisition of the gatekeeper mutation is dependent on a cytosine to thymine transition, we 
hypothesize that two different possibilities may be occurring to promote the transition, which 
include increased cytosine deamination or malfunctions in DNA repair. Interestingly, a recent study 
highlighted a role for wild type Ras in mediating the DNA damage response in RAS-mutant cancers, 
and in conjunction, studies in thyroid cancer have demonstrated that oncogenic Ras promotes 
genome instability 201,202.  Therefore a differential DNA damage response, between BRAF- and RAS-
mutant cancers, may drive differential acquisition of the c-SRC gatekeeper mutation. Thus, further 
studies are needed to define the mechanism(s) of gatekeeper acquisition in order to enhance our 
ability to predict and combat resistance mechanisms to dasatinib.   
 In addition, increased levels of ERK1/2 phosphorylation were observed in all four DasRes cell 
lines, which correlated with increased B-Raf and c-Raf dimerization (Fig. 3A & 3B). While our data 
indicates B-Raf and c-Raf dimerization is likely a key mechanism promoting MAPK pathway 
reactivation in response to dasatinib, we have also observed downregulation of negative regulators 
of the MAPK pathway, including DUSP1, DUSP4, and SPRY1 (data not shown), as well as increased B-
Raf protein levels in the BRAF-mutant, BCPAP, cell line in the dasatinib-resistant cells (Fig. 3B).  
These results are similar  to previous reports showing that  loss of negative regulators of the MAPK 
pathway and BRAF gene amplification can promote resistance to targeted therapies 172,203,204, and 
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will be evaluated in more detail in future studies. We further determined an early role for the MAPK 
pathway in mediating dasatinib resistance, as treatment of parental cells with dasatinib resulted in 
an initial inhibition of ERK1/2 phosphorylation, and a recovery in ERK1/2 phosphorylation within 4-
48 hours after dasatinib treatment (Fig. 3C).  
 Interestingly, whereas we observed increased dimerization in our BRAF-mutant cell lines 
upon dasatinib treatment, a previous report did not observe dimerization in two BRAF-mutant 
melanoma cell lines upon treatment with dasatinib and concluded that B-Raf and c-Raf dimerization 
occurs in a Ras-dependent manner 182.  To better understand the observed dimerization in the 
thyroid cancer BRAF-mutant cell lines, we compared B-Raf and c-Raf dimerization in our thyroid 
cancer cell lines to the melanoma cell line A375 upon treatment with dasatinib. Consistent with 
dasatinib having limited effects on dimerization in the melanoma cell lines, we observed larger 
increases in dimerization in the thyroid cancer cell lines in comparison to the melanoma cell line, 
A375, with the largest levels being observed in the RAS-mutant, Cal62, cell line. In support of this, 
recent evidence demonstrates that BRAF-mutant thyroid cancer cells may be more primed to 
increase Raf dimers upon MAPK pathway inhibition in comparison to melanoma 42,192. Therefore, 
future studies will aim to explore in more detail the discrepancies between dasatinib-mediated 
dimerization in thyroid versus melanoma cancer cell lines.  
 Having demonstrated that the MAPK pathway is primed for activation upon dasatinib 
treatment in thyroid cancer cells, we next analyzed MEK1/2 inhibition in the control and DasRes cell 
lines, and demonstrate the MEK1/2 effectively inhibits growth with a trend towards greater MAPK 
pathway dependence in the DasRes cell lines (Fig. 4A & S4). Interestingly, despite having acquired 
the c-SRC gatekeeper mutation, the RAS-mutant DasRes cell lines still remained sensitive to MEK1/2 
inhibition. A potential explanation for maintained MEK1/2 inhibitor sensitivity is through an 
increased in Src-mediated phosphorylation of Y925FAK in the DasRes RAS-mutant cell lines (Fig 4C).  
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Previous studies have shown that phosphorylation of Y925FAK generates a Grb2 binding site, and 
therefore activation of the MAPK pathway, representing another potential mechanism by which 
gatekeeper mutant Src signaling contributes to MAPK pathway dependence 85. 
 Next, we further defined the role of MAPK signaling in dasatinib resistance through 
evaluation of MEK1/2 inhibition in overcoming dasatinib-resistance in vivo. Using the RAS-mutant, 
Cal62, cell line as a model, we observed sensitivity to MEK1/2 inhibition in both the parental and 
DasRes tumors. Intriguingly, we observed a significant increase in MEK1/2 inhibitor sensitivity in the 
Cal62 DasRes tumors in vivo even though we observed similar responses in vitro (Fig. 5A, 5B & S5), 
which was further exemplified by two complete tumor responses in the DasRes tumors (Fig. 5C). The 
in vivo data therefore further supports a role for increased MAPK pathway dependence in the 
DasRes tumors. 
 Herein, we report increased dimerization of B-Raf and c-Raf, as a potential mechanism of 
resistance to dasatinib, as recently reported by Packer et al (Fig. 3B & 4B) 182. Increased B-Raf and c-
Raf dimerization is important from a therapeutic perspective, as this is a key mechanism of 
resistance to B-Raf inhibitors in BRAF-mutant melanoma 61,145,205, and this mechanism may be more 
primed in BRAF-mutant thyroid cancer cells 42,192. In order to combat this mechanism of resistance, 
current therapies are focused on combined B-Raf and MEK1/2 inhibition. Unfortunately, however, a 
potential caveat may derive from this strategy, as a recent study from Moriceau et al suggests that 
inhibition of multiple nodes in the same pathway (e.g. B-Raf and MEK1/2) primes and amplifies 
resistance mechanisms that enhance the activation of resistant signaling pathways 206. Thus, the 
inhibition of distinct pathways (e.g. Src and MEK1/2) may be more effective. Consistent with this 
hypothesis, here we demonstrated that MEK1/2 inhibition was able to effectively overcome 
resistance to dasatinib both in vitro and in vivo (Figs. 4 and 5). Additionally, we and others have 
shown enhanced anti-growth and pro-apoptotic responses over single agent therapy when Src and 
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MAPK pathway inhibitors are used in combination in vitro 102,103 (Fig. 6). Furthermore, we show for 
the first time that combined Src inhibition with dasatinib and MEK1/2 inhibition with trametinib 
results in enhanced anti-tumor responses and increased survival (Fig. 6), similar to a previous study 
that evaluated B-Raf inhibition with vemurafenib in combination with dasatinib 102.  In support of 
this, recent data with a dual dimerization-breaking Raf inhibitor that also targets Src appears 
promising, and may be an effective new strategy to prevent or delay resistance to single agent 
therapy 64.   Finally, recent data has demonstrated that MEK1/2 inhibition can improve standard of 
care radioiodine for patients with advanced thyroid cancer 52.  Therefore further analysis of the 
potential for combined Src and MAPK pathway inhibition to enhance radioiodine uptake represents 
a promising therapeutic direction, and an important area for continued investigation.  
 In summary, we have discovered that thyroid cancer cell lines acquire the c-SRC gatekeeper 
mutation, and mechanisms of MAPK pathway activation upon acquisition of resistance to the Src 
inhibitor, dasatinib. Importantly dasatinib resistant cell lines exhibit increased sensitivity to MAPK 
pathway inhibition both in vitro and in vivo.  Taken together, MAPK pathway inhibition is a 











RIBOSOMAL PROTEIN S6 PHOSPHORYLATION IS A PREDICTIVE BIOMARKER OF RESPONSE TO 
COMBINED SRC AND MEK1/2 INHIBITION IN ADVANCED PAPILLARY AND ANAPLASTIC THYROID 
CANCER 
Introduction 
 Poorly differentiated and anaplastic thyroid cancers are characteristic of poor overall 
survival with an average of 3.2 and 0.6 years, respectively 6. Papillary thyroid cancers present with a 
high prevalence of mutations in the MAPK pathway including, point mutations in BRAF and RAS, as 
well as RET rearrangements. As these cancers progress towards poorly differentiated or anaplastic 
thyroid cancer, they acquire additional mutations in the PI3K/MTOR effector pathway, TP53, TERT 
promoter, and epigenetic modifying enzyme mutations 18,19. This increase in mutational burden is 
one possible explanation for the profound decreased responsiveness to B-Raf inhibition in BRAF-
mutant thyroid cancer, in comparison to BRAF-mutant melanoma 42,48,49. Despite the decreased 
responsiveness in thyroid cancer, recent trials have demonstrated some modest efficacy with B-Raf 
inhibition in thyroid cancer, as one patient, in a B-Raf inhibitor basket trial, exhibited a complete 
response when treated with vemurafenib 47. Taken together, this data supports the need for further 
elucidation of the differences between thyroid cancer and melanoma, so that we can more 
effectively treat thyroid cancer patients.  
 Our work and the work of others has highlighted a role for the non-receptor tyrosine 
kinase, Src, in mediating thyroid tumorigenesis 99–101, and importantly we have demonstrated that 
prolonged inhibition of Src reprograms cells to become more reliant on the MAPK pathway 106.  In 
support of this, multiple laboratories have demonstrated that the combined inhibition of Src and the 
MAPK pathway results in synergistic inhibition of growth and increased apoptosis both in vitro and 
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in vivo 102,103,106.  Together, these data support the hypothesis that Src may mediate resistance to 
MAPK pathway targeted therapies, and that co-targeting Src and the MAPK pathway will result in 
enhanced clinical responsiveness.  Based on the sub-optimal clinical responses observed with single 
agent MAPK pathway inhibitors, in thyroid cancer 42,45,46,48, and single agent Src inhibitors in solid 
tumors 111,112,114,115,207, it is therefore important that these mechanisms be further characterized in 
order to better inform clinical trial development and future therapeutic strategies.  Importantly, Src 
has been demonstrated to regulate growth, invasion, migration, and survival through activation of 
numerous tumorigenic signaling pathways including the RAS-ERK MAPK pathway, the PI3K-AKT 
pathway, STAT3, and FAK, which suggests multiple factors may be responsible for mediating 
resistance to MAPK pathway inhibitors, in thyroid cancer 208. In this study, using a panel of 
authenticated thyroid cancer cell lines expressing clinically relevant mutations, we identified a 
correlation between increased signaling in the PI3K pathway and resistance to Src Inhibition. This 
finding led us to uncover a potential role for Src in regulating activation of the PI3K pathway, and 
that upon combined inhibition of Src and the MAPK pathway, signaling through the PI3K pathway is 
effectively reduced in BRAF- and RAS-mutant cell lines, but not in PIK3CA-mutant cell lines.  A recent 
study utilizing thyroid cancer cell lines further supports a role for Src in signaling through the PI3K 
pathway, as treatment with combined MAPK and PI3K pathway inhibitors results in enhanced 
growth inhibition, similar to combined Src and MEK1/2 inhibition 161.  In addition, this data is further 
supported by research highlighting important feedback mechanisms between the MAPK and PI3K 
pathway, in which inhibition of either pathway results in an increase in signaling through the other 
147.    
 Src has been demonstrated to regulate the PI3K pathway through multiple different 
mechanisms including phosphorylation and inhibition of PTEN function, regulation of the p85 
regulatory subunit of PI3K through p130Cas, and direct phosphorylation of AKT 89,92–95. Herein, we 
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discovered that PIK3CA-mutant cell lines had decreased responsiveness to the combined inhibition 
of Src and the MAPK pathway, suggesting that the regulation of the PIK3CA pathway by Src may lie 
upstream of AKT. In addition, knockdown of PTEN was unable to abrogate growth inhibition in BRAF- 
and RAS-mutant cell lines treated with the combined inhibition of Src and the MAPK pathway, 
suggesting that Src does not regulate PTEN function in these cell lines. Intriguingly, PTEN mutations 
are rarely associated with BRAF- and RAS-mutations in thyroid cancer, suggesting that Src may play a 
role in mediating direct activation of the PI3K pathway, therefore decreasing the selective pressure 
for a loss of PTEN, in BRAF- and RAS-mutant thyroid cancer. 
 Lastly, we demonstrate in this study that rpS6 phosphorylation status may represent an 
important indicator of the effectiveness of therapies targeting both the Src and MAPK pathways. 
Importantly, three different mRNA signatures developed in Breast Cancer to stratify patients that 
would or would not respond to dasatinib single agent therapy, failed to significantly predict 
responses178. Thus, this data suggests that additional dasatinib predictive gene signatures may also 
struggle to determine patient responses clinically 209,210.  As cancer cells are a function of time and 
placement within the tumor microenvironment, we hypothesize that post-treatment biomarkers 
may be more informative, since treatments should theoretically promote an increased 
normalization of signaling pathways 211,212.  Identification of downstream biomarkers of response will 
also provide important indications of the effectiveness of therapeutic strategies and identification of 
drug resistant populations of cancer cells.  Furthermore, rpS6 represents an intriguing biomarker of 
response, as it is a downstream effector of both the MAPK and PI3K pathways.  Herein, we 
demonstrate that cells sensitive to the combined inhibition of both Src and the MAPK pathway 
exhibit an enhanced reduction in rpS6 phosphorylation, whereas cell lines resistant to the 
combination therapy maintain rpS6 phosphorylation to a greater extent.  Surprisingly, even cell lines 
that exhibit increased sensitivity to the combination therapy still maintain a small subset of cells that 
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maintain rpS6 phosphorylation suggesting that these cells may give rise to drug tolerant persisters.  
Furthermore, we demonstrate that there may be additional activity through the PI3K pathway that 
is maintaining rpS6 phosphorylation, and therefore suggesting that increased dosage or increased 
inhibitor effectiveness is necessary to completely eliminate these cells.   
 Taken together, we provide evidence for the first time in thyroid cancer that Src promotes 
PI3K pathway activation in BRAF- and RAS-mutant cell lines, which provides further evidence for the 
decreased responsiveness of thyroid cancers to MAPK pathway targeted therapies.  In addition, 
these results also provide important rationale linking negative feedback mechanisms between the 
MAPK and PI3K pathway as a potential mechanism for the increased synergy between combined Src 
and MAPK pathway inhibition in BRAF- and RAS-mutant thyroid cancer.  Lastly, our data highlights 
the importance of developing biomarkers of response to better define drug tolerant persistence to 
targeted therapies, so that we can more effectively identify and eliminate drug tolerant persisters, 
which may be responsible for relapse, in the clinic. 
Results 
Activation of the PI3K Pathway is Associated with Dasatinib Intrinsic Resistance 
 We previously reported that cells with acquired resistance to dasatinib exhibited an 
increased reliance on the MAPK pathway, which correlated with an increase in ERK1/2 
phosphorylation.  Therefore, we hypothesized that we may observe similar mechanisms of 
resistance, in cell lines that are intrinsically resistant to dasatinib, and that through a better 
understanding of these mechanisms, we can better define patients that will and will not respond to 
the combined inhibition of Src and the MAPK pathway. Thus, we first analyzed the sensitivity and 
resistance of 36 thyroid cancer cell lines, to the Src inhibitor dasatinib, and IC50 values were 
generated using CellTiter-Glo assays (Promega).  We then determined dasatinib sensitive and 
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resistant cell lines, using an IC50 cutoff of 90nM, which is based on the peak plasma/serum 
concentrations of dasatinib, in patients treated for Chronic Myelogenous Leukemia 213.  Based on 
this cutoff, 11 thyroid cancer cell lines were determined, to be sensitive to single agent dasatinib, 
(<90 nM), and 25 were found to be resistant (>90 nM) (Figure 4.1).  Interestingly, there does not 
appear to be a specific mutation status associated with sensitivity to dasatinib, as 5 out of 16 BRAF-, 
3 out of 7 RAS-, 1 out of 5 PIK3CA/PTEN, and 2 out 2 RET/PTC cell lines were found to be sensitive to 
dasatinib (Figure 4.1). 
We next performed Reverse Phase Protein Analysis (RPPA) to determine signaling 
differences between the sensitive and resistant cell lines. To determine proteins and 
phosphorylation sites that correlated with dasatinib sensitivity or resistance, we performed an 
elastic-net linear regression analysis using an alpha value of 0.8 and minimal error. Antibodies that 
correlate with either dasatinib sensitivity (positive coefficients) or resistance (negative coefficients) 
are listed in Figure 4.2A.  Importantly, both Src and p-Src were associated with sensitivity to 
dasatinib (Fig. 4.2A). As our previous study uncovered an increase in MAPK pathway activation in 
response to acquired dasatinib resistance 106, we were next interested to see if any MAPK pathway 
proteins were significantly enriched in the dasatinib resistant group, and to our surprise we only 
discovered p-B-Raf S445 as being enriched in the resistant group (Fig. 4.2A). Interestingly, S445 has 
been demonstrated to be constitutively phosphorylated on BRAF 214, however we do not observe a 
similar correlation with total B-Raf levels, which may cofound the predictive ability of p-B-Raf S445 
to stratify sensitive and resistant cell lines.  Rather, we instead observed numerous negative 
correlations with members of the PI3K pathway (Rictor pT1135 and IGF1R pY1135/pY1136), and 
do st ea  effe to s of AKT P‘A“  pT , G“K α&β p“ /p“ , p  pT , a d Me it  p“ , 
which suggests that cell lines intrinsically resistant to dasatinib may exhibit an increased 






   
Figure 4.1: Absolute quantification of the IC50 value for dasatinib, in 36 thyroid cancer cell lines.  
Growth curves were measured across the cell lines using the CellTiter-Glo Assay (Promega), and 
the IC50 values were calculated. An IC50 cut-off of 90nM (dashed line) was used to determine cell 
lines sensitive and resistant to dasatinib.  The drug dependency screen was performed by Dr. 





Figure 4.2: Proteins and phosphorylation sites associated with dasatinib sensitivity and 
resistance A.) Antibodies with increased and decreased correlation with dasatinib intrinsically 
sensitive cell lines.  Antibodies were filtered using elastic-net linear regression and an alpha 
value of 0.8 and with minimal error. Elastic-net linear regression analysis was performed by Dr. 
Nikita Pozdeyev in Dr. B a  Hauge s la . B.  Phospho latio  a ti od  luste i g ith ell li es 
in dasatinib IC50 order from most sensitive to most resistant.  C.) Isolation and expansion of a 
cluster of phosphorylation antibodies identifies a cluster of antibodies in the PI3K pathway 
highly expressed and associated with dasatinib resistance. The color bar represents low to high 
antibody enrichment, with blue indicating low protein phosphorylation and yellow indicating 
high protein phosphorylation.  
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resistance, through clustering analysis of the phosphorylated antibodies quantified using RPPA 
(Figure 4.2B).  Importantly, when we clustered the phosphorylated proteins and maintained the cell 
lines in dasatinib IC50 order, we were able to observe a cluster that appeared to be highly correlated 
with increased expression and dasatinib resistance (Figure 4.2B & C; highlighted in red).  Analysis of 
this cluster identified multiple proteins associated with resistance from the linear regression model 
G“K α&β p“ /p“ , Merit40 pS29, NDRG1 pT346, p27 pT198, and PRAS40 pT246), as well as 
additional components of the PI3K pathway (AKT pS473, AKT T308, mTOR pS2448, p70S6K T389, 
4EBP1 pS65, S6 S235/236, and S6 S240/244) and downstream targets of AKT (Tuberin pT1462 and 
YB1 pS102) (Figure 4.2C). 
A Reduction in PI3K Pathway Signaling Correlates with Sensitivity to the Combined Inhibition of Src 
and the MAPK Pathway 
 Having previously identified that the MAPK pathway promotes acquired resistance to the 
Src inhibitor, dasatinib, we next wanted to examine the efficacy of combined inhibition of Src and 
the MAPK pathway in cell lines that are intrinsically resistant to dasatinib.  To test this, we chose 
thyroid cancer cell lines containing mutations in the commonly mutated oncogenes; BRAF, RAS, and 
PIK3CA.  To this extent, the combination therapy was analyzed in 6 cell lines, two BRAF- (BCPAP 
(Dasatinib-Sensitive)); (8505C (Dasatinib-Resistant)), two Ras- (Cal62 (Dasatinib-Sensitive)); (C643 
(Dasatinib-Resistant)), one BRAF/PIK3CA- (T238 (Dasatinib-Resistant)); and one PIK3CA- (THJ16T 
(Dasatinib-Resistant)) mutant cell lines (Table 4.1). We chose to include the BRAF-mutant, BCPAP, 
and the RAS-mutant, Cal62, cell lines as dasatinib-sensitive controls, as they have previously been 
demonstrated to respond to the combined inhibition of Src and the MAPK pathway 106. To 
determine sensitivity, we analyzed the induction of apoptosis in these 6 cell lines, upon treatment 
with either single agent trametinib, dasatinib, or the combination at 24 hours (Fig. 4.3A). 
Surprisingly, only the BRAF- (BCPAP and 8505C) and RAS- mutant (Cal62 and C643) cell lines, 
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regardless of their intrinsic sensitivity or resistance to dasatinib, exhibited significant 2.5-5-fold 
increases in apoptosis upon treatment with the combination therapy (p-value < 0.01), in comparison 
to the PIK3CA-mutant cell lines, as no increase in apoptosis was observed in the PIK3CA-mutant cell 
lines (T238 and THJ16T) (Fig. 4.3A).  Given the distinct responses observed amongst the differential 
oncogenic drivers, we next analyzed the signaling responses in relation to the inhibitory effects of 
either the single agents or the combination.  Consistent with the Cleaved Caspase 3/7 activity data, 
we only observed an increase in Poly ADP-ribose polymerase (PARP) cleavage in the BRAF- and RAS-
mutant cell lines treated with the combination therapy (BCPAP, 8505C, Cal62, and C643).  We next 
analyzed the downstream effectors of Src and MEK1/2, and observed a similar reduction in FAK 
Y861 and ERK1/2 phosphorylation, respectively, in all of the cell lines treated with either the 
respective single agent or the combination, which suggests that the inhibitory effects of the 
combination are not due to a lack of drug efficacy in the PIK3CA-mutant cell lines (Fig. 4.3B & Table 
4.2). We next analyzed the phosphorylation status of the downstream target of both the MAPK and 
PI3K pathways, rpS6 (Fig. 4.3B). Interestingly, treatment with the combination therapy in the BRAF- 
and RAS- mutant cell lines resulted in a significant 13-66 fold reduction in rpS6 S235/S236 
phosphorylation (p-value < 0.05) and a 4-20 fold reduction in rpS6 S240/S244 phosphorylation, in 
comparison to combination treated PIK3CA-mutant cell lines, as the combination treatment resulted 
in only a 2.5-3 fold reduction in rpS6 S235/S236 phosphorylation and a 1.5 fold reduction in rpS6 
S240/S244 phosphorylation in the PIK3CA-mutants (Fig 4.4 & Table 4.2).  We next analyzed AKT 
phosphorylation, and observed elevated levels of AKT phosphorylation in all of the dasatinib 
intrinsically resistant cell lines, in comparison to the dasatinib intrinsically sensitive cell lines, which 
is consistent with the RPPA analysis (Fig. 4.2 and 4.3B). Thus, we next analyzed the effects of the 
targeted therapies on AKT phosphorylation, and interestingly, only the BRAF- and RAS-mutant 




Table 4.1: Cell line characteristics.   
  
Figure 4.3: Analysis of Src and MEK1/2 Inhibitor Sensitivity in BRAF-, RAS-, and PIK3CA-mutant 
cell lines.  A.) Cleaved caspase 3/7 activity was measured after a 24 hour incubation with either 
DMSO, 100nM trametinib, 100nM dasatinib, or dasatinib + trametinib in the BCPAP, 8505C, T238, 
Cal62, C643, or THJ16T cell line. Data as means +/- SEM (n=3; student t-test; *, P < 0.05, **, P < 
0.005, ***, P < 0.0005) B.) The BCPAP, 8505C, T238, Cal62, C643, or THJ16T cells were treated for 
24 hours with the indicated inhibitors, and then whole cell lysates were analyzed by Western blot 













Figure 4.4: Quantification of rpS6 phosphorylation.  Densitometry quantification of rpS6 
phosphorylation at S235/236 and S240/244 in BCPAP, 8505C, T238, Cal62, C643, and THJ16T 
cell lines following a 24 hour treatment with 100nM trametinib, 100nM dasatinib, or an 
equivalent amount of DMSO. Quantification is based on at least 3 independent replicates for 
each cell line. Data as means +/- SEM (n=3; student t-test; *, P < 0.05). 
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 (pAKT T308)  reductions in the BRAF-mutant, 8505C, cell line and 18.7-fold (p-AKT S473) and 21.4-
fold (pAKT T308)  reductions in the RAS-mutant, C643, cell line, in comparison to the DMSO control 
(Fig.4.3B & Table 4.2).  Taken together this data supports a hypothesis in which the combined 
inhibition of Src and the MAPK promotes sensitivity through inhibition of both the MAPK and PI3K 
pathways. 
A Reduction in rpS6 Phosphorylation Correlates with an Increase in Overall Survival In Vivo 
 Having observed a substantial reduction in rpS6 phosphorylation in the cell lines that 
responded to the combination therapy, we next wanted to retrospectively analyze tumors 
generated from the RAS-mutant, Cal62, cell line, which exhibited an increased overall survival to the 
combined inhibition of Src and the MAPK pathway, in comparison to either single agent inhibitor 
(Fig. 3.9B) 106.   From this study, tumors were harvested after 42 days of treatment with either the 
vehicle, trametinib, dasatinib, or the combination (Fig 3.9B). We then performed western blot 
analysis on 6 vehicle, 4 trametinib, 8 dasatinib, and 5 dasatinib + trametinib treated tumors. 
Interestingly, both pS6 S235/236 and pSRC Y416 levels were reduced with the combination therapy 
in comparison to either the vehicle or the single agent inhibitors (Fig 4.5).  Phosphorylation of 
ERK1/2 exhibited similar inhibition with both trametinib and the combination of trametinib and 
dasatinib (Fig 4.5).  Thus, this data supports rpS6 as biomarker of response to the combined 
inhibition of Src and the MAPK pathway in an in vivo model of thyroid tumorigenesis.   
Expression of Drug Resistant c-Src Abrogates the Growth Inhibitory Effects of the Combined 
Inhibition of Src and the MAPK Pathway 
 Due to the ability of dasatinib to target a number of kinases 215,216, we wanted to next 
validate the role of Src in mediating tumorigenesis and PI3K activation, in the dasatinib intrinsically 











Figure 4.5. Increased tumor responsiveness correlates with a decrease in rpS6 
phosphorylation.  Cal62 tumors treated with either vehicle, 0.5 mg/kg QD trametinib, 12.5 
mg/kg BD dasatinib, or the combination were harvested after 42 days of treatment.  Tumors 
were homogenized and whole cell lysates were analyzed by western blot analysis for the 
indicated antibodies. Densitometry was averaged across each treatment group. Data as means 
+/- SEM (n=4-8; student t-test; *, P < 0.05).  
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 (GK), as well as c-SRC wild type (WT), and empty vector (EV) constructs into the BRAF-mutant 
dasatinib-intrinsically resistant cell line, 8505C.  Comparison of the three constructs demonstrates 
that the c-Src gatekeeper mutant maintains FAK Y861 phosphorylation in the presence of dasatinib 
or the combination, but does not prevent the reduction in ERK1/2 phosphorylation observed with 
either single agent trametinib or the combination (Fig. 4.6A).  Importantly, the c-Src gatekeeper 
mutant prevents the reduction in AKT and rpS6 phosphorylation observed with either single agent 
or the combination, suggesting that the ability of dasatinib to reduce signaling through the PI3K 
pathway is likely mediated through its inhibitory effects on Src (Fig. 4.6A). We next analyzed the 
ability of the c-Src gatekeeper mutant to promote resistance to Src inhibition or to the combined 
inhibition of Src and the MAPK pathway.  Comparison of the c-Src gatekeeper mutant expressing 
cells with the cells expressing the empty vector showed only a small difference in response to 
dasatinib treatment, with IC50 values of 878 nM and 575 nM, respectively, however expression of 
the c-Src wild type construct resulted in an enhanced sensitivity to dasatinib, with an IC50 value of 
140 nM (Fig. 4.6C). Consistent with there being no difference in the ability of trametinib treatment 
to reduce phospho-ERK1/2 phosphorylation (Fig 4.6A), we also observed no difference in the growth 
inhibitory effects of trametinib between the empty vector, wild type, and gatekeeper-mutant 
expressing cell lines (Fig 4.6B).  Interestingly, despite the lack of differences to the single agent 
therapies, expression of the c-Src gatekeeper mutant was able to block the inhibitory effects of the 
combination of dasatinib and tramentinib treatment, with an IC50 value of 265 nM, in comparison to 
the empty vector and wildtype IC50 values of 15 nM and 9.8 nM, respectively (Fig. 4.6B).  Therefore, 
this data supports a role for Src mediated PI3K pathway activation, in thyroid cancer cell lines. 
Src Regulation of PTEN Activity in Thyroid Cancer 
 As phosphorylation of PTEN by Src has previously been demonstrated to regulate PTEN 





Figure 4.6: The drug resistant c-Src mutation mediates resistance to the combined 
inhibition of Src and the MAPK pathway. A. & B.) Western blot analysis was performed on 
whole cell lysates from the 8505C cell line expressing either an empty vector (EV), wild type 
Src (WT) or drug resistant gatekeeper mutant Src (GK) treated with either DMSO, 100nM 
trametinib, 100nM dasatinib, or the combination for 24 hours.  Lysates were analyzed using 
the indicated antibodies. Western blots are representative of three independent replicates. C. 
& D.) The 8505C cell line expressing either an empty vector (EV), wild type Src (WT) or drug 
resistant gatekeeper mutant Src (GK)  were treated with increasing doses of dasatinib ranging 
from (0.019 μM to 1.25 μM) for 72 hours, in the presence of either DMSO or 100nM 
trametinib. Cell growth was measured using the Sulforhodamine B assay.  
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through modulation of PTEN 92.  To test this, we choose to knockdown PTEN using two short-hairpin 
RNAs (shRNAs) (Sigma-TRC1 collection).  Knockdown of PTEN in the BRAF-mutant, 8505C, and HRAS-
mutant, C643, cell lines resulted in a 45 – 70% reduction in PTEN protein expression (P < 0.05) (Fig. 
4.7A). Having validated sufficient knockdown of PTEN, we next tested these cells for their ability to 
prevent the inhibition of growth observed with either single agent dasatinib or the combination 
therapy (Fig. 4.7B).  However, in contrast to expression of the c-Src gatekeeper mutant, loss of PTEN 
did not promote an increase in resistance to the combined inhibition of Src and the MAPK pathway 
(Fig 4.7B).  Analysis of signaling revealed a trend towards an increase in AKT and rpS6 
phosphorylation in response to knockdown of PTEN, using the shPTEN 47 construct, which suggests 
that sufficient knockdown of PTEN may potentially promote a further increase in PI3K pathway 
activation (Fig. 4.7D). Interestingly, despite reduced levels of PTEN expression, the combined 
inhibition of Src and the MAPK pathway was still able to effectively reduce both AKT and rpS6 
phosphorylation (Fig. 4.7C & D), suggesting that Src may function to mediate PI3K pathway 
activation more directly, at either the level of PI3K or AKT. 
Inhibition of rpS6 Phosphorylation is Neither Necessary nor Sufficient to Meditate the Growth 
Inhibitory Effects of the Combined Inhibition of Src and the MAPK Pathway 
 Taken together, our data currently points towards a role for rpS6 in mediating sensitivity 
and resistance to the combined inhibition of Src and the MAPK pathway.  In addition, P70S6K 
activation and rpS6 phosphorylation have previously been demonstrated to correlate with an 
increase in resistance to targeted therapies in head and neck squamous carcinoma cell lines 160.  To 
test a role for rpS6 phosphorylation in mediating sensitivity to the combination therapy, we 
expressed a doxycycline inducible, constitutively active, P70S6K-E389-ΔCT P “ K-CA), construct 














Figure 4.7: Src signaling bypasses PTEN regulation.  A.) Quantification of PTEN expression in 
scrambled and knockdown conditions in the BRAF-mutant, 8505C, and HRAS-mutant, C643, 
cell lines. (n=3-4; student t-test; *, P < 0.05, **, P < 0.005, ***, P < 0.0005) B.) Dasatinib 
growth analysis in BRAF- and RAS-mutant cell lines expressing either scrambled controls or 
shPTEN knockdowns.  C.) Western blot analysis of BRAF- and RAS-mutant cell lines 
expressing scrambled control or shPTEN constructs treated with either DMSO, 100 nM 
trametinib, 100 nM dasatinib, or the combination for 24 hours. D. Quantification of pAKT 
S473 and pS6 S235/S236 densitometry.  Data as means +/- SEM (n=3-4). 
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respectively.  P70S6K-CA allows for P70S6K to function independent of mTORC1 regulation, as it 
contains a phosphomimetic glutamine instead of threonine at the primary mTORC1 activating 
phosphorylation site (T389), as well as a deletion of the negative regulatory c-terminus 217. The 
addition of doxycycline induced the expression of P70S6K, however no increase in basal rpS6 
phosphorylation was observed (Fig. 4.8A). Expression of P70S6K-CA was able to partially rescue the 
inhibition of rpS6 phosphorylation in the presence of the combination therapy, as we observed a 
108-fold and 16- fold reduction in phospho-rpS6 in the control 8505C and C643 cell lines, 
respectively, whereas only a 17-fold and 3-fold reduction was observed in the 8505C and C643 cell 
lines expressing P70S6K-CA, respectively (Fig. 4.8A). Therefore, we next analyzed the ability of 
P70S6K-CA to prevent a reduction in clonogenic growth in response to either single agent 
(trametinib or dasatinib) or the combination. Despite a rescue in rpS6 phosphorylation, expression 
of P70S6K-CA was unable to rescue the growth inhibitory effects of the combination therapy or 
either single agent alone (Fig. 4.8B). These data suggest that a reduction in rpS6 phosphorylation is 
not necessary for the growth inhibitory effects of the combination therapy.  
 Thus, we next asked whether a reduction in rpS6 phosphorylation is sufficient to induce the 
increase in apoptosis observed with the combination therapy.  Treatment of the dasatinib 
intrinsically resistant cell lines (8505C and C643) with the MTORC1 inhibitor, everolimus, resulted in 
a 3-4 fold enhanced reduction in rpS6 phosphorylation at both the S235/S236 and S240/S244 sites in 
comparison to the combined inhibition of dasatinib and trametinb, however only the combination 
therapy was able to induce an increase in apoptosis (Fig. 4.8C). As expected, no reduction in FAK, 
ERK, or AKT phosphorylation was observed with the MTORC1 inhibitor, whereas we did observe 
inhibition of these targets with Src and/or MEK1/2 inhibition (Fig. 4.8C). Therefore, inhibition of rpS6  
is not sufficient to phenocopy the induction of apoptosis observed with the combination therapy. To 
support this, we performed clonogenic growth assays in both the BRAF- and RAS- mutant dasatinib 
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intrinsically resistant cell lines, 8505C and C643, respectively.  Cells were treated with either DMSO, 
trametinib, dasatinib, trametinib + dasatinib, or everolimus. Importantly, despite the ability of 
everolimus to more effectively inhibit rpS6 phosphorylation (Fig. 4.8C), we did not observe a similar 
or enhanced inhibition of cell growth in comparison to the combined inhibition of Src and the MAPK 
pathway (Fig. 4.8D & E).  Taken together, these results suggest that the effectors of the PI3K 
pathway that are necessary for growth and survival are upstream of P70S6K and downstream of Src. 
Single Cell Analysis Identifies Heterogeneous Phospho-rpS6 Responses to Single Agent and 
Combination Therapy 
 Whereas there is a significant reduction in rpS6 phosphorylation in the BRAF- and RAS-
mutant cell lines, in comparison to the PIK3CA-mutant cell lines treated with the combination 
therapy, rpS6 phosphorylation is not completely abrogated in the BRAF- and RAS-mutant cell lines 
and the combination therapy is unable to completely eliminate colony formation in the clonogenic 
assays. Therefore, to better define the role of rpS6 phosphorylation status, as a biomarker of 
response to the combination therapy, we analyzed rpS6 phosphorylation at the single cell level using 
immunofluorescence in the two dasatinib-intrinsically-resistant cell lines that respond to the 
combination therapy, 8505C and C643. Surprisingly, treatment with either single agent MEK1/2 or 
Src inhibitor, or the combination, did not result in a universal reduction in rpS6 phosphorylation (Fig. 
4.9A & B).  Rather, a subset of cells remain after treatment that do not exhibit a reduction in rpS6 
phosphorylation (phospho-rpS6 persisters). In order to quantify the number of phospho-rpS6 
persisters we chose to use half the average intensity of the DMSO treated cells as the cut off for 
classification of phospho-rpS6 low or high expression.  This cutoff resulted in less than 25% of the 
DMSO treated control cells being classified as p-rpS6 low, and therefore a significant change in the 
number of cells with p-rpS6 low expression represents an increased efficacy as a result of 
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Figure 4.8: rpS6 phosphorylation is neither necessary nor sufficient for the growth inhibitory 
effects of the combined inhibition of Src and the MAPK Pathway. A.) Western blot analysis was 
performed on whole cell lysates from the 8505C or C643 cell line expressing a doxycycline inducible 
P “ K T  ΔCT o st u t.  Cells e e t eated ith o  ithout do li e fo   hou s p io  to 
treatment. After 24 hours the cells were treated with either DMSO, 100 nM trametinib, 100 nM 
dasatinib, or the combination of dasatinib and trametinib.  Lysates were analyzed for the indicated 
antibodies. Quantification was performed using the Odyssey Image Studio V.4.0 Software. Data as 
means +/- SEM (n=2)   B.) Clonogenic growth was detected by crystal violet staining in the 8505C or 
C  ell li es e p essi g the do li e i du i le P “ K T  ΔCT o st u t. Cell li es e e 
treated with or without doxycycline upon plating. 24 hours later the cell lines were treated with 
either DMSO, 100 nM trametinib, 100 nM dasatinib, or the combination for 6 days. Following 6 
days of treatment, the cells were released for an additional 7 days. Colony area signal intensity was 
measured using Odyssey CLx imager (Li-Cor), and presented as percent fold change relative to the 
DMSO treated wells. Data as means +/- SEM (n=3).  C.) Western blot analysis was performed on 
whole cell lysates from the parental 8505C or parental C643 cell lines treated with either DMSO, 
 M t a eti i ,  M dasati i , o   μM E e oli us fo   hou s fo  the i dicated 
antibodies.  Quantification was performed using the Odyssey Image Studio V.4.0 Software. Data as 
means +/- SEM (n=2-3) D.) Clonogenic growth was detected by crystal violet staining in the 8505C 
and C643 cell lines.  Cell lines were treated for 24 hours with either DMSO, 100 nM trametinib, 100 
nM dasatinib, dasatinib + trametinib, or 1 µM everolimus. Colony area signal intensity was 
measured using Odyssey CLx imager (Li-Cor), and presented as percent fold change relative to the 
DMSO treated wells. Data as means +/- SEM (n=3).   
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66% and 59% increase in the number of phospho-rpS6 low expressing cells, respectively, and the 
combination therapy resulted in a 96% increase in cells with phospho-rpS6 low expression, which is 
also a significantly larger increase in comparison to both MEK1/2 and Src inhibition alone (P = 0.0011 
and P= 0.0003, respectively) (Fig 4.9B).  In the RAS-mutant, C643, cell line, MEK1/2 inhibition 
resulted in a 33% increase in phospho-rpS6 low expressing cells, whereas in the dasatinib treated 
group there was a 53% increase in phospho-rpS6 low expressing cells.  The combination therapy did 
not have nearly the same effect in the C643 cell line, as it did in the 8505C cell line, as we observed 
only a 68% increase in the percentage of p-S6 low expressing cells (Fig. 4.9B). We next analyzed cells 
for evidence of cell death, by quantifying cells that were positive for PARP cleavage. Similar to 
western blot analysis, PARP cleavage was primarily observed in cells treated with combined Src and 
MAPK pathway inhibitors (Fig 4.9C). Importantly, when analyzing cells treated with the combination 
therapy, we observed a significant increase in cleaved PARP positive cells, in cells expressing low 
levels of rpS6 phosphorylation, in comparison to the DMSO treated cells with high rpS6 
phosphorylation (8505C; P = 0.008 and C643; P = 0.0001) (Fig. 4.9C).  We also observed PARP 
cleavage in 1 DMSO and 1 combination treated 8505C cell that exhibited p-S6 high expression, 
however as these results were inconsistent, we did not observe a significant correlation. Taken 
together, these data suggest that rpS6 phosphorylation may be a biomarker of response for cancer 
cells that are responsive to the combined inhibition of Src and the MAPK pathway, and that an 
inability to inhibit rpS6 phosphorylation correlates with cells that appear to be resistant to 
apoptosis, when treated with the combination therapy. 
Analysis of AKT Inhibition in Relation to Src and MEK1/2 Inhibition 
 Having observed that 4% and 32% of the 8505C and C643 cells, respectively, maintain rpS6 
phosphorylation upon treatment with the combination therapy (Fig. 4.9B), we next hypothesized  
112 
 
Figure 4.9:  Single cell analysis identifies heterogeneous phospho-rpS6 responses to single 
agent and combination therapy. A.) the BRAF-mutant, 8505C, and RAS-mutant, C643, cell lines 
were analyzed by immunofluorescence for pS6 S235/S236 (Green), PARP Cleavage (Red), and 
Dapi (Blue) after 24 hours of treatment with either DMSO, 100 nM trametinib, 100 nM dasatinib, 
or the combination.  Images were acquired using 40x magnification. B.) Individual cells were 
analyzed for each treatment group for their intensity levels of S6 phosphorylation. P-S6 low 
represents signal intensity below half of the average intensity for the DMSO treated cells, and p-
S6 high represents any cells expressing greater than half of the average intensity for the DMSO 
treated cells. Data as means +/- SEM (n=3; student t-test; **, P < 0.005; ***, P < 0.0005). C.) 
Average Percent Cl. PARP positive cells for both the p-S6 high and low groups were averaged 
across 3 individual experiments. Significance is calculated in relation to the DMSO treated p-S6 
high values. Values indicated by (0) represent no Cl. PARP+ cells being observed. Data as means 
+/- SEM (n=3; student t-test; *, P < 0.05; ***, P < 0.0005).  
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that more effective inhibition of rpS6 phosphorylation may potentiate the cytotoxic effects in these 
cell lines. Thus, we tested the effects of Src and MEK1/2 inhibition in combination with an 
AKT/P70S6K inhibitor, AT7867, to determine if more effective inhibition of the PI3K pathway would 
enhance the reduction in rpS6 phosphorylation, and promote a decrease in cell growth and an 
increase in apoptosis. To test this, we first analyzed the ability of combined Src, MEK1/2, and AKT 
inhibition to effectively reduce rpS6 phosphorylation after 4 hours of treatment. Comparison of the 
dual inhibitory combinations resulted in a similar inhibition of rpS6 phosphorylation in the 8505C 
cell line, however we observed a larger percent decrease in rpS6 phosphorylation occurring with 
combined Src and AKT/P70S6K inhibition in comparison to the Src and MEK1/2 or AKT/P70S6K and 
MEK1/2 inhibitory combinations (Fig. 4.10A). Interestingly, when inhibiting both the MAPK pathway, 
as well as the PI3K pathway, with trametinib plus dasatinib and/or AT7867, respectively, the ability 
of these inhibitors to reduce rpS6 phosphorylation correlates with growth inhibition and increased 
apoptosis (Fig. 4.10B & C). Important for future considerations is the observation that the combined 
inhibition of Src and AKT/P70S6K results in the largest decrease in rpS6 phosphorylation in 
comparison to the other dual inhibitory combinations, however this decrease in rpS6 does not 
correlate with a similar increase in apoptosis or decrease in growth (Fig. 4.10A-C). Consistent with 
our hypothesis that there may be residual PI3K pathway signaling in cells treated with the combined 
inhibition of Src and the MAPK pathway, we observe the greatest reduction in rpS6 phosphorylation 
in the cells treated with Src, MEK1/2, and AKT/P70S6K inhibitors (Fig. 4.10A-C).  Larger reductions in 
rpS6 phosphorylation are also consistent with an enhanced inhibition of growth and an increase in 
apoptosis Fig. 4.10B & C). 
Discussion 
 Src-driven oncogenesis has been well documented in a number of cancers, however unlike 
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Figure 4.10: Analysis of combined AKT/P70S6K, Src, and MAPK pathway inhibition in thyroid 
cancer cell lines. A.) Western blot analysis was performed on whole cell lysates from the 
8505C or C643 cell line after a 4 hour treatment with either DMSO, 100 nM trametinib, 100 
M dasati i , .  μM AT , o  the o i atio s.  L sates e e a al zed fo  the i di ated 
antibodies. Quantification was performed using the Odyssey Image Studio V.4.0 Software. 
Data as means +/- SEM (n=3) B.) Clonogenic growth was detected by crystal violet staining in 
the 8505C or C643 cell lines treated with either DMSO, 100 nM trametinib, 100 nM dasatinib, 
.  μM AT 7, or the combinations for 3 days. Following 3 days of treatment, the cells were 
released for an additional 6 days. Colony area signal intensity was measured using Odyssey 
CLx imager (Li-Cor), and presented as percent fold change relative to the DMSO treated wells. 
Data as means +/- SEM (n=3).  C.) Cleaved caspase 3/7 activity was measured after an 8 hour 
i u atio  ith eithe  DM“O,  M t a eti i ,  M dasati i , .  μM AT , o  the 
combinations in the 8505C and C643 cell lines. Data as means +/- SEM (n=3; student t-test; *, 
P < 0.05). 
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inhibition promotes an increased reliance of thyroid cancers on the MAPK pathway, and that the 
upfront combined inhibition of Src and the MAPK pathway can prevent/delay resistance from 
occurring (Chapter III) 106. Our study, along with others highlighting synergy between the combined 
inhibition of Src and the MAPK pathway, support a role for Src in mediating resistance to inhibitors 
of the MAPK pathway in thyroid cancer 102,103,106. Therefore, in this study we set out to determine 
which patients would benefit from combined inhibition of Src and the MAPK pathway, to better 
inform therapeutic strategies in the clinic. Mutations in the RAS/MAPK pathway and the PI3K 
pathway make up the majority of driver mutations in advanced thyroid cancer, therefore we chose 
to analyze the efficacy of the combined inhibition of Src and the MAPK pathway in cell lines 
harboring these clinically relevant mutations 19.  To this extent, we were able to demonstrate an 
increased efficacy for the combination therapy in BRAF- and RAS-mutant cell lines, but observed no 
increase in apoptosis in cell lines harboring PIK3CA-mutations. Consistent with the apoptosis data, 
the combination of dasatinib and trametinib more effectively reduced AKT and rpS6 
phosphorylation in BRAF- and RAS-mutant cell lines but not in PIK3CA-mutant cell lines, suggesting 
that the ability of combined inhibition of Src and the MAPK pathway to induce growth arrest and 
apoptosis, correlates with inhibition of AKT and rpS6 phosphorylation. rpS6 is a key downstream 
effector of both the MAPK and PI3K pathways, as it can be phosphorylated by both Ribosomal S6 
Kinase (RSK) and P70S6 Kinase (P70S6K).  In further support, additional studies in thyroid cancer 
have evaluated the efficacy of MEK1/2 and PI3K, AKT, and/or mTOR inhibitors, and found that the 
combinations that were the most effective correlated with increased inhibition of rpS6 
phosphorylation 161,218. Indeed, multiple studies in different tumor types have also highlighted the 
efficacy of targeting both the MAPK and PI3K pathway 148,219–221, which further supports the 
examination of rpS6 as a biomarker of response for to the combined inhibition of the MAPK kinase 
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pathway in combination with either Src or the PI3K pathway in additional tumor types.  In addition, 
a recent salvage therapy case for a patient with anaplastic thyroid cancer treated with the B-Raf 
inhibitor, dabrafenib, and the MEK1/2 inhibitor, trametinib, utilized rpS6 phosphorylation status as 
an indicator for a lack of responsiveness to the targeted therapies 222. Importantly, upon observing 
rpS6 phosphorylation, post-treatment, the mTOR inhibitor, everolimus, was added to the 
therapeutic regimen, and a dramatic regression in tumor volume was observed 222.  
 As Src can regulate a number of pathways, it is important to define the mechanisms 
promoting the increased efficacy of the combined inhibition of Src and the MAPK pathway, so as to 
better inform future therapeutic development, and more effectively identify patients that will 
respond to the combination therapy 208.  Therefore, having observed reduced activation of the PI3K 
pathway upon inhibition of Src and/or the combined inhibition of Src and the MAPK pathway, we 
next asked whether Src plays a role in activation of the PI3K pathway in thyroid cancer. To test this, 
we expressed either a c-Src wild type or a c-Src gatekeeper mutant into two BRAF-mutant cell lines, 
and found that expression of the c-Src gatekeeper mutant, but not wild type c-Src was able to 
abrogate the reduction in rpS6 phosphorylation, as well as the reduction in AKT phosphorylation. 
Taken together, these data suggest that a primary mechanism of Src mediated tumorigenesis in 
BRAF- and RAS-mutant thyroid cancer cells is through its role in mediating activation of the PI3K 
pathway. To the best of our knowledge, this is the first indication that Src may play a role in 
activating the PI3K pathway in thyroid cancer. In addition, it aligns recent discoveries highlighting 
the importance of targeting Src or the PI3K pathway in combination with MAPK pathway inhibitors, 
in thyroid cancer 102,103,106,161,218.  However, as we only analyzed growth and apoptosis in this study, 
the role of Src in mediating invasion and migration warrants further exploration, as there may be 
additional benefits from targeting Src, and inhibiting the metastatic potential of thyroid cancer cells, 
as well.    
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Src regulation of the PI3K pathway has been well documented throughout the literature, as 
Src can mediate indirect activation of AKT through the inhibition of PTEN 92, or PIK3CA membrane 
recruitment through activation of PTK2 (FAK) or p130Cas 93 .  Alternatively, Src  can activate the PI3K 
pathway by directly phosphorylating AKT at Y315 and Y326 89.  Interestingly, recent sequencing 
efforts identified PTEN mutations in only 0.5% of papillary thyroid cancers, which were independent 
of either BRAF- or RAS-mutations 18.  In poorly differentiated and anaplastic thyroid cancers, 7% of 
the tumors sequenced contained PTEN mutations 19.  Interestingly, in the PDTC and ATC dataset, 0 
out of 43 BRAF-mutant tumors, and 1 out of 33 RAS-mutant tumors had coexisting PTEN mutations 
(cBioPortal) 19. In contrast, analysis of the TCGA cutaneous melanoma dataset identified PTEN 
alterations in 16 out 123 BRAFV600E-mutant and 1 out of 13 RAS-mutant tumors, which once again 
highlights a difference between thyroid cancer and melanoma (cBioPortal) 223.   This data therefore 
suggests that Src may bypass PTEN activation, by promoting the direct activation of the PI3K 
pathway, in BRAF- and RAS-mutant thyroid cancers.  Thus, it is therefore intriguing to speculate that 
Src may play a role in driving the clonal evolution of BRAF- and RAS-mutant thyroid cancers away 
from acquisition of PTEN mutations or deletions, by decreasing a selective pressure or advantage for 
cells having acquired these mutations.  Therefore, we chose to analyze the role of PTEN in mediating 
sensitivity to the combined inhibition of Src and the MAPK pathway. Surprisingly, when growth was 
assessed in cells containing a scrambled control shRNA or shPTEN constructs, the shPTEN expressing 
cells exhibited no increase in resistance to the combined inhibition of Src and the MAPK pathway in 
comparison to the controls. As we were unable to completely knockdown PTEN, we cannot rule out 
the possibility that the remaining levels of PTEN are sufficient to promote the growth inhibitory 
effects of the combination therapy, however given a lack of resistance with a 40-70% knockdown, it 
provides rationale for fu the  e plo atio  of “ s ole i  ediati g a di e t egulatio  of the PI3K 
pathway, in future studies. Previous reports in thyroid cancer suggest that PTEN is downregulated at 
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the transcriptional level due to promoter methylation, however, in contrast we do not observe a 
lack of PTEN expression in the cell lines tested, which once again supports a direct role for Src in 
regulating PI3K pathway activation 224.  Therefore, future analysis of PTEN expression and Src 
activation will be important for bioma ke  dis o e , a d fu the  dete i atio  of “ s ole i  
mediating PI3K pathway activation. 
 Having demonstrated a strong role for Src in regulating activation of the PI3K pathway, we 
next determined the role of rpS6 in mediating tumorigenesis in thyroid cancer. rpS6 represents a 
downstream target of both the MAPK and PI3K pathways and therefore represents an important 
downstream effector of both of these pathways. Having observed a correlation with a reduction in 
rpS6 phosphorylation and apoptosis in cell lines sensitive to the combination therapy, we 
hypothesized that maintaining rpS6 phosphorylation by expressing a constitutively active P70S6K 
construct would promote resistance in our cell lines. We based this hypothesis off of a discovery 
from Axelrod et al who demonstrated that overexpression of a constitutively active P70S6K 
construct is able to overcome sensitivity to the combined inhibition of the HER-family kinases with 
lapatinib, and AKT inhibition with LY294002, through the maintenance of rpS6 phosphorylation 160. 
Surprisingly, we did not observe a similar effect, which may likely be due to a difference in the 
mutational landscape of the cell lines tested, as the aforementioned study did not analyze cell lines 
with BRAF- or RAS-mutations. Importantly, we also observed similar results with everolimus, or the 
combination of Src and AKT/P70S6K inhibition, in which both resulted in a greater reduction in rpS6 
phosphorylation, yet enhanced inhibition of growth or apoptosis was not observed. This is 
potentially due to an increased reliance on both the MAPK and PI3K pathways in thyroid cancer, as 
we were not able to completely prevent the reduction in rpS6 phosphorylation with CA-P70S6K 
expression, which is likely due to MAPK pathway regulation of rpS6 phosphorylation.  Importantly, 
rpS6 is not the only node of convergence between the MAPK and PI3K pathways, as additional 
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effectors include: the forkhead box O (FOXO) family members, c-myc, BCL2-associated agonist of cell 
death (BAD), GSK3, as well as others 147. Therefore, our data demonstrates that there may be 
alternative effectors mediating the oncogenic signaling outputs derived from the MAPK and PI3K 
pathways, and that these alternative effectors should be analyzed in more detail to determine the 
key downstream nodes mediating growth and survival. 
 Finally, despite enhanced sensitivity in response to the combination therapy, we were still 
unable to completely eradicate all of the cancer cells in our clonogenic assays, and this also 
correlated with an inability to completely inhibit rpS6 phosphorylation.  Therefore, we further 
explored the role of rpS6 as a biomarker of response to the combination therapy.  To accomplish 
this, we performed immunofluorescence analysis of rpS6 phosphorylation, upon treatment with the 
combination therapy, in both the BRAF- and RAS-mutant cell lines. Surprisingly, a universal 
reduction in rpS6 phosphorylation was not observed upon treatment with the combination therapy, 
but rather a sporadic reduction was observed at the individual cell level.  In addition, whereas there 
was a greater increase in the number of cells with reduced rpS6 phosphorylation in the combination 
treated group, a percentage of cells still persisted with high levels of rpS6 phosphorylation.  Based 
on a potential role for rpS6 phosphorylation as a biomarker of response to the combination therapy, 
these data suggest that these phospho-rpS6 persister cells may give rise to the drug tolerant 
population observed within the clonogenic assays.   
The addition of a third inhibitor, AT7867,  targeting AKT and P70S6K, to the dasatinib and 
trametinib combination, resulted in an enhanced inhibition of growth and survival in these cell lines, 
which suggests that there may be some residual activity through the PI3K pathway.  It has previously 
ee  de o st ated that PTEN a  sele ti el  egulate P β PIK3CB) in breast cancer, and 
therefore providing rationale that Src may selectively regulate a specific PIK3CA isoform that can be 
compensated for by an alternative isoform 225.  
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Going forward with these studies, it will be important to determine the role of the PI3K 
isoforms in mediating thyroid cancer cell growth and survival, as this will help to better determine 
the roles for PI3K isoform specific inhibitors in thyroid cancer. In addition, our data provides a critical 
piece of information in regards to the role of Src in thyroid cancer, and the patient populations most 
likely to respond to the combined inhibition of Src and the MAPK pathway. Lastly, the identification 
of rpS6 as a biomarker of response to the combined inhibition of Src and the MAPK pathway, 
provides an important tool for the identification of drug tolerant persisters, and the future 
determination of pathways that mediate resistance to this combination strategy.  Taken together, 
we predict that the discoveries presented in this study will pave the way for improved responses, 















Summary of Key Findings and Conclusions 
 The development of targeted therapies has vastly improved patient tumor responses and 
progression free survival.  However, despite similar oncogenic drivers these responses are not 
universal across all tumor types 184. One major therapeutic difference exists between BRAF-mutant 
melanoma and BRAF-mutant thyroid cancers, in relation to the responses observed with the B-Raf 
inhibitor, vemurafenib, in which thyroid cancers exhibit an increased resistance in comparison to 
melanoma 42.  Interestingly, our lab and others have demonstrated that Src inhibitors represent a 
potentially more promising therapeutic strategy for thyroid cancer patients 99–101,103. However, 
despite promising preclinical data, the patient responses to Src inhibition have not been as robust as 
would have been predicted in other tumor types. Therefore the goal of this thesis was to define 
strategies in which we can more effectively target Src in the clinic.  Interestingly, in addition to 
answering these questions, I also believe that the work provided in this thesis also provides 
evidence to suggest that Src may be an important factor in mediating the confounding resistance to 
MAPK pathway inhibitors, in thyroid cancer. 
 First in Chapter III, I used a model of acquired resistance to dasatinib to uncover a role for 
the MAPK pathway in mediating resistance to Src inhibition, in thyroid cancer.  Surprisingly, despite 
differential acquisition of the c-SRC gatekeeper mutation in the RAS-mutant cell lines in comparison 
to the BRAF-mutant cell lines, all of the dasatinib resistant cell lines exhibited an increased 
dependence on the MAPK pathway.  This is likely due to an initial inhibition of ERK phosphorylation, 
followed by a rapid rebound within 48 hours, which represents an early mechanism of resistance in 
response to Src inhibition. Along these lines, combined upfront inhibition of Src and the MAPK 
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pathway resulted in enhanced inhibition of growth and an increase in apoptosis in vitro, and an 
enhanced inhibition of growth and increased overall survival in vivo. In chapter IV, I provided 
evidence to suggest that the synergy observed between the combined inhibition of Src and the 
MAPK pathway, is likel  a esult of “ s a ilit  to regulate activation of the PI3K pathway, 
specifically in BRAF- and RAS-mutant cell lines.  Interestingly, elevated levels of PI3K pathway 
activation also correlate with intrinsic resistance to the Src inhibitor, dasatinib. In addition, I also 
identified that rpS6 phosphorylation status correlates with the ability of the combination therapy to 
effectively inhibit both the MAPK and Src/PI3K pathways, which suggests that rpS6 phosphorylation 
status represents a potential biomarker of response and an important indicator of the efficacy of the 
combination therapy.  Taken together, the data presented throughout this thesis has identified that 
inhibition of Src signaling promotes an increased reliance on the MAPK pathway, increased PI3K 
pathway activation correlates with intrinsic resistance, and that rpS6 phosphorylation may be an 
important clinical biomarker that should be taken into consideration when monitoring patients 
treated with combined Src and MAPK pathway inhibitors. 
Prolonged Src Inhibition Promotes an Increased Reliance on the MAPK Pathway in Thyroid Cancer 
 The data presented in chapter III uncovers important mechanisms that mediate the 
reprogramming of thyroid cancer cells in response to prolonged Src inhibition.  Importantly, 
dasatinib-resistant tumors respond to MAPK pathway inhibitors more similar to melanoma, in which 
there is an increased dependence on the MAPK pathway.  Clinically, this is a very important 
discovery, as the lack of efficacy of MAPK pathway inhibitors in thyroid and colorectal cancers 
remains a major dilemma 42.  In contrast to thyroid and colorectal cancers, Src is not typically 
overexpressed and activated in melanoma, which further highlights Src as a potential upfront 
mechanism of resistance to MAPK pathway inhibitors.  In support of this, Src activity has been 
demonstrated to be elevated in response to B-Raf inhibitors, in melanoma, which further mediates 
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resistance to B-Raf inhibitor therapy 107.  Importantly, this finding may help to pave the way for the 
development of more effective biomarkers that predict patient responses to MAPK pathway 
targeted therapies, and further supports the continued development of inhibitors that target these 
important signaling nodes.   
The MAPK Pathway is a Promising Co-Target in Combination with Src Inhibition in Thyroid Cancer. 
 Taken together, the data presented in chapter III provides important preclinical evidence in 
support of a clinical trial in thyroid cancer co-targeting Src and the MAPK pathway.  Our data 
demonstrates that inhibition of Src results in an early inhibition of the MAPK pathway, however a 
rapid recovery of MAPK pathway signaling is observed within 8-48 hours. Co-targeting of these two 
pathways results in synergistic inhibition of growth and an increase in apoptosis in vitro, as well as 
an increase in overall survival in vivo.  Therefore, combined Src and MAPK pathway inhibition has 
the potential to prevent or delay resistance to either single agent inhibitor. Importantly, combined 
Src and MAPK pathway inhibition has also been demonstrated to be effective in a syngeneic model 
of murine thyroid cancer, which provides further rationale for the advancement of this therapeutic 
combination into the clinic 102. Briefly, treatment of these mice with the B-Raf-inhibitor, PLX4720, 
promoted a robust increase in the infiltration of cytotoxic CD8+ T cells, B cells, and macrophages, 
which is maintained with the combination therapy. In addition, the combination therapy resulted in 
a significant increase in apoptosis and a significant reduction in tumor volume in comparison to the 
control and single agent arms of the study 102.  Taken together, this data suggests that the combined 
inhibition of Src and the MAPK pathway may even further benefit from the addition of 
immunotherapies. Furthermore, recent development of inhibitors targeting both B-Raf and Src, 
CCT196969 and CCT241161, may help to further advance this therapeutic combination, through a 
decrease in the toxicities associated with multiple inhibitors, which may allow for the further 
addition of immunotherapies 107.  
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Src Regulates Activation of the PI3K Pathway in BRAF- and RAS-Mutant Thyroid Cancer Cell Lines 
 In chapter IV, I discovered that a primary mechanism of Src mediated tumorigenesis is likely 
through its role in mediating activation of the PI3K pathway.  Analysis of BRAF-, RAS-, and PIK3CA-
mutant cell lines treated with the combined inhibition of Src and the MAPK pathway resulted in an 
increase in apoptosis in the BRAF- and RAS-mutant cell lines, despite their intrinsic sensitivity or 
resistance to single agent Src inhibition. However, no increase in apoptosis was observed in the 
PIK3CA-mutant cell lines.  Interestingly, this sensitivity correlated with a reduction in AKT and rpS6 
phosphorylation, which was not observed in the PIK3CA-mutant cell lines.  In further support, 
expression of the c-Src gatekeeper mutant prevented a reduction in the PI3K pathway upon 
treatment with the Src inhibitor, dasatinib, which indicates that the inhibition of the PI3K pathway is 
not due to off-target effects of dasatinib. 
rpS6 Phosphorylation Represents a Biomarker of Response to the Combined Inhibition of Src and the 
MAPK Pathway 
 In chapter IV, we analyzed a downstream target (rpS6) of both the MAPK pathway and the 
PI3K pathway, as a potential biomarker of response, to the combined inhibition of Src and the MAPK 
pathway.  Interestingly, we discovered that there was a greater reduction in rpS6 phosphorylation in 
cell lines sensitive to the combination therapy.  In addition, this reduction was dependent on Src, as 
expression of the c-Src gatekeeper mutant effectively abrogated the reduction in rpS6 
phosphorylation. Surprisingly, analysis of rpS6 phosphorylation by immunofluorescence uncovered a 
population of cells that maintain rpS6 phosphorylation, despite treatment with the combination 
therapy. Importantly, this population of phospho-rpS6 persister cells did not show signs of 
apoptosis.   
Based on data from other tumor models demonstrating that maintained phosphorylation of 
rpS6 could mediate resistance to targeted therapies, we analyzed whether this was a mechanism in 
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our cell lines.  Interestingly, expression of a constitutively active P70S6K construct was unable to 
mediate resistance to the combination therapy, despite maintaining higher levels of rpS6 
phosphorylation, in comparison to the controls. In support of this, treatment with the mTOR 
inhibitor, everolimus, effectively shut down rpS6 phosphorylation, however was unable to promote 
an increase in apoptosis or a decrease in clonogenic growth, in comparison to the combined 
inhibition of Src and the MAPK pathway.  These data importantly demonstrate that maintained 
phosphorylation of rpS6 may represent an important biomarker for cells that are unresponsive to 
the combined inhibition of Src and the MAPK pathway, however it also suggests that there may be 
additional effectors, downstream of Src and the MAPK pathway that play a larger role in mediating 
cell survival. 
Future Directions 
 The work provided in this thesis has critically advanced the understanding of Src inhibitors in 
thyroid cancer, and has provided important framework for the continued understanding of the 
mechanisms of Src mediated thyroid tumorigenesis.  Whereas previous research has shed light on 
the importance of Src in thyroid cancer, very little has been uncovered in relation to the 
mechanisms mediating the ability of Src to drive thyroid tumorigenesis.  Herein, we identified that 
Src promotes activation of the PI3K pathway, in BRAF- and RAS-mutant cell lines, and that inhibition 
of Src promotes an increased reliance on the MAPK pathway, which likely drives the synergy 
between the combined inhibition of Src and the MAPK pathway. Despite this understanding, 
identification of the mechanism(s) of Src mediated PI3K pathway activation remain to be fully 
elucidated.  The uncovering of this mechanism(s) will hopefully identify critical therapeutic targets 
and biomarkers, as well as provide evidence for the selective acquisition of the c-SRC gatekeeper 
mutation in RAS- uta t ell li es.  Mo e lies ahead i  the elu idatio  of “ s ole i  th oid a e , 
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and the discoveries will enhance the development of more effective therapeutics, with the goal of 
increasing the overall survival of patients with advanced thyroid cancer. 
Defining the Mechanism of c-SRC Gatekeeper Mutation Acquisition in RAS-Mutant Cell Lines   
 As our understanding of the resistance mechanisms to targeted therapies continues to 
develop, it is becoming more and more evident that heterogeneous mechanisms of resistance exist 
226.  In lung cancer, acquisition of the EGFR gatekeeper mutation is a prominent mechanism of 
resistance in response to EGFR inhibition, however it has also been well documented that 
alternative mechanisms including MET amplification or FGFR activation can also mediate resistance 
138,164,200.  Importantly, it has been demonstrated that prolonged periods of reprogramming, prior to 
acquisition of the gatekeeper mutation, can greatly affect the responses to secondary therapies. 
This is due to an increased likelihood of cells reprogramming and harboring additional mechanisms 
of resistance, which increases with the length of time it takes for cells to acquire gatekeeper 
mutations 134.  In chapter III, I discovered that the c-SRC gatekeeper mutation was only acquired in 
the RAS-mutant cell lines, upon acquisition of dasatinib resistance. To address the question of a 
general Ras-dependent mechanism of acquisition, and rule out a specific Ras-isoform mediated 
acquisition, I generated two additional cell lines resistant to the Src inhibitor, dasatinib, in appendix 
A.1.  Importantly, the BRAF-mutant, BHT101, cell line did not acquire the gatekeeper mutation, 
whereas the NRAS-mutant, ACT1, cell line did acquire the c-SRC gatekeeper mutation.  This data 
therefore suggests that acquisition of the gatekeeper mutation may have an increased propensity in 
RAS-mutant cell lines, and that there does not appear to be a dependence on a particular Ras 
isoform.  
 Importantly, acquisition of the gatekeeper mutation does not appear to be due to an 
inability of the gatekeeper mutation to mediate resistance in the BRAF-mutant cell lines, as we have 
previously demonstrated that exogenous expression of the c-Src gatekeeper mutant effectively 
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mediates resistance to dasatinib in the BRAF-mutant cell lines, BCPAP, SW1736, and 8505C (Fig. 
4.6B) 100.  This data therefore raises the question of whether or not there is a lack of selection, or a 
lack of acquisition for c-SRC gatekeeper mutations, in the BRAF-mutant cell lines.  Determination of 
this mechanism will importantly shed light on whether the mechanisms present in the RAS-mutant 
cell lines are related to an increased dependence on Src or differences in DNA repair.   
 An important experiment to perform, to address this question, will be to incubate the BRAF-
mutant cell lines at various stages of resistance with a single isogenic clone that harbors the c-SRC 
gatekeeper mutation. Briefly, the BRAF-mutant cell lines, BCPAP and SW1736, will be transfected 
with both a c-SRC gatekeeper mutant construct as well as an RFP nuclear label.  The cells will then 
be single cell sorted, by serial dilutions, in a 96 well plate.  Wells containing single cells will be 
identified, and 1000 GFP-labeled dasatinib-resistant cells, of varying stages of resistance (ability to 
grow through 100nm, 200nM, 600nM, 1µM, and/or 2µM dasatinib), will be added to the wells 
containing single RFP-labeled cells. Sensitive GFP-labeled parental cells will be grown alongside as a 
control.  24 hours later, the cells will be treated with their respective concentrations of dasatinib, as 
well as a concentration one step higher (e.g. 100nm to 200nM; 600nM to 1µM), and the RFP-
positive cells will be analyzed using live-cell imaging (Incucyte – Essen Bioscience) for their ability to 
selectively outgrow the GFP-positive dasatinib-resistant cells.  An ability for the gatekeeper mutant, 
RFP-positive cells to exhibit an increased selective advantage, will suggest that the mutation was not 
acquired during that stage of resistance, and it will likely predict a role for differences in DNA repair 
mechanisms between the BRAF- and RAS-mutant cell lines.  In contrast, a lack of selective advantage 
for the RFP-labeled gatekeeper mutant cells, will suggest that the BRAF-mutant cell lines are able to 
reprogram to become less dependent on Src signaling.  Interestingly, a correlation between two 
recent studies points towards a role for Src in regulating wild type-Ras mediated DNA repair, as Src 
has been show to preferentially phosphorylate and inactivate wild type-Ras in relation to mutant-
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Ras, and wild type-Ras has been demonstrated to be important for the activation of the DNA 
damage response in tumors driven by muntant-Ras 86,201. Therefore, inhibition of Src may lead to an 
increase in wild type-Ras activation and alterations in the DNA damage response, which could lead 
to an increase in mutation acquisition through more error prone methods of DNA repair, such as 
non-homologous recombination. Thus, I hypothesize that we will likely observe differences in 
acquisition rather than selection for the gatekeeper mutation. 
 The previously mentioned experiment will importantly shed light on the mechanism driving 
acquisition in the RAS-mutant cell lines, however an additional question will still remain, which is 
whether a cell harboring the c-SRC gatekeeper mutation is present prior to treatment. In Figure A.2, 
I provide evidence using the HRAS-mutant, C643, cell line to demonstrate heterogeneity in the 
dasatinib-resistant cells, which suggests that the gatekeeper mutation is acquired as a later event. 
Initial presence versus acquisition remains a largely debated question in the field of resistance 
mechanisms, and determining the mechanism is becoming an important issue to take into further 
consideration, as cells that acquire gatekeeper mutations post-treatment harbor additional 
mechanisms of resistance and decreased responsiveness to secondary therapies 134.  
 To further support our data demonstrating that the c-SRC gatekeeper mutation is acquired 
rather than preexisting, pools of 5000 GFP-labeled, parental, RAS-mutant cells will be spiked with a 
single RFP-labeled isogenic cell harboring the c-SRC gatekeeper mutation. The cells will then be 
treated with varying concentrations of dasatinib (0, 100 nm, 200 nM, 600 nM, 1 µM, and 2 µM), and 
progressively analyzed for the presence of GFP- and RFP-labeled cells.  An enrichment for the RFP-
labeled cells will suggest that the gatekeeper mutation does not preexist prior to treatment, 
whereas an enrichment for both GFP- and RFP-labeled cells will suggest the gatekeeper mutation 
pre-exists in the parental population. 
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 Defining the mechanism of c-SRC gatekeeper acquisition will provide important information 
to determine combination strategies to prevent resistance from occurring.  In Chapter III, we 
observed an increased reliance on the MAPK pathway in tumors from acquired dasatinib resistance 
models that acquired the c-SRC gatekeeper mutation, and therefore it is will be interesting to 
discover if the cell lines from chapter IV, with exogenous expression of the c-Src gatekeeper mutant, 
also exhibit an increased sensitivity to MAPK pathway inhibition in vivo.  If both the cell lines with 
acquired and exogenous expression of the c-SRC gatekeeper mutation exhibit increased sensitivity 
to MAPK pathway inhibition in vivo, it will suggest that the c-Src gatekeeper mutant can induce the 
reprogramming necessary for increased reliance on the MAPK pathway.  However, our data points 
towards later acquisition of the c-SRC gatekeeper mutation in the acquired resistance models, 
therefore, I hypothesize that we will observe more reprogramming and likely increased reliance on 
the MAPK pathway in the acquired resistance models in comparison to the models with exogenous 
expression of the c-Src gatekeeper mutant 134.  Therefore, this data would suggest that if the c-SRC 
gatekeeper mutation is present prior to treatment with Src inhibitors, the efficacy of the combined 
inhibition of Src and the MAPK pathway may be reduced.  In this case, the use of allosteric Src 
inhibitors, such as KX-01, may have increased efficacy against the c-Src gatekeeper mutants, due to 
a lack of reliance on the gatekeeper residue for binding 227.  
Mechanisms of Src Mediated Regulation of the PI3K Pathway 
 Toxicity remains a primary concern and limitation when using inhibitors of the PI3K 
pathway. Thus, the recent development of more specific inhibitors of the PI3K pathway, including 
the development of PIK3CA-specific inhibitors, provides promise for the reduction of therapy related 
toxicity 228. Src has been demonstrated to regulate the PI3K pathway at numerous levels including: 
PTEN, PI3K, and AKT (Fig. 5.1A-C) 89,92,94.   Thus, the uncovering of Src-activated signaling nodes will 
importantly facilitate the identification of more specific therapeutic targets, and will hopefully 
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decrease the toxicity associated with therapies. Having demonstrated that both loss of PTEN, as well 
as overexpression of a constitutively active P70S6K construct, are unable to mediate resistance to 
the combined inhibition of Src and the MAPK pathway, it therefore suggests Src regulation of the 
PI3K pathway is likely occurring at the level of PI3K or AKT.  To narrow in on the level of regulation, it 
will be important to express both a constitutively active PIK3CA construct, as well as a 
myristoylated-AKT construct, to determine which pathway component mediates resistance to the 
combined inhibition of Src and the MAPK pathway. Myristoylation of AKT bypasses the regulation of 
AKT membrane recruitment by PtdIns(3,4,5)P3, which results in constitutive activation of AKT 
229
. An 
inability of the constitutively active PI3K construct, and ability of the myristoylated-AKT construct to 
mediate resistance, will suggest that Src regulation of the PI3K pathway occurs at the AKT level (Fig. 
5.1A).  Caveats, however, likely exist from this strategy, as it is possible that Src regulation of the 
PI3K pathway can occur at the AKT level, and yet constitutive activation of PIK3CA may be able to 
overcome this regulation, as this is observed with PIK3CA-mutant cell lines in chapter IV.  In 
addition, the experiment outlined does not create a perfect picture of how this regulation may be 
occurring, as Src may regulate the alternative Class IA PI3K isoforms, PIK3CB or PIK3CD, which may 
be compensated for by PIK3CA constitutive activation. To address these issues, future studies can 
utilize cells expressing the c-Src WT and c-Src GK mutations, which were described in chapter IV.  For 
the first approach, these cells will be treated with and without dasatinib, and then AKT will be 
immunoprecipated with an IgG control being used alongside.  Once immunoprecipitated, AKT will be 
analyzed using western blot analysis for phosphorylated-tyrosine to determine if dasatinib 
treatment can reduce AKT phosphorylation in the c-Src WT expressing cells, but not in the c-Src GK 
expressing cells, which will support a role for Src mediated regulation of AKT. The second approach 
will utilize inducible shRNAs against all three class 1A PI3K isoforms, to determine if loss of either of 
the three isoforms can promote sensitivity in cells expressing the c-Src wild type and gatekeeper 
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mutant constructs 225. Finally, isoform specific inhibitors have also been developed, which can 
further support the shRNA studies, and promote the translation of these studies into the clinic 33. 
 Lastly, Src can indirectly regulate activation of the PI3K pathway through activation of 
Paxillin and P130Cas (Fig 5.1B). Src phosphorylation of  Paxillin at Y88 has been demonstrated to 
regulate p130Cas phosphorylation at Y165 94,95, which leads to an increased association between 
p130Cas and the p85 regulatory subunit of PI3K 93.  Expression of a doxacycline inducible p130Cas 
shRNA will importantly demonstrate whether or not Src regulation of the PI3K pathway is mediated 
through p130Cas, as western blot analysis should depict a reduction in AKT phosphorylation upon 
knockdown, if this mechanism is mediated by p130Cas. In addition, p130Cas has also been 
demonstrated to be phosphorylated and activated through Src mediated phosphorylation at Y138. 
To further confirm a role for Src in mediating p130Cas regulated PI3K activation, p130Cas will be 
knocked-down, and then p130Cas WT, Y138F, and Y165F constructs, that lack the shRNA targeting 
site, will be expressed to determine the role for Src dependent p130Cas phosphorylation in 
mediating activation of the PI3K pathway 230.  Identification of p130Cas as a primary mechanism of 
Src mediated activation of the PI3K pathway, will provide evidence for the development of inhibitors 
targeting this Src/Paxillin/p130Cas signaling axis. Src has the ability to regulate many different 
signaling pathways, however Src inhibitors have unfortunately struggled clinically in the treatment 
of solid tumors. Therefore it is important to elucidate the mechanisms behind Src mediated 
tumorigenesis, so that we can more effectively align novel therapeutics in the treatment of patients 
with advanced thyroid cancer. Finally, the ability of Src  to regulate numerous signaling pathways 
likely drives increased toxicity upon treatment with Src inhibitors, hindering our ability to obtain 
effective inhibitory concentrations in patients, which has been demonstrated to be a reason behind 
the lack of responsiveness to Src inhibitors in breast cancer 117.  Therefore, the identification of the 















Figure 5.1: Src mediated regulation of the PI3K Pathway.   A.) Src mediated tyrosine 
phosphorylation of AKT.  B.) Src mediated activation of p130Cas promotes an increased 
association of p130Cas and the negative regulatory subunit of PI3K, p85. C.) Src mediated 
downregulation of PTEN activity. 
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inhibitor strategies that may reduce toxicity while maintaining the therapeutic efficacy. 
Is Src Activated in Thyroid Cancer to Bypass PTEN Regulation 
 As our understanding of the oncogenic drivers and the mutational spectrum of thyroid 
cancers evolves, it is clear that Src is an important driver in thyroid cancer, however the factors 
driving selection for Src mediated tumorigenesis remain unclear. In chapter IV, we provide 
important preliminary data to support a role for Src in mediating the activation of the PI3K pathway, 
through the bypass of PTEN and direct activation of either PI3K and/or AKT. Interestingly, oncogenic 
models of both KRAS- and BRAF-mutant thyroid cancer exhibit increased aggressiveness when 
combined with a PTEN knockout model, and furthermore loss of PTEN drives progression of these 
tumors towards anaplastic thyroid cancer 218,231. Whereas loss of PTEN can drive this progression, it 
unfortunately is not consistent with recent sequencing efforts, which demonstrate that very few 
BRAF- and RAS-mutant thyroid tumors acquire PTEN mutations/deletions 18,19. Interestingly, 
comparison of the poorly-differentiated and anaplastic thyroid cancers (MSKCC, JCI 2016) dataset to 
the skin cutaneous melanoma (TCGA, Provisional) dataset identifies a significant tendency for the 
mutual exclusivity of BRAF- and PTEN-mutations in thyroid cancer, but a significant tendency 
towards co-occurrence of BRAF- and PTEN-mutations in melanoma (cBioPortal) 19,223. This data 
therefore raises an interesting question in regards to the development of advanced thyroid cancers, 
and in light of the data presented throughout this thesis, it is interesting to speculate that Src 
activation may decrease the selective advantage for PTEN mutations, in thyroid cancer progression.  
In addition, recently developed mouse models containing constitutively active BRAFV600E, along with 
either PTEN or TP53 loss, have been used to analyze the combined inhibition of Src and B-Raf 102.  
Importantly, both models exhibit sensitivity to the combined inhibition of Src and the MAPK 
pathway, which is consistent with our data presented in Chapter IV (Fig. 4.7B). Interestingly, the ATC 
cells harboring BRAFV600E and a homozygous TP53 deletion develop significantly larger tumors in 
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comparison to the cells harboring BRAFV600E and PTEN loss, which provides an additional mechanism 
for the decrease in selective advantage for PTEN mutations in BRAF-mutant thyroid cancers 232. 
Taken together, this data suggests that Src may play an important role in regulating the PI3K 
pathway, and that there is a potentially a lack of selective pressure for tumors with Src activation to 
acquire PTEN mutations/deletions.   
To further explore the role of Src in mediating thyroid cancer progression, future studies 
utilizing a tamoxifen regulated thyroid peroxidase promoter driven BRAFV600E mouse model of 
thyroid tumorigenesis (TPOCreER; Braftm1Mmcm/WT), which expresses normal B-Raf in the thyroid 
prior to Cre-mediated recombination, and upon tamoxifen mediated recombination switches to 
expression of BRAFV600E 232,233. Importantly, this model avoids the abnormal hypothyroidism 
associated with earlier models, and generates more localized lesions, that more accurately mimic 
human papillary thyroid cancer 234.  Briefly, an empty vector or c-Src wild type construct can be 
overexpressed in a cell line derived from the TPOCreER; Braftm1Mmcm/WT tumors, and directly 
injected into the left lobe of the thyroid gland in B6129SF1/J mice. As an alternative approach, 
knockdown of the Src negative regulator, CSK, has previously been demonstrated to promote 
increased Src activation, in vivo 235. As loss of PTEN has been demonstrated to promote the 
progression of papillary thyroid tumors towards anaplastic thyroid cancer, we will also inject cells 
containing either a scrambled shRNA control or cells containing a shPTEN construct 236.  Based on 
our recent identification of Src regulated PI3K pathway activation in thyroid cancer, I hypothesize 
that Src overexpression may result in a similar progression of the TPOCreER; Braftm1Mmcm/WT 
tumors, in comparison to the tumors expressing shPTEN.  To define a role for Src in promoting a 
progression from PTC to ATC, tumors will be stained for the thyroid specific markers galectin-3 and 
CK-19 237.  Progression from PTC to ATC has previously been associated with a loss of CK-19 
expression in ATC tumors 218.  In addition, these tumors will also be analyzed for an increase in 
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aggressiveness based on loss of epithelial marker, E-cadherin, and gain of mesenchymal marker, 
Vimentin, as well as an increase in proliferation as denoted by Ki-67 staining.  Importantly, this data 
will provide a novel mouse model of thyroid tumorigenesis that may more accurately mimic thyroid 
cancer progression. Furthermore, this model will provide critical information into the role of Src in 
mediating thyroid cancer progression, which will enhance our understanding of Src biology in 
thyroid cancer, and further advance therapeutic strategies targeting the advanced stages of thyroid 
cancer. 
Do Cells that Maintain rpS6 Phosphorylation, Post-Treatment, Represent Drug Tolerant Persisters 
 Tumor heterogeneity is a major barrier towards the effective eradication of entire 
populations of cancer cells, when treating with targeted therapeutics.  This heterogeneity accounts 
for the presence of subpopulations of cells, that are resistant to targeted therapies, termed drug 
tolerant persisters (DTPs) 165.  Identification and targeting of these DTPs is a central theme 
throughout this thesis, and remains an important clinical concern for research moving forward.  
Early identification of these persisters holds the potential for more effective implementation of 
combination therapies, which will hopefully prevent the outgrowth of these persisters, and the 
development of additional mechanisms of resistance. In Chapter IV, we were able to demonstrate 
that there is an increased correlation with cells that undergo apoptosis, and an ability of combined 
Src and MEK1/2 inhibition to reduce rpS6 phosphorylation.  This data suggests that rpS6 
phosphorylation may be an important biomarker of response, and that an inability to inhibit rpS6 
phosphorylation appears to correlate with drug tolerant persistence, in relation to the combined 
inhibition of Src and the MAPK pathway. Therefore, it provides important clinical benefit to further 
distinguish if the cells maintaining rpS6 phosphorylation give rise to drug tolerant persisters, so that 
we can further define mechanisms of resistance in these cells and provide information relating to 
the efficacy of the combination therapy in patients.  However, to demonstrate that rpS6 
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phosphorylation is indeed a biomarker of response to the combined inhibition of Src and the MAPK 
pathway, a number of experiments still need to be performed.  
The first experiments will determine if there is an enrichment of phospho-rpS6 persisters 
after prolonged treatment with the combination therapy. These experiments can be performed 
using flow cytometry to analyze the cells after 24, 48, and 72 hours of treatment with dasatinib and 
trametinib.  I hypothesize that there will be an enrichment of rpS6 positive cells when comparing 
the 24 hour treatment to either the 48 hour or 72 hour timepoints, further supporting the 
hypothesis that cells with reduced rpS6 phosphorylation undergo apoptosis and those that maintain 
rpS6 phosphorylation resist cell death and promote the outgrowth of resistant populations.   
The second approach will build off of a stem cell PCR array performed in Appendix B.  The 
PCR array was performed after 72 hours of treatment with the combined inhibition of Src and the 
MAPK pathway or either single agent alone. The goal of the array was to identify cell surface 
markers that are enriched in cells that persist after being treated with the combination therapy, so 
that we can isolate these persisters using flow sorting techniques.  Importantly, we were able to 
identify MUC1 and ABCG2 as being enriched in the combination therapy treated cells (Table B).  
Functionally, both ABCG2 and MUC1 have been associated with drug resistance, with ABCG2 
mediating the efflux of dasatinib (Fig. 5.2A), and MUC1 mediating the upregulation of other multi-
drug resistance genes to promote the efflux of chemotherapies in pancreatic cancer 238,239 (Fig. 
5.2B).  Therefore it will be important to validate MUC1 and ABCG2, as being enriched in the 
combination treated cells, which can be addressed by analyzing MUC1 and ABCG2 by flow 
cytometry, in cells treated with either the combination therapy or single agent for 24, 48, or 72 
hours. In addition, it will be important to identify whether MUC1 and/or ABCG2 are selectively 
expressed with the phospho-rpS6 persister cells that remain after treatment.  Co-expression of 
either cell surface marker with the phospho-rpS6 persister cells will allow us to flow sort the cells 
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expressing MUC1 and/or ABCG2, and further determine whether or not these cells are intrinsically 
resistant to the combination therapy.  In addition, isolation of these cells will provide an additional 
model in which we can define methods to effectively eliminate these persisters. 
 Along these lines, we also observed an increase in STAT3 expression in the cells remaining 
after treatment with the combination therapy for 72 hours (Fig. B.2).  Of importance, STAT3 has 
been demonstrated to regulate the transcription of MUC1, which suggests an important signaling 
node that may be targeted in the drug tolerant persister cells (Fig. 5.2C) 240. Further verification of 
STAT3 activation by western blot analysis in Appendix B, demonstrates that STAT3 increases in 
phosphorylation upon treatment with the combination therapy after both 24 and 48 hours. It will 
therefore be important to test whether there is enhanced sensitivity with the addition of a STAT3 
inhibitor, and whether STAT3 plays a role in mediating the maintained activation of rpS6 
phosphorylation.  To test this, cells will be treated with the combination therapy, as well as a STAT3 
inhibitor (or shRNA), and cells will be analyzed by both immunofluorescence, as well as by western 
blot analysis, for rpS6 phosphorylation. I hypothesize that we will observe a reduction in phospho-
rpS6 persisters in the cells treated with the STAT3 inhibitor, if STAT3 regulates rpS6 phosphorylation. 
In the event that we are able to identify relevant cell surface markers, and flow sort the drug 
tolerant persister cells, it will be important to analyze these cells for elevated levels of STAT3 
phosphorylation, and to treat these cells with a STAT3 inhibitor to evaluate their reliance on STAT3 
activation for survival.  Importantly, a recent dasatinib clinical trial in HNSCC identified a correlation 
between increased pSTAT3 expression and a lack of tumor responsiveness to single agent dasatinib, 
which further supports a role for STAT3 in mediating resistance to dasatinib 241. 
 Interestingly, ABCG2, MUC1, and STAT3 appear to potentially co-exist in a regulatory loop, 
in which STAT3 has been demonstrated to mediate the transcription of MUC1, which in turn has 













Figure 5.2: Potential mechanisms mediating survival in phospho-rpS6 positive drug tolerant 
persisters resistant to the combined inhibition of Src and the MAPK pathway. A.) 
Upregulation of the multidrug transporter ABCG2 can mediate the efflux of dasatinib. B.) 
Upregulation of the glycoprotein MUC1 has previously been demonstrated to promote the 
upregulation of multidrug transporters to mediate resistance to chemotherapies.  C.) 
Upregulation of STAT3 has previously been demonstreated to mediate resistance to 
dasatinib, and has furthermore been demonstrated to promote the transcription of MUC1.  
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potentially be regulating the expression of ABCG2.  Furthermore, expression of ABCG2 can 
potentially decrease the efficacy of dasatinib, through efflux, and therefore promote survival of 
these cells (Fig. 5.2). 
 Based on recent data supporting the important roles of both the MAPK pathway and the 
PI3K pathway in thyroid cancer, as well as our data supporting a role for Src in regulating the PI3K 
pathway, therapies targeting these pathways are likely to be critical moving forward clinically.  
Therefore, identification of the mechanisms mediating tumorigenesis and biomarkers of response to 
the therapies targeting these pathways are going to be vital in the determination of the efficacy of 
these therapeutic strategies.  Importantly, the use of rpS6 phosphorylation status holds great 
promise for the determination of patients receiving clinical benefit from these therapies, and the 
determination of alternative therapeutic strategies for patients unresponsive to the therapy. 
Significance and Implications of This Work 
 Taken together, the work provided in this thesis identifies critical information in regards to 
resistance mechanisms that hinder the advancement of Src inhibitors in the clinic.  The overall 
survival for patients with poorly differentiated and anaplastic thyroid cancer remains discouraging, 
which is a result of a lack of effective therapies for these aggressive diseases 6.  Fortunately, data 
provided in this thesis generates important pre-clinical rationale for the advancement of the 
combined inhibition of Src and the MAPK pathway, in the clinic.  In addition, as Src inhibitors have 
been demonstrated to be effective in pre-clinical models for other tumor types, it is also likely that 
findings identified in this thesis can be applied to abrogate resistance to Src inhibitors in other 
tumor types. 
The MAPK pathway represents the highest percentage of driver mutations in thyroid cancer, 
however MAPK pathway inhibitors have not obtained the efficacy that many researchers would 
have predicted, based off of their application in melanoma 42.  Thus, exploration into the 
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mechanisms that mediate the lack of efficacy are important for the treatment of thyroid cancer 
patients.  The work provided in chapter III demonstrates that upon prolonged inhibition of Src, 
thyroid cancer cells exhibit an increased reliance on the MAPK pathway.  This data, along with data 
provided from other studies 102,103, supports the hypothesis that Src may mediate resistance to 
MAPK pathway inhibitors, and that inhibition of Src allows for the increased efficacy of inhibitors 
targeting the MAPK pathway.   
 Multiple studies have identified Src as an important driver in thyroid cancer 101,104, however 
in addition, studies have also identified a role for the PI3K pathway 242.  Both Src and PI3K pathway 
inhibitors have been demonstrated to have enhanced efficacy in combination with MAPK pathway 
inhibitors, in BRAF- and RAS-mutant thyroid cancers 102,103,106,161,218.  Importantly, the data presented 
in Chapter IV, is the first to align both Src signaling and PI3K pathway activation in thyroid cancer, 
and therefore suggests that inhibitors targeting these pathways are acting through similar inhibitory 
mechanisms.  Interestingly, we also identified that PIK3CA mutations appear to bypass Src 
regulation, and that these mutations promote an increased resistance to Src inhibitors.  Therefore, 
the work in Chapter IV importantly identifies patients harboring PIK3CA-mutations as being unlikely 
to respond to the combined inhibition of Src and the MAPK pathway. 
 Finally, the studies presented in this thesis are among the first to highlight heterogeneous 
inhibition of rpS6 phosphorylation in response to targeted therapeutics, which furthermore provides 
a strategy for the isolation and characterization of drug tolerant persisters.  The consistency of 
studies highlighting the enhanced efficacy of Src or PI3K pathway inhibitors in combination with 
inhibitors of the MAPK pathway in thyroid cancer, suggests that therapies for advanced thyroid 
cancer patients will inevitably have to target these nodes in order to promote complete tumor 
regression 102,103,106,161,218.  Therefore, rpS6 phosphorylation status will likely be an important 
biomarker moving forward for either combination therapy approach, in the clinic.  In addition, 
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advances in single cell technology continue to improve our ability to isolate these drug tolerant 
persisters, and allows for the definition of targetable mechanisms, and elimination of drug tolerant 
persisters.  Therefore, the findings within this thesis provide the necessary pre-clinical 
advancements for patients with advanced thyroid cancer, which will lead to the more effective 
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MECHANISMS MEDIATING ACQUISITION OF THE C-SRC GATEKEEPER MUTATION  
 In Chapter III, we discovered that the two BRAF-mutant cell lines, with acquired resistance 
to dasatinib, did not acquire the c-SRC gatekeeper mutation (Fig. 3.1B). These results raised an 
interesting question as to whether or not acquisition of the c-SRC gatekeeper mutation is 
preferential to RAS-mutant cell lines. To address this, I generated two additional cell lines resistant 
to dasatinib, the BRAF-mutant, BHT101, and the NRAS-mutant, ACT1, cell line.  Interestingly, once 
again only the RAS-mutant cell line acquired the c-SRC gatekeeper mutation, and the BRAF-mutant 
cell line did not, which provides evidence for an increased propensity for RAS-mutant cell lines to 
acquire the c-SRC gatekeeper mutation (Fig. A.1A). Importantly, there also does not appear to be a 
distinction between Ras-isoforms, in regards to acquisition of the gatekeeper mutation.  Consistent 
with acquisition of the c-SRC gatekeeper mutation, in the ACT1 DasRes cell line, we do not observe a 
decrease in Src phosphorylation when this cell line is maintained in dasatinib, however we do 
observe a reduction in phosphorylated Src in the BHT101 cell line that did not acquire the 
gatekeeper mutation (Fig. A.1B). Interestingly, when analyzed for activation of the MAPK pathway, 
the ATC1 cell line exhibited increased activation of the MAPK pathway, but the BHT101 cell line did 
not, which suggests that activation of the MAPK pathway is a prominent mechanisms of dasatinib 
resistance, however it likely is not the only mechanism of resistance (Fig. A.1B). In addition, the c-
SRC gatekeeper mutation was acquired after 3 months of treatment in the KRAS-mutant, Cal62, cell 
line, 6 months in the HRAS-mutant, C643, cell line, and 3 months in the NRAS-mutant, ATC1, cell 
line, which suggests that the c-SRC gatekeeper mutation may be acquired as a later event.  
Acquisition of the c-SRC gatekeeper mutation as a later mechanism of resistance, supports the 





   
Figure A.1: Analysis of additional cell lines generated to be dasatinib resistant. A.) Sanger 
Sequencing for the c-SRC gatekeeper region in control and dasatinib-resistant (DasRes), 
BHT101 and ACT1, cell lines.  B.) Western Blot analysis for Src and ERK1/2 in control and 
dasatinib-resistant, BHT101 and ACT1, cell lines.  
Figure A.2:  Analysis of the c-SRC gatekeeper region in isogenic C643 DasRes clones. Sanger 
Sequencing was performed to analyze the c-SRC gatekeeper region in 8 (A,B,D,E,F,G,I, and J) 
isogenic clones derived from the C643-DasRes cell line. DasRes represents sequencing results for 
the parental C643-DasRes cell population. 
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We therefore chose to analyze the C643 DasRes cell line for heterogeneous acquisition of the c-SRC 
gatekeeper mutation, as this cell line took the longest to acquire the c-SRC gatekeeper mutation. To 
determine heterogeneity, single cell clones were isolated from the C643 DasRes cell line, using serial 
dilutions.  Upon generation of clonal populations, the clones were sequenced using primers for the 
c-SRC gatekeeper mutation, as described in chapter III.  Intriguingly, 1 out of 8 clones did not harbor 
the c-SRC gatekeeper mutation, which suggests that heterogeneous mechanisms of resistance likely 
occur in response to prolonged dasatinib treatment (Fig. A.2). These data therefore support our 
discovery in chapter III, in which the MAPK pathway mediates early resistance prior to the 
acquisition of the c-SRC gatekeeper mutation.  Therefore, future studies will aim to further define 
timepoints at which the c-SRC gatekeeper mutation is acquired, and will further determine 














ANALYSIS OF DRUG TOLERANT PERSISTERS IN RESPONSE TO THE COMBINED INHIBITION OF SRC 
AND THE MAPK PATHWAY  
In Chapter IV, we provided evidence suggesting that phospho-rpS6 represents a biomarker 
of response to the combined inhibition of Src and the MAPK pathway, and that cells with maintained 
rpS6 phosphorylation are likely cells that mediate drug tolerant persistence and drive therapy 
resistance.  Therefore, it is important to further define the role of rpS6 phosphorylation status as an 
indicator of drug tolerant persistence, so that these findings can be effectively translated to thyroid 
cancer clinical trials.  
 As an initial approach, we asked whether or not rpS6 phosphorylation is present in a BRAF-
mutant, BCPAP, cell line with acquired resistance to both the Src inhibitor, dasatinib, and the 
MEK1/2 inhibitor, trametinib (DRTR). Katie Mishall generated this model by culturing the cells in 
gradually increasing concentrations of dasatinib and trametinib, until the cells were able to be 
grown in 200 nM dasatinib and 200 nM trametinib (Figure B.1A).  Importantly, both the downstream 
targets of Src and MEK1/2, pFAK and ppERK1/2, respectively, are inhibited in the DRTR cell line, 
suggesting that no drug resistant mutations have been acquired to reactivate these pathways 
(Figure B.1B).  Interestingly, we instead observed an increase in AKT phosphorylation and a trend 
towards an increase in rpS6 and STAT3 phosphorylation (Figure B.1B).  This data therefore supports 
the hypothesis that cells resistant to the combined inhibition of Src and the MAPK pathway exhibit a 
mechanism of resistance that prevents the reduction in phosphorylation of rpS6, in the presence of 
Src and MEK1/2 inhibitors.  Further analysis of this cell line, as well as the generation of additional 
combination therapy resistant cell lines, will promote the elucidation of resistance mechanisms, and 





Figure B.1: Analysis of cells resistant to combined Src and MAPK pathway inhibition.  A.) 
Growth analysis was performed using the SRB assay.  BCPAP control and DRTR cells were treated 
with increasing doses of either trametinib or dasatinib.  B.) Western blot analysis on control and 
DRTR BCPAP cells.  DRTR cells are maintained in 200 nM dasatinib and 200 nM trametinib and 
control cells were maintained in DMSO.  Quantification of AKT, S6, and STAT3 phosphorylation is 
based on at least 3 independent replicates. 
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The DRTR model importantly supports a correlation between rpS6 phosphorylation and 
resistance to the combination therapy.  However, further method development is needed in order 
to fully define rpS6 phosphorylation as a biomarker of drug tolerant persistence. To accomplish this, 
it is necessary to isolate these drug tolerant persisters to determine if these cells exhibit intrinsic 
resistance.  In order to isolate these persisters, it is also necessary to identify cell surface markers 
associated with these populations, so that they can be isolated using flow sorting techniques.  To 
begin to address these limitations, we performed a cancer stem cell qPCR array analyzing the 
transcriptomes of drug tolerant persisters after 72 hours of treatment with either DMSO, 100 nM 
trametinib, 100 nM dasatinib, or the combination of dasatinib and trametinib in the HRAS-mutant, 
C643, cell line.  Importantly, after performing the stem cell qPCR array, we observed an enrichment 
in cell surface markers/receptors in cells treated with the combination therapy, in comparison to 
either single agent or DMSO control (Table B).  Table B highlights the top 5 genes enriched in the 
combination treated cells, in comparison to the DMSO control.  The top gene enriched in the 
combination treated cells is CD24 (62-fold), however CD24 expression was elevated to higher levels 
in the trametinib treated group (335-fold), in comparison to the combination treated group. 
Therefore, future studies will initially focus on genes with increased expression in the combination 
treated group in comparison to the single agent treatments, which will include cell surface 
markers/receptors: MUC1, ABCG2, and ERBB2 (1.2-4-fold).  Importantly, ABCG2, has previously been 
demonstrated to mediate the transport and efflux of dasatinib, which correlates with a decreased 
ability of the combination therapy to inhibit rpS6 phosphorylation238.  In addition, the alignment of 
ABCG2 with rpS6 phosphorylation will warrant the targeting of these drug tolerant persisters with 
inhibitors against ABCG2, with the goal of enhancing the efficacy of the combined inhibition with 
dasatinib and trametinib.  
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Furthermore, we also identified an enrichment in STAT3 mRNA after 72 hours of treatment 
with the combination therapy (Table B).  STAT3 has previously been demonstrated to mediate 
resistance to dasatinib, as well as also being a common mechanism of resistance in response to cell 
stress 98,183.  We therefore chose to analyze STAT3 phosphorylation after 24 and 48 hours of 
treatment with DMSO, dasatinib, trametinib, or the combination.  Consistent with previous reports, 
we observe an increase in STAT3 phosphorylation upon treatment with both the single agents and 
the combination therapy, which supports a role for STAT3 in response to cell stress 183.  However, 
important for future consideration, we observed >20-fold increases in STAT3 activation when 
treating with the combination therapy for 48 hours, in the BRAF- and RAS-mutant cell lines (Fig. B.2).  
Future analysis will therefore evaluate the co-expression of STAT3 phosphorylation with maintained 
rpS6 phosphorylation, upon treatment with the combination therapy, using single cell analysis 
techniques, such as flow cytometry or mass cytometry.  Co-expression would also highlight a 
potential therapeutic node, in which targeting of STAT3 activation or signaling, could reduce survival 














Table B: Top 5 mRNA transcripts enriched in the C643 cell line after 72 hours of treatment with 
combined inhibition of Src and MEK1/2.   
 
 
Figure B.2: Enrichment of pSTAT3 in cells treated with the combination therapy for 24 and 
48 hours. Western blot analysis of BRAF- and RAS-mutant, 8505C and C643, cell lines, 
respectively.  Cells were treated with either DMSO, 100 nM trametinib, 100 nM dasatinib, or 
the combination, for 24 or 48 hours.  Lysates were then collected and subjected to western 
blot analysis using the indicated antibodies.  Quantification of pSTAT3 Y705 was performed 




METABOLIC RESPONSES TO TREATMENT WITH SRC AND MAPK PATHWAY INHIBITORS 
 Both Src and the MAPK pathway have been demonstrated to play important roles in 
regulating cancer cell metabolism. Specifically, BRAF-mutations have been associated with 
ketogenesis in melanoma 243, RAS-mutations have been associated with central carbon metabolism 
in pancreatic cancer 244, and Src has been demonstrated  to promote the Warburg effect through 
inhibition of pyruvate dehydrogenase in breast cancer 245. As thyroid cancers tend to be more 
resistant to traditional therapies targeting specific oncogenic drivers, such as the B-Raf inhibitor, 
vemurafenib, we hypothesized that we may be able to uncover additional metabolic therapeutic 
targets, that when inhibited may act as circuit breakers to prevent the reprogramming associated 
with resistance to many tyrosine kinase inhibitors.  In addition, defining metabolic regulation in 
response to targeted therapies can provide important information in regards to how Src and the 
MAPK pathway cooperate to drive the metabolic dependencies that promote oncogenesis.  
 As an initial approach towards defining the tumor metabolome in relation to therapeutic 
intervention, we chose to employ Ultra-high-performance liquid chromatography and mass 
spectrometry (UHPLC/MS) to identify alterations in metabolites upon treatment with either DMSO, 
100 nM trametinib, 100 nM dasatinib, or the combination for 2, 8, or 24 hours, as this approach has 
been previously demonstrated to effectively isolate cellular metabolites 189,246.  We chose these 
timepoints to analyze early metabolic changes prior to and upon the initiation of apoptosis, to 
obtain an understanding of the responses that lead up to and potentially promote the cytostatic and 
cytotoxic effects of these inhibitors (Fig. C.1A). Principle component analysis highlights large 
differences between the 24 hour timepoints, and smaller differences between the earlier timepoints 
(Fig. C.1B).  Importantly, single agent trametinib and dasatinib treatment at 24 hours does not result 
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in an increase in apoptosis, which suggests that compounding or selective events observed in the 
combination treated cells at 24 hours, may be important for the induction of apoptosis (Fig. C.1A). In 
addition, similar events observed between either single agent and the combination treatment may 
signify important mechanisms of inhibitor action, that are specific to the single agent inhibitor.  
After 24 hours of treatment with the combination therapy, we observe large reductions in 
amino acids, and metabolites in the glycolysis and pentose phosphate pathways (Fig. C.1C). 
Interestingly, the levels of amino acids and metabolites in the glycolysis pathway appear to be 
regulated by both dasatinib and the combination therapy at early treatment timepoints (2hr and 
8hr), whereas reductions in the pentose phosphate pathway appear to be regulated only at the 24 
hour timepoint (Fig. C.1C). Therefore these data suggest that dasatinib and the combination therapy 
may play a larger role in regulating glycolysis and amino acid metabolism, and that reductions in the 
pentose phosphate pathway may be instead associated with apoptosis.  Having observed a 
reduction in metabolites associated with the glycolysis pathway upon treatment with dasatinib or 
the combination, we chose to analyze the regulation of this pathway in closer detail (Fig. C.2). 
Interestingly, we observed a pronounced dasatinib regulation of the energy investment phase of 
glycolysis (Glucose 6-phosphate  Fructose-1,6-Biphosphate), in which 2 ATP molecules are 
required for each molecule of glucose (Fig. C.2A). In contrast, we do not observe as much dasatinib 
regulation during the energy payoff phase of glycolysis (Bisphosphogluycerate  Pyruvate), in which 
2 molecules of ATP are generated (Fig. C.2B). Instead, we only observe a substantial reduction in the 
energy payoff phase metabolites, after 24 hours of treatment with the combination therapy (Fig. 
C.2).   
One potential explanation for the differential regulation of the energy investment phase 
versus the energy production phase, is that dasatinib treatment may increase the demand for 









Figure C.1: Metabolic analysis upon treatment with Src and MAPK pathway inhibitors.  A.) The 
RAS-mutant, Cal62, cell line was treated with DMSO, 100 nM trametinib, 100 nM dasatinib, or 
the combination for 8 and 24 hours.  The cells were then analyzed for induction of apoptosis 
using the cleaved caspase 3/7 activity assay (Promega).  The data presented for the 24 hour 
timepoint was also presented in Figure 4.3A. Data as means +/- SEM (n=3; student t-test; *, P < 
0.05). B.) and C.) The Cal62 cell line was treated with DMSO, 100 nM Tram, 100 nM Das, or the 
combination for 2, 8, and 24 hours in replicates of three.  Cell extracts were analyzed for 
metabolite levels using UHPLC-MS. B.) Principle component analysis (PLS-eDA) was performed 
using the GENE-E software (Broad).  C.) Heatmap highlighting the variations observed across 
various metabolites under the indicated treatment conditions using Morpheus (Broad).  Relative 
intensities are normalized to each section of metabolites (e.g. Amino Acids or Nucleotides). 
Meta olite a al sis as pe fo ed  A gelo D Alessa d o and Travis Nemkov, in Dr. Kirk 
Ha se s la o ato . 
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nucleic acid synthesis. Interestingly, we do however observe a reduction in lactate that is regulated 
by both dasatinib and the combination therapy. Specifically, this reduction begins at 2 hours with 
the combination and 8 hours with dasatinib, and the reductions are maintained throughout the 
timecourse.  A reduction in lactate is supported by previous reports suggesting that Src inhibits 
pyruvate dehydrogenase to promote the Warburg effect and increase lactate production 245.  
Therefore, inhibition of Src would allow for increased pyruvate dehydrogenase activity and a shift 
from a conversion of pyruvate into lactate and an increase in the conversion of pyruvate into Acetyl-
CoA to fuel the TCA cycle.   Taken together, future studies will aim to address the roles of nucleotide 
synthesis and Acetyl-CoA in relation to the inhibition of Src and the MAPK pathway. 
Interestingly, upon global metabolic analysis we observed a significant 50% decrease in 
average amino acid levels in both the dasatinib treated group and the combination treated group (p 
< 0.0001) (Fig. C.1C).  In addition, we also observed a 60% reduction in intracellular glucose 
concentrations when cells were treated with the combination therapy for 24 hours and a 40% 
reduction in intracellular glucose when cells were treated with either single agent inhibitor (Fig. C.2). 
Interestingly, both glucose and amino acid levels are sensed by the PI3K pathway. Specifically, when 
glucose levels are low, AMPK is the primary mediator of glucose signals opposing AKT regulation of 
TSC1 and TSC2 interaction, and the Rag GTPases that activate mTORC1 at the lysosome are the 
primary sensors of amino acid levels 247.   
These results suggest that the reduction of glucose and amino acid levels upon inhibitor 
treatments may be key mechanisms underlying the ability of combined Src and MEK1/2 inhibitors to 
shut down the PI3K pathway and prevent rpS6 phopshorylation leading to apoptosis. Therefore, 
analysis of the metabolic role for PI3K pathway regulation is another interesting alternative 






Figure C.2: Regulation of the glycolysis pathway in response to Src and MEK1/2 inhibition. A.) 
& B.) The Cal62 cell line was treated with DMSO, 100 nM Tram, 100 nM Das, or the combination 
for 2, 8, and 24 hours in replicates of three.  Cell extracts were analyzed for metabolite levels 
using UHPLC-MS.  A.) Energy investment phase of glycolysis. B.) Energy payoff phase of 
glycolysis. 
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Lastly, we also observed an interesting regulation of the one-carbon metabolism pathway, 
as a reduction in one-carbon metabolites occurs after 24 hours of treatment with single agent 
trametinib and dasatinib, as well as the combination (Fig. C.1C). Therefore this data suggests that 
prolonged treatment with either Src or MEK1/2 inhibition may force the Cal62 cells to over utilize 
these metabolites or that the inhibitors disrupt the production of these metabolites.  
Methionine synthesis is an important component of the one-carbon metabolism pathway, 
and interestingly, it has recently been demonstrated that S-methyl- -thioadenosine phosphorylase 
(MTAP), an important enzyme in the methionine salvage pathway, is co-deleted with CDKN2A 248, 
and that MTAP may contribute to tumor progression 249,250. Importantly, since deletion of MTAP is 
associated with tumorigenesis, researchers have attempted to take advantage of potential 
metabolic vulnerabilities associated with this deletion 251,252.  Interestingly, the Cal62 cell line 
harbors a deletion of both MTAP and CDKN2A (Cancer Cell Line Encyclopedia). Taken together, we 
therefore chose to analyze the methionine cycle component of the one-carbon metabolism 
pathway, in more detail (Fig. C.3).   MTAP is an important enzyme for generation of methionine in 
the methionine salvage pathway, however, we only observe a reduction in methionine in cells 
treated with either dasatinib or the combination (Fig. C.3). Consistent with our observations that 
one-carbon metabolism is reduced after 24 hours of treatment with single agent and combination 
therapies, we observed large reductions in S-Adenosyl-L-Methionine, L-Homocysteine, and 
Cystathionine after 24 hour treatments with either single agent or the combination (Fig. C.3). 
Interestingly, we observed an increase in S-Ribosyl-L-Homocysteine over the treatment timecourse, 
with either single agents or the combination.  Conversion of S-Adenosyl-methionine to to S-
adenosyl-Homocysteine is an important reaction in the transfer of methionine, by 
methyltransferases.  Based on a build-up in S-Ribosyl-L-Homocysteine and a reduction in S-
Adenosyl-Methionine, it is interesting to speculate that cells treated with either single agents or the 
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combination may be highly dependent on the methionine pathway for maintaining methylation 
homeostasis.  Therefore, targeting methyltransferases may have important therapeutic benefit in 
combination with either the single agent treatments or the combination therapy in cell lines and 




















Figure C.3: Analysis of the Methionine cycle of the one-carbon metabolism pathway. The Cal62 
cell line was treated with DMSO, 100 nM trametinib, 100 nM dasatinib, or the combination for 
2, 8, and 24 hours in replicates of three.  Metabolites involved in the methionine cycle were 
analyzed over the course of these treatments and graphed using GraphPad Prism 5. 
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APPENDIX D 
ANALYSIS OF THE COMBINATION EFFECTS OF SARACATINIB AND SELUMETINIB IN THYROID 
CANCER CELL LINES 
 
 Having demonstrated an increased efficacy of the combined inhibition of Src and the MAPK 
pathway, in Chapter III and Chapter IV, using the Src inhibitor, dasatinib, we wanted to further 
support these data with an additional Src inhibitor, saracatinib.   
 Therefore, we treated both BRAF- and RAS-mutant cell lines with the Src inhibitor, 
saracatinib, and the MEK1/2 inhibitor, selumetinib.  We first analyzed apoptosis using the cleaved 
caspase 3/7 activity assay, and consistent with data from Chapter III (Fig. 3.11B) we observed an 
increase in apoptosis with the combination therapy in comparison to either single agent alone ≥ -
fold; Fig. D.1A). We next analyzed the cells for enhanced growth inhibition with the combination 
therapy.  Thus, we treated all four cell lines with increasing concentrations of the Src inhibitor, 
saracatinib (0.075 – 5 μM), in combination with the MEK1/2 inhibitor, selumetinib (BRAF-mutants = 
0.025 – 0.4 μM and RAS-mutants = 0.1 – 1 μM).  In support of the data from Chapter III, the 
combination therapy resulted in synergistic inhibition of growth in all four cell lines (Fig. D.1B), with 
combination index (CI) values < 0.7, indicated by varying shades of green along the curve.   
Having confirmed an increase in apoptosis and synergistic inhibition of growth, using the 
alternative Src inhibitor, saracatinib, we next determined if similar reductions in rpS6 
phosphorylation observed in the BRAF- and RAS-mutant cell lines that are sensitive to dasatinib and 
trametinib (Fig. 4.3B), were also observed with the combination of saracatinib and selumetinib.  
Consistent with only marginal increases in apoptosis and inhibition of growth with saracatinib and 





















Figure D.1: Increased sensitivity of thyroid cancer cells to saracatinib when combined with 
MEK1/2 inhibition. A.) cleaved caspase 3/7 was measured after a 24-hour incubation with 
DM“O, .  μM selu eti i  “el ,  μM sa acatinib (Sar), or the combination in the BCPAP, 
SW1736, C643, and Cal62 cell lines. Data as mean ± SEM (n = 2-3; Student t test; **, P < 0.005). 
Significance was calculated based on comparison of the combination treated group and the 
selumetinib treated group.  B.) Cell lines BCPAP, SW1736, C643 and Cal62 were treated with 
i easi g doses of sa a ati i  a gi g f o  .  μM to  μM fo   hou s, i  o i atio  ith 
increasing doses of selumetinib (BRAF- uta ts; .  μM to .  μM and RAS- uta ts; .  μM to 
 μM). Cell growth was measured using the SRB assay. Synergy was measured by determining 
the CI using the Calcusyn software. Combinations that elicited a synergistic response are 
depicted by their corresponding shade of gray (0.3–0.7, synergism; 0.1–0.3, strong synergism; 
<0.1, very strong synergism).  
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FAK phosphorylation (pFAK Y861) as effectively as dasatinib (Fig. D.2A). Selumetinib, however, does 
appear to effectively inhibit MEK1/2, as determined by effective reductions in ERK1/2 
phosphorylation (Fig. D.2A). Despite decreased efficacy with saracatinib, the combination of 
saracatinib and selumetinib more effectively reduces rpS6 phosphorylation in the BRAF- and RAS-
mutant cell lines, in comparison to the PIK3CA-mutant cell lines (Fig. D.2B). Interestingly, whereas 
we do observe a trend towards enhanced inhibition of rpS6 phosphorylation with the combination 
therapy in the BRAF- and RAS-mutant cell lines, in comparison to the PIK3CA-mutant cell lines, we 
do not observe a significant separation in the RAS-mutant cell lines, which correlates with the 
decreased ability of saracatinib to effectively reduce FAK phosphorylation, in the Cal62 and C643 cell 
lines (Fig. D.2A & B).  Therefore, this data functions as an important example of the utility of rpS6 
phosphorylation status in determining responses to the combined inhibition of Src and the MAPK 
pathway, as the combined treatment of dasatinib and trametinib resulted in greater increases in 
apoptosis and synergy, and a greater reduction in rpS6 phosphorylation, in comparison to the 
combined treatment of saracatinib and selumetinib, in the BRAF- and RAS-mutant cell lines. Taken 
together, this data further supports a role for combined Src and MEK1/2 inhibition in effectively 
reducing signaling through the PI3K pathway, in BRAF- and RAS-mutant cell lines, and that despite 
the use of alternative inhibitors, rpS6 once again appears to be an important biomarker of response 





Figure D.2: Analysis of saracatinib and selumetinib inhibitor sensitivity in BRAF-, RAS-, and 
PIK3CA-mutant cell lines.  A.) The BCPAP, 8505C, T238, Cal62, C643, or THJ16T cells were treated 
for 24 hours with DM“O, .  μM selu eti i ,  μM sa a ati i , o  the o i atio , a d the  
whole cell lysates were analyzed by Western blot analysis using the indicated antibodies. Western 
blots are representative of 3 independent replicates. B.) Densitometry quantification of rpS6 
phosphorylation at S235/236 and S240/244 in BCPAP, 8505C, T238, Cal62, C643, and THJ16T cell 
lines following a 24 hour treatment with DM“O, .  μM selu eti i ,  μM sa a ati i , o  the 
combination. Data as means +/- SEM (n=3; student t-test; *, P < 0.05). 
 
